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The development of nanomedical devices has led to a considerable number of clinically applied 
nanotherapeutics. Yet, the overall poor translation of nanoparticular concepts into marketable systems 
has not met the initial expectations and led to increasing criticism in recent years. Most novel nano 
approaches thereby use highly refined formulations including a plethora of active targeting sequences, 
but ultimately fail to reach their target due to a generally high off-target deposition in organs such as the 
liver or kidney. In that regard, we propose a novel research strategy, arguing that the initial focus of 
nanoparticle (NP) development should not exclusively lie on formulation aspects, but also analyze 
general sites of mostly undesirable NP in vivo deposition and assess how accumulation in these organs 
or tissues can be harnessed to develop therapies for site-related pathologies. In that regard, we give a 
comprehensive overview of existing nanotherapeutic targeting strategies for specific cell types within 
three of the usual suspects, i.e. the liver, kidney, and the vascular system. We discuss the physiological 
surroundings and relevant pathologies of described tissues as well as the implications for NP-mediated 
drug delivery. Additionally, successful cell-selective NP concepts using active targeting strategies are 
assessed. By bringing together both (patho)physiological aspects and concepts for cell-selective NP 
formulations, we hope to show a novel opportunity for the development of more promising 


































When it comes to the field of nanomedicine, i.e. the design of materials in the nanometer size range to 
treat any form of disease, authors frequently mention Paul Ehrlich´s concept of a “magic bullet”, that is 
able to “chemically aim” at its intended target within the body.1 Thereby, the underlying principle is to 
equip nanomaterials with suitable surface functionalities enabling the specific recognition of distinct 
cell types, that require therapy. The applied vehicles such as liposomes or polymeric nanoparticles (NPs) 
should thereby act as a sort of shuttle, that transports pharmacologically active substances specifically 
to the intended target, while off-target sites remain unaffected. In that regard, several approaches already 
showed their potential to significantly improve existing therapy options and in several cases even 
reached marketability.2 Especially when it comes to the treatment of cancerous diseases, many 
publications were able to demonstrate, that (non-)targeted NP systems can substantially increase 
therapeutic efficacy and/or decrease unfavorable side-effects of administered substances. Most concepts 
thereby focused on the differences between tumors and healthy tissues regarding morphology, cell 
metabolism or the expression of cell surface markers. Yet, while many of these approaches showed a 
considerable potential for tumor-specific targeting, the overall transferability of nanoparticulate systems 
from bench to bedside still remains at a poor level and has been one of the central points of criticism 
over the years. In that context, Wilhelm et al. found in 2016 in an intensively discussed meta-study, that 
the overall bioavailability of tumor-targeted nanomaterials was merely 0.7%.3 When they assessed the 
average amount of NPs, that reached not only the tumor tissue, but also the actual cancer cell, results 
were even more sobering with only 14 out of 1 million administered NPs accumulating in their 
respective target cell on average.4 Taking into account these observations and the general lack of 
clinically translated nanomedicine approaches, Kinam Park recently postulated “the beginning of the 
end of the nanomedicine hype”, arguing that the overall benefits of nanotherapy concepts were not 
sufficient to justify further funding.5 He additionally criticized the fact, that the vast majority of 
published studies focused on the targeting of tumor cells and cancerous diseases while non-cancerous 
pathologies were generally neglected, even though these account for far more deaths worldwide.6 
Despite the fact that some aspects of the general critique of nanomaterials need to be put into 
perspective7, it is undoubted, that the overall poor transferability of nanoparticulate concepts into clinical 
applications calls for fundamental improvement. In that regard, an excellent review by Hua et al. 
discussed the most critical impediments for a successful bed-to-bedside transition of nanomedicine 
(NNM) approaches. One key aspect, that they identified, was that “traditionally, NNM development has 
been based on a formulation-driven approach, whereby novel delivery systems are firstly engineered 
and characterized from a physicochemical perspective”.8  In many cases, novel NP concepts would then 
fail to perform under physiological and, more importantly, pathological in vivo conditions. In this 




body presents a major limitation for using nanotechnology”3 and should therefore be included much 
more profoundly during the development of NP concepts. One critical obstacle that the authors 
mentioned, was the oftentimes substantial clearance of administered nanomaterials by the mononuclear 
phagocyte system (MPS), i.e. the uptake of opsonized NPs by phagocytic macrophages or monocytes 
and subsequent accumulation in MPS organs such as the spleen and, in part, the liver.9,10 Trying to 
overcome this limitation, numerous approaches tried to extend NP blood circulation by equipping 
nanomaterials with additional “stealth” elements such as poly-(ethylene glycol) (PEG) surface groups.11–
14 But although these strategies proved to be beneficiary to some extent, the predominant portion of 
administered NPs is generally still accumulating in the usual suspects, i.e. the kidney, liver, spleen and 
lungs.3 This is not surprising, as all these organs share a strong blood supply and a considerable number 
of circulating NPs will always be deposited due to unspecific binding, uptake or extravasation out of the 
blood vessels. To our estimation, it is therefore rather surprising, that, compared to the field of tumor 
targeting, only a limited number of approaches have tried to turn this generally “undesired” 
accumulation in respective organs into possible strategies to target pathologically remodeled cell types 
in these tissues. In our view, combination of the described inevitable passive NP accumulation with 
additional active targeting elements for the specific cell type could potentially open a new field of 
nanomedicine, that has only been poorly investigated in the past.  
However, as already mentioned above, a NP-assisted therapy of described tissues will only be 
successful, if it does not only include the necessary formulation parameters but also considers the actual 
in vivo conditions, that NPs are going to face upon target site accumulation.3,8 Consequently, this review 
aims to cover both the (patho)physiological aspects of above discussed organs or tissues and their 
implications on NP concepts using both active and passive targeting.  
We will therefore analyze currently existing concepts for nanotherapy of cell types in the kidney, liver, 
and the vascular system in general (mainly the lungs and atherosclerotic areas). We decided to exclude 
the above-mentioned spleen, as NP accumulation in this organ is mainly due to described MPS uptake 
of NPs. For each organ or tissue, we will focus on four essential aspects: 1. The (patho)physiological 
structure and function of the respective area. 2. The implication for passive NP accumulation. 3. Possible 
active targeting strategies for cell-specific NP deposition. 4. Applications of described NP concepts to 
treat non-cancerous, organ-based pathologies. Taken together, this analysis should help to develop novel 
strategies for nanomedicine-assisted therapy concepts, as it provides the necessary insights into the 









2 Kidney targeting 
2.1 Renal Structure 
Within the human organism, the kidneys serve as the major excretory organs, facilitating the elimination 
of both metabolic products and partly toxic xenobiotics. The entire blood volume is thereby filtrated for 
approximately 300 times a day, generating up to 180 liters of primary urine that is then further 
concentrated. Apart from this excretory function, the kidneys are also able to regulate blood pressure 
and electrolyte homeostasis through described filtration and further control elements such as the renin-
angiotensin-aldosterone system (RAAS). Additionally, the organ has an essential endocrine function in 
the formation of vital hormones such as renin or erythropoietin. Although renal pathologies are usually 
underrepresented in public perception, chronic kidney disease (CKD) shows a striking global prevalence 
of more than 13%15, with high blood pressure and poorly managed diabetes ranking among the most 
common causes.16,17  
Within the kidney, roughly 1-1.5 million nephrons act as the actual functional units18, consisting of a 
renal corpuscle (glomerulus), where blood is filtrated into primary urine, and a connected tubular 
system, where the primary urine is concentrated and modified via several resorptive and secretory 
processes.19 The glomerulus itself consists of a complex capillary system and several highly 
differentiated cell types that form the renal filter (Figure 1). For a successful passage of this filter and 
excretion into the tubular lumen, intracapillary substances thereby have to cross the so-called glomerular 
filtration barrier (GFB), which is a highly sophisticated network of fenestrated vascular endothelial 
cells, a densely structured glomerular basement membrane (GBM) and visceral epithelial cells 
(podocytes) with their numerous foot processes.20–22 Located in the glomerular center, mesangial cells 
(MCs) provide structural support of the capillary loops by secreting and controlling the turnover of the 
extracellular matrix.23,24 During CKD, renal fibrosis is gradually increasing and accompanied by 
elevated levels of inflammation, mesangial hyperproliferation and glomerulosclerosis.25–29 As a 
consequence, endothelial cells and podocytes eventually lose their functional integrity, leading to an 
irreversible decline in glomerular filtration rate (GFR), proteinuria and a generally impaired kidney 
function.17 Currently predominant therapeutic options mainly focus on the systemic control of the 
RAAS, effective diabetes management or, in the case of more advanced kidney damage, the application 
of anti-inflammatory or immunomodulatory drugs. Especially in the latter case, nanotherapeutic options 
could provide a more refined transport of highly potent substances to their site of action.30,31 
Due to the kidney´s immense blood supply, circulating NPs will mandatorily be subject to renal passage, 
where they either are freely filtrated into the urine, extravasate into kidney-resident cells or leave the 
kidney without deposition. In this regard, Du et al. provided an excellent discussion of possible NP 
routes within the kidney.32 Targeting specific cell types within the kidney is thereby dependent on a 
whole plethora of factors including NP size and surface characteristics but also the equipment with 
suitable targeting sequences.  





Figure 1. The physiology of renal filtration. Within each of the nephrons, blood is initially filtrated in the 
glomerulus. Resulting primary urine is subsequently concentrated and modified via a plethora of absorptive and 
secretory processes both in the proximal and the distal tubule, until it is collected and transported to the ureter. The 
glomerulus itself consists of a highly complex network of capillaries, structurally stabilizing mesangial cells and 
the glomerular filtration barrier (GFB), which consists of fenestrated vascular endothelial cells, a meshwork-like 
glomerular basement membrane as well as a slit diaphragm formed by the numerous foot processes of visceral 
podocytes. Consequently, the accessibility of each glomerular cell component is highly dependent on the size and 
physicochemical characteristics of the respective nanomaterial. Adapted with permission from33. Copyright 2020, 





2.2 Mesangial Cells 
As described above, glomerular MCs play a vital role in preserving the functional integrity of the renal 
corpuscle by secretion and control of the extracellular matrix, which is essential for structural support 
of the renal filter. Besides, they also show extensive crosstalk with all adjacent cell types and thereby 
greatly influence proper function of the glomerular tuft.34 However, since the mesangium is essential 
for glomerular homeostasis, it also greatly contributes to pathological remodeling during kidney diseases 
such as diabetic nephropathy.29 MCs thereby oftentimes undergo a significant myofibroblast 
differentiation and show increasing profibrotic and proinflammatory signaling.27,35 Consequently, 
targeted therapy of MCs would be a viable option for a more refined therapy of various pathologies. 
Within the nephron, the mesangium is only accessible via passage through endothelial fenestrations with 
a diameter of approximately 60 - 100 nm.36,37 Therefore, targeted nanomaterials need to be manufactured 
below respective size threshold to guarantee effective accumulation at the site of interest. Despite this 
limitation, the actual location of the mesangium also offers a chance for a highly effective passive 
targeting strategy comparable to the EPR effect (enhanced permeation and retention), which has been 
successfully exploited in the application of various tumor targeted nanomaterials.38 
Choi et al. analyzed the possibility to transfer this targeting principle to the mesangium and concluded, 
that PEGylated gold NPs with a diameter of 75 ± 25 nm were able to efficiently accumulate in the 
mesangium, even if they did not carry any additional active targeting sequences.37 In accordance with 
this assessment, Li et al. recently showed, that dexamethasone-loaded PEG- poly(lactic-co-glycolic 
acid) (PEG-PLGA) particles with a diameter of 90 nm also had a significantly enhanced intraglomerular 
accumulation compared to bigger NPs of 110 nm, which they explained with a successful extravasation 
into mesangial regions.39 Guo et al. described a similar effect, using albumin-based nanoparticles 
containing anti-inflammatory agent celastrol to treat mesangioproliferative glomerulonephritis.40 They 
found that NP species with a diameter of 95 nm showed maximum levels of intra-mesangial 
accumulation, compared to NPs of 130 nm. In a rat nephritis model, celastrol-carrying NPs could 
significantly reduce mesangial hyperproliferation and fibrosis. Additionally, celastrol-loaded particles 
showed a far lower toxicity and accumulation in off-target regions compared to the free drug. 
Interestingly, Li and Guo also used smaller NP species with a diameter of around 70 nm, which in both 
cases showed lower deposition in the kidney and mesangium, respectively. While Li et al. concluded 
that this observation was due to a lower stability of smaller nanoparticles, Guo et al. stated that NPs of 
95 nm had a greater potential to benefit from various endocytosis pathways such as micropinocytosis, 
caveolae- and clathrin-mediated endocytosis. In this context, it is noteworthy that the actual size of 
endothelial fenestrations can significantly vary, depending on the animal type and, most importantly, 
the used disease model.36,41 
While the aforementioned concepts were mainly based on successful extravasation of NPs through the 
fenestrated endothelium, various other approaches tried to expand this passive targeting by equipping 
particles (< 100 nm) with additional active targeting sequences in order to further enhance intra-
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mesangial accumulation of nanomaterials. Since smooth muscle cells and the closely related MCs have 
been reported to exhibit elevated surface levels of negatively charged chondroitin sulfate 
proteoglycans42,43, Harigai et al. developed liposomes of 100 nm carrying a special cationic lipid (TRX-
20), that significantly increased surface attachment to both smooth muscle and MCs in vitro.44 The 
authors additionally stated that binding to endothelial cells was thereby minimal because here, heparan 
sulfate proteoglycans were predominant, which were not bound by TRX-20. In a follow-up study, Liao 
et al. encapsulated prednisolone phosphate into TRX-20 liposomes, that were able to efficiently 
accumulate in glomerular areas in an IgA nephropathy mouse model.45 Drug-loaded particles thereby 
also showed a higher efficiency in limiting glomerular expansion compared to free prednisolone. 
Morimoto et al. subsequently showed, that kidney deposition of prednisolone-loaded TRX-20 liposomes 
was generally elevated in a nephritis rat model compared to a healthy control, whereas nanoparticles 
almost exclusively accumulated in glomerular areas within the cortex.46 Additionally, drug-loaded TRX-
20 liposomes showed a greater efficiency in their antiproliferative effect compare to unmodified PEG 
liposomes. Recently, Yuan et al. tried to refine the targeting principle by lowering the surface density 
of TRX-20, thereby reducing toxic effects on the target MCs. Encapsulation of anti-inflammatory and 
immunosuppressing drug triptolide into TRX-20 liposomes could additionally improve the therapeutic 
effect in a nephropathy rat model.47 
While TRX-20 was used as a rather unspecific binding facilitator, Tuffin et al. used Thy1.1 antigen 
(CD90), which is commonly used to induce glomerulonephritis disease models48, as a promising 
candidate for highly selective mesangial targeting49,50. When they coupled a corresponding monoclonal 
antibody against Thy1.1 (OX7) to liposomes with a diameter of 100 nm, a significant increase in 
intraglomerular accumulation was detected, compared to untargeted liposomes. Interestingly, this effect 
could be significantly reduced by co-application of free OX-7, thereby proving the Thy1.1-related 
targeting effect. As a further proof of concept, the encapsulation of cytotoxic doxorubicin into targeted 
immunoliposomes led to a visible glomerular damage. In a follow-up study, Suana et al. successfully 
prepared OX-7 immunoliposomes carrying immunosuppressant mycophenolat mofetil to treat anti-
Thy1.1 nephritis.51 
In contrast to the predominant use of liposomes as nanocarriers, Zuckerman et al. manufactured 
polycationic cyclodextrin nanoparticles, that successfully delivered encapsulated siRNA into renal 
glomeruli in vivo. In a second step, they added targeting ligands for either the mannose receptor, which 
is expressed exclusively by MCs within the kidney, or the transferrin receptor, which can be found in 
various other tissues as well. Both targeted siRNA NPs showed an increase in glomerular deposition, 
however results varied to some extent.52 
Since MCs also play an important role in the production and regulation of extracellular matrix (ECM) 
components, targeting integrins could also be a viable option as they are essential in facilitating cell-
ECM adhesion. In that regard, Scindia et al. equipped liposomes with an antibody against integrin α8, 




Manufactured immunoliposomes showed a significantly enhanced intraglomerular accumulation with 
low off-target tissue deposition except for CD11b-positive macrophages.53 
While all described targeting strategies for MCs were based on the addition of merely one targeting 
sequence, our working group was able to develop a multi-ligand NP concept, thereby mimicking viral 
cell infiltration strategies, that usually include several surface recognition sequences.54 We therefore 
manufactured polymeric PEG-poly(lactic acid)/PLGA (PEG-PLA/PLGA) nanoparticles in a size range 
of 70-80 nm, that carried pro-ligand Angiotensin I (AT-I) on their surface. Mimicking influenza A virus 
cell entry55, particles thereby initially bound angiotensin converting enzyme (ACE) on the mesangial 
surface whereupon enzymatic conversion would transform AT-I into secondary ligand AT-II, that only 
then activated G-Protein coupled angiotensin II receptor type 1 (AT1r), initiating NP endocytosis. The 
stepwise particle-cell interaction with two distinct surface structures led to a significantly enhanced 
target cell selectivity in an in vitro co-culture assay.56 In a follow-up study, particles were additionally 
equipped with a potent AT1r inhibitor (EXP3174) in order to increase initial cell surface binding. 
Resulting triple-targeted nanoparticles showed a highly selective intra-mesangial accumulation in vivo 
compared to both untargeted and mono-targeted control NPs, thereby proving the virus-mimetic 
concept.57 
Building on this observation, we recently presented a related targeting concept, which was inspired by 
the cell infiltration process of human adenovirus and is independent from any previous enzymatic 
activation.58 Particles thereby also initially bind mesangial AT1r, but finalize particle endocytosis via a 
previously sterically hidden agonist for the αvβ3 integrin, which is highly expressed by MCs.59,60 
Resulting NPs showed a significant accumulation in the mesangium in vivo with no off-target deposition 
in any other cell type within the kidney (Figure 2).33 Remarkably, NP uptake was maximal for hetero-
functional particle types that profited from a sequential ligand presentation. To our estimation, this 
outcome showed that NPs can only sufficiently profit from a functionalization with targeting sequences, 
if their cell-particle interplay is thereby realistically mimicking natural models such as viruses.54 In a 
recent follow-up study, we were also able to load this NP system with cinaciguat, a promising anti-
fibrotic drug candidate, whose pharmaceutical potency for its intracellular enzymatic target could be 
substantially enhanced via a more efficient transport into the mesangial cell cytosol.61 
Chapter 1: General Sites of Nanoparticle Biodistribution 
22 
 
Figure 2. Adenovirus-inspired targeting of mesangial cells. (a) Virus-mimetic NPs present their ligands in a 
sterically controlled manner, leading to a sequential and thus highly selective particle-cell interplay. (b) In contrast 
to homo-functional or non-functionalized NPs (row 1-3), hetero-functional EXPcRGD NPs (bottom row) showed 
a drastically increased glomerular in vivo deposition. (c) Within the renal system, adenovirus-mimetic NPs 
exclusively targeted mesangial structures while no tubular deposition was visible. Adapted with permission from 
33. Copyright 2020, Advanced Chemical Society. 
   
2.3 Glomerular endothelial cells and podocytes 
Apart from the glomerular basement membrane, the GFB is mainly composed of vascular endothelial 
cells with the already described intracellular fenestrations and viscerally located podocytes, that form a 
slit diaphragm with their foot processes (Figure 1). Consequently, excessive damage and pathologic 
remodeling of endothelial cells and/or podocytes can quickly lead to renal dysfunctions such as a 
reduced glomerular filtration rate or proteinuria.62 Due to their close proximity, both cell types thereby 
also greatly influence each other during renal disease progression, which generally includes advancing 
loss of endothelial integrity and podocyte function.63 
For a possible cell-directed therapy of these pathologies, glomerular endothelial cells would generally 
be readily accessible for targeted NPs due to the strong intraglomerular supply of blood. However, 
nanocarriers can also be washed away much more easily due to the immediate impact of the bloodstream. 
Therefore, applied NPs need to quickly induce sufficient binding to the endothelium to enable 
satisfactory target accumulation. One possible approach is to exploit the role of endothelial cells in 
attracting leukocytes during inflammatory processes within the nephron.64 In that regard, Ásgeirsdóttir 




antibody targeting cell adhesion molecule E-selectin.65,66 In a glomerulonephritis mouse model, drug-
loaded immunoliposomes significantly improved renal function. Although free dexamethasone showed 
a comparable effect, the authors stated, that systemic side effects were significantly lower for the 
nanocarrier system. 
Located on the visceral side of the GFB, podocytes create a slit diaphragm of 10 - 70 nm with their 
numerous interdigitated foot processes.67  Consequently, podocyte injury and subsequent foot process 
effacement or cell apoptosis is one of the major causes for proteinuria and critical loss of glomerular 
filtration capacity during CKD.68,69 Targeting podocytes requires nanomaterials to cross both vascular 
endothelial cells and the underlying negatively charged GBM with a size cut-off of approximately 10 
nm.19,21 To that regard, Bruni et al. synthesized PEGylated nanocarriers in a size range from 5-30 nm, 
whose hydrophobic polycaprolactone core could be loaded with anti-inflammatory dexamethasone.70 
Apart from their positive effect on podocyte repair in vitro, nanoparticles could also cross the glomerular 
filter and were found in the urine. Thereby, clearance was significantly increasing in a nephropathy 
model, possibly due to an advanced damage of the glomerular filter and a consequently higher size cut-
off. In that context, Wu et al. also stated, that under nephritic conditions, glomerular permeability for 
usually non-filtered albumin is significantly enhanced and therefore synthesized an albumin-
methylprednisolone complex that could be able to cross the GFB and be recognized by podocytes via 
the neonatal Fc receptor.71 The complex showed a significantly enhanced in vitro uptake into podocytes 
and could ameliorate drug-induced cell apoptosis. In a biodistribution study, the nanoconjugate 
accumulated mainly in the liver and the kidney, which the authors explained with a deposition in 
glomerular podocytes upon glomerular filtration. 
Pollinger et al. identified αvβ3 integrin as a further possible candidate for a selective podocyte targeting.72 
PEGylated Qdots were therefore functionalized with integrin activator cyclo(-Arg-Gly-Asp-D-Phe-Cys) 
(cRGDfC) and showed a significantly increased uptake in receptor-positive podocytes in vitro as well 
as a selective accumulation in podocyte regions of ex vivo cultured glomeruli. In an approach for further 
recognition structures, Visweswaran et al. describe an upregulation of vascular cell adhesion molecule 
1 (VCAM-1) in podocytes upon stimulation with TNF-α, which they used to mimic inflammatory 
conditions during glomerulopathy. As this surface receptor can facilitate receptor-mediated endocytosis, 
a lipid-based SAINT-O-some carrying a corresponding VCAM-1 antibody was manufactured.73 
Following up on this, the working group encapsulated rapamycin, a potent inhibitor for the mechanistic 
target of rapamycin (mTOR), which had previously been shown to be associated with podocyte injury. 
Drug-loaded nanocarriers showed a beneficial effect on inflammation-activated podocytes in vitro, 
however in vivo biodistribution was not assessed, which would have been particularly interesting, 
regarding the considerable lipid carrier size of 120 nm. 
Finally, Colombo et al. analyzed the impact of particle size and physicochemical characteristics on the 
in vitro uptake behavior of untargeted PCL nanoparticles in podocytes.74 In a follow-up experiment, 
they used a more realistic 3D in vitro system, in which they co-cultured endothelial cells and podocytes 
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and induced podocyte damage with adriamycin, followed by enhanced permeability for albumin. The 
application of dexamethasone-loaded NPs led to a significant podocyte repair and decreased levels of 
albumin permeability. 
Many of described approaches showed a noteworthy targeting potential for podocytes. Also, 
encapsulated substances oftentimes significantly reduced podocyte injury. However, so far, only Bruni 
and Wu et al. could show an actual in vivo deposition of nanomaterials in podocyte regions. 
Interestingly, those two nanocarrier systems were below the size-cutoff of the healthy GFB while all 
other concepts worked with nanoparticulate systems that were too large for renal passage under normal 
conditions. Although authors stated that the permeability of the renal filter is enhanced under 
pathological conditions, it is questionable whether a nanotherapeutic invention at this advanced stage of 
illness would still have a significant effect on slowing disease progression as podocyte injury in most 
cases is an irreversible process.75 
 
2.4 Tubular cells 
After passage of the renal filter, primary urine is largely reabsorbed in the proximal tubular system, 
which is able to precisely steer excretion and reuptake of substances through various absorptive and 
secretory mechanisms. During CKD, fibrotic remodeling and inflammatory injury of tubular epithelial 
cells can significantly contribute to a worsening of renal function.76 Many approaches therefore try to 
harness endocytic mechanisms of proximal epithelial cells to selectively treat tubulus-associated 
pathologies.77 Most concepts are thereby based on the application of low molecular weight peptides or 
proteins as carriers, as these can easily cross the GFB. One frequently exploited peptide is lysozyme, 
which is freely filtrated into the tubular lumen where it is reabsorbed by epithelial cells via the megalin 
receptor.78 In several studies, coupling of lysozyme to pharmacologically active substances led to a 
significant increase in target concentration and drug efficacy.79–82 Apart from that, further low molecular 
weight carriers such as chitosan have been identified as promising candidates for an efficient drug 
delivery to proximal tubulus cells.83–85 While these studies show the potential of the megalin receptor as 
a promising candidate for cell-selective NP targeting,  the application of nanocarriers is significantly 
limited due to the size-cutoff of the GFB. In that regard, Nair et al. successfully proved the general 
applicability of nanomaterials in this area, showing that dextran- and dendrimer-nanoparticles < 10 nm 
efficiently accumulated in renal tubular cells in vivo with megalin expression significantly increasing 
upon NP injection.86 Oroojalian et al. concluded, that in vivo transfection efficiency of siRNA-
containing PEI nanoparticles was significantly increased by introduction of polymyxin B as targeting 
ligand for the megalin receptor of proximal tubule epithelial cells.87 However, they did not discuss the 
exact transport mechanism of the NPs, whose size of 150 nm was too large for passage of the renal filter. 
In that regard, Williams et al. reported a highly interesting finding. So-called “mesoscale” PEGylated 
PLGA nanoparticles with a diameter of 400 nm showed a surprisingly high in vivo accumulation in renal 




this finding with a possible uptake of NPs via peritubular capillaries, which they could reach due to their 
physicochemical characteristics, that minimized MPS clearance. According to the authors, particles 
were endocytosed by peritubular endothelial cells and subsequently transported to the basolateral 
membrane of the tubulus cells, resulting in a significantly increased kidney accumulation compared to 
other organs.88  
Table 1 summarizes described targeting approaches for a cell-selective kidney nanotherapy. Most 
nanoparticular concepts can thereby be found for the glomerular mesangium, as it is more easily 
accessible through endothelial fenestrations. However, as described above, promising studies have also 
been reported for other components of the nephron. 
 
Table 1. Kidney-targeted nanomaterials. 
Cell type NP type Size 
(nm) 





PEG-PLGA 90 - - Dexamethasone 
acetate 
+ 39 
 Albumin-based 95 - - Celastrol + 40 
 Liposomes 100 TRX-20 Proteoglycans Prednisolone 
phosphate 
+ 44–46 
 Liposomes 110 TRX-20 Proteoglycans Triptolide + 47 
 Liposomes 100 OX-7 Thy1.1 Mycophenolate 
mofetil 
+ 49–51 
 Cyclodextrin 70 Mannose/Transferrin M..-/T.- 
receptor 
siRNA + 52 
 Liposomes 100 Anti-Integrin α8 Integrin α8 - + 53 




- - 56 






- + 57 




Cinaciguat + 33,61 
Endothelium Liposomes 110 Anti-E-Selectin E-Selectin Dexamethasone + 65,66 
Podocytes PEG-PCL 5-30 - - Dexamethasone + 70 
 Albumin 10 Albumin FcRn Methylprednisolone + 71 
 QDots 10 cRGDfC Integrin αvβ3 - - 72 
 SAINT-O-Somes 120 Anti-VCAM-1 VCAM-1 Rapamycin - 73 
 PEG-PCL 30/60/120 - - Dexamethasone - 74 
Tubular  
Cells 
Dextran/Dendrimer 5-10 - Megalin 
receptor 
- + 86 
 PEI 150 Polymyxin B “-“ siRNA + 87 




3 Liver targeting 
3.1 Hepatic Structure 
As the key metabolic organ, the liver is involved in the breakdown, synthesis as well as storage of a 
variety of vital substances. It thereby precisely steers the homeostasis of glucose, fats and proteins in 
the human organism via a highly coordinated system of  regulatory processes such as gluconeogenesis 
or lipogenesis.89 Apart from that, it also has a central role in the degradation and detoxification of both 
metabolic and xenobiotic substances via a versatile system of different enzymatic reactions. 
Consequently, exposure to detrimental substances such as pollutants, alcohol or even pharmacological 
substances oftentimes initially leads to liver damage, before other organs are affected.90 In many cases, 
these injuries can lead to progredient liver fibrosis or even cirrhosis and, in the long-term, cause liver 
failure and call for organ transplantation.91  
Within the liver, hepatic lobules act as the functional unit (Figure 3). Within these hexagonal structures, 
blood from the portal venule and hepatic arteriole is transported within the so-called liver sinusoids 
towards the central vein. As described above for the glomerular endothelium, liver sinusoidal endothelial 
cells (LSECs) also possess fenestrations of 50 - 150 nm.92 Due to this large pore size and the lack of a 
basement membrane, the endothelium is highly permeable which is essential for the efficient passage of 
metabolic substances to the underlying hepatocytes, where the majority of liver processes such as the 
enzymatic conversion takes place. However, liver-residential macrophages (Kupffer cells) within the 
sinusoidal vessel act as a gatekeeper and phagocytose possibly harmful blood cargoes. As a central 
element of the MPS, Kupffer cells also show excessive uptake of nanomaterials, especially after 
previous opsonization, i.e. the adsorption of blood plasma proteins.93 Consequently, most 
nanotherapeutic approaches try to minimize MPS recognition and resulting liver uptake by equipping 
NPs with above mentioned stealth elements such as PEGylated surfaces. However, hepatic accumulation 
of NPs can also be harnessed to deliver potent pharmacological substances for a more beneficial therapy 
of liver diseases such as fibrosis. To that regard, administered NPs would not only have to passively 
accumulate in hepatic regions, but also be able to specifically steer further NP-cell interaction with 










Figure 3. Hepatic cell physiology. The liver is supplied with oxygen-rich blood from the hepatic artery as well 
as nutrient-rich blood from the portal vein. Within the organ, hexagonal hepatic lobuli act as the functional units, 
where arterial and venous blood is mixed and transported through sinusoidal capillaries, that eventually merge into 
a central vein. Thereby, blood components can extravasate through endothelial cell fenestrations into the 
perisinusoidal space of Disse, where they finally reach metabolically active hepatocytes, that account for the 
majority of liver-related processes. Within the sinusoidal capillaries, phagocytic Kupffer cells act as highly 





3.2 Hepatic stellate cells 
When it comes to liver fibrosis, perisinusoidal hepatic stellate cells (HSCs) play a central role in disease 
progression. Being located in the space of Disse between the endothelium and the underlying 
hepatocytes, inactive HSCs mainly store nutrients in their cytosol under healthy conditions. However, 
progressive hepatic injury can activate HSCs to become contractile myofibroblasts, that significantly 
contribute to inflammation and fibrotic remodeling of the sinusoid via an altered secretion of 
extracellular matrix components as well as regulatory proteins such as transforming or hepatocyte 
growth factor.94 Cell-selective delivery of pharmacological substances would significantly increase 
therapeutic success as the untargeted application of anti-fibrotic substances can also cause side-effects 
in off-target regions.95 
Already in 1999, Beljaars et al. identified the Mannose 6-phosphate (M6P) / insulin like growth factor 
II receptor as a potential target for M6P-carrying albumin (M6P-HSA), as it is involved in the activation 
of pro-fibrotic transforming growth factor β (TGF-β) and overexpressed in HSCs during liver fibrosis.96 
Building on that finding, several follow-up studies successfully coupled various pharmacologically 
promising substances such as antiproliferative doxorubicin (Greupink et al.), anti-inflammatory 
pentoxifylline (Gonzalo et al.), as well as rho kinase or TGF-β receptor inhibitors (van Beuge et al.) to 
M6P-HSA and selectively targeted HSCs in vivo, which led to significant therapeutic effects in different 
fibrosis models.97–100 Adrian et al. refined this concept by incorporating M6P-HSA into liposomes.101 
This targeted carrier was later fused with hemagglutinating virus of Japan (HVJ) to selectively transfect 
HSCs with a plasmid DNA in vitro.102 In that regard, Patel et al. used a comparable M6P-HSA coupled 
liposomal carrier to encapsulate peroxisome proliferator-activated receptor γ (PPARγ) agonist 
rosiglitazone, which – apart from its antidiabetic effect – also has been shown to inhibit HSC 
proliferation and activation in fibrosis. M6P-targeted liposomes thereby displayed an enhanced 
accumulation in HSCs and could significantly improve various fibrosis parameters.103 As under healthy 
conditions, HSCs mainly store vitamin A (retinol) in intracellular droplets, the corresponding retinol 
binding protein receptor (RBPR) has also been used to implement a HSC-selective nanotherapy. Sato et 
al. manufactured vitamin A-coupled liposomes containing siRNA against heat shock protein 47, which 
is involved in collagen excretion of activated HSCs. In three different cirrhosis models, siRNA-loaded 
liposomes drastically reduced liver injury and prolonged survival rate of tested animals.104 Duong et al. 
used a comparable concept by covalently attaching both vitamin A and nitric oxide (NO) donor S-
nitrosoglutathione to a diblock copolymer, resulting in RBPR-targeted, NO-delivering NPs with a size 
of 35 nm. Particles thereby efficiently accumulated in HSCs both in vitro and in vivo and significantly 
reduced portal hypertension - a major secondary symptom of liver fibrosis – due to the release of 
vasorelaxing and anti-fibrotic NO.105 While the RBPR is also expressed in dormant HSCs, Li F. et al. 
decided to target mainly activated HSCs, using the plateled-derived growth factor receptor (PDGFR), 
which is a prominent mediator of fibrosis progression in various tissues.106 Therefore, liposomal carriers 
were modified with a cyclic peptide with a previously demonstrated high affinity for the PDGFR107, and 
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loaded with interferon-γ (IFN- γ), that had been shown to slow hepatic fibrosis. Liposomal IFN-γ 
showed a significantly prolonged circulation half-life as well as an enhanced intrahepatic accumulation, 
leading to a considerable therapeutic effect in vivo.108 As liver fibrosis is accompanied by an excessive 
excretion of highly contractile extracellular matrix proteins such as collagen, targeting the corresponding 
receptors with suitable cyclic peptides has also proven to facilitate HSC targeting.109 Especially the 
already above mentioned (cyclic) amino acid sequence RGD provided excellent affinity for the collagen 
VI receptor, which is upregulated in HSCs during fibrosis.110 In that regard, both Chai et al. and Yang 
et al. encapsulated oymatrine, a promising antifibrotic alkaloid, into either liposomes or PEG-
poly(caprolactone) (PEG-PCL) nanoparticles, that were modified with an RGD sequence. Both 
nanoparticulate systems showed a significantly enhanced HSC targeting and could decrease fibrosis in 
an in vivo disease model.111,112  Li et al. analogically used cRGD-modified liposomes carrying 
hepatocyte growth factor to substantially ameliorate liver parameters in a cirrhosis model.113 Finally, 
several studies suggest the implementation of hyaluronic acid (HA) as active targeting element, since 
the corresponding receptor CD44 also plays a vital role in fibrotic HSC activation and proliferation. 
While Chen et al. encapsulated anti-inflammatory curcumin in HA-modified PLA NPs and reached a 
promising therapeutic effect in vivo114, Thomas et al. could significantly reduce fibrosis parameters in 
vivo with HA micelles containing AT1r antagonist losartan.115 However, it is unclear whether the latter 
effect was mainly due to HSC inactivation as the prepared HA micelles had a diameter of 300 nm and 
should, in theory, not be able to extravasate into the perisinusoidal space to reach activated HSCs. 
 
3.3 Hepatocytes 
As described above, nanotherapeutic concepts for HSCs are mainly focused on the targeting of surface 
receptors, that are involved in the pro-fibrotic activation and proliferation of activated stellate cells. 
Although hepatocytes also play a significant role during fibrosis, their primary role – especially under 
healthy conditions – lies in the performance of metabolic processes for the liver. Consequently, most 
concepts to target hepatocytes are based on the exploitation of suitable surface receptors for metabolic 
products. In that context, the asialoglycoprotein receptor (ASGPR) plays a central role for many 
hepatocyte-directed approaches. While the ASGPR is essential for the clearance of a multitude of blood 
components such as IgA or apoptotic cells, there is also evidence that viruses such as Hepatitis virus B 
(HBV) use the receptor to induce cell uptake.116 ASGPR-mediated endocytosis itself is initiated via 
binding of terminal galactose or structurally similar groups that are exposed due to a previous cleavage 
of sialic acid groups of various glycoproteins. Analogically, nanotherapeutic concepts try to facilitate 
ASGPR-mediated hepatocyte targeting by equipping NPs with suitable surface groups such as 
galactose.117 Mandal et al. successfully encapsulated antioxidant quercetin into galactose-modified 
liposomes, that were able to significantly ameliorate hepatic injury after exposure to sodium arsenite, a 
widespread pollutant in developing countries.118 Jiang et al. used a comparable system of galactose-




associated toll-like receptor 4 (TLR-4), which is a key contributor to hepatic injury after liver 
transplantation (ischemia-reperfusion injury), resulting in a beneficial therapeutic effect in an in vivo 
model.119 Arima et al. as well as Motoyama et al. identified lactose as another suitable surface group to 
initiate ASGPR-mediated hepatocyte targeting, thereby modifying circular polyamidoamine 
(PAMAM)-cyclodextrin with a size of approximately 160 nm as a nanoparticular vector for a plasmid 
DNA.120,121 In a follow-up study, Hayashi et al. complexed the described lactosylated cyclodextrin with 
siRNA against the amyloidogenic transthyretin (ATTR) gene, which is expressed in hepatocytes and 
associated with amyloidotic polyneuropathy. Targeted NPs showed an efficient uptake in HepG2 cell in 
vitro and could significantly decrease TTR expression in vivo.122 Wang et al. presented a diblock 
copolymer NP system, that was modified with N-acetyl-D-galactosamine (NAcGal) as another possible 
targeting sequence for hepatocyte ASGPR.123 Resulting NPs showed a significantly enhanced in vivo 
accumulation in the liver compared to untargeted NPs. Besides, encapsulated siRNA successfully 
silenced liver-specific apolipoprotein B expression. However, fluorescently labeled siRNA could also 
be found in the kidney, which could indicate insufficient stability of the NPs and subsequent renal 
clearance of the remnants. In a highly promising study, Sato et al. used the same NAcGal sequence to 
manufacture targeted lipid NPs carrying HBV-inhibitory siRNA.124 While untargeted NPs showed a 
considerable toxicity on off-target LSECs, introduction of NAcGal significantly increased hepatocyte 
selectivity, leading to both a reduction in LSEC injury and a sufficient inhibitory effect on HBV levels. 
Apart from the ASGPR, only a few other approaches to target hepatocytes exist so far. Jin et al. 
suggested harnessing the hepatocyte LDL receptor by incorporating cholesterol-coupled siRNA into 
purified LDL nanoparticles.125 Although HepG2 uptake and gene silencing were promising in vitro, no 
in vivo studies have yet been presented. In that context, one obstacle could be the significant LDL 
receptor expression in almost all cell types. As HBV possesses a considerable liver/hepatocyte 
selectivity, Yamada et al. suggested to harness HBV infiltration by preparing so-called L particles, that 
consist of one of the envelope proteins of HBV.126 L particles thereby showed a significant, cell-selective 
delivery of a green fluorescent protein (GFP) plasmid both in vitro and in vivo. In that context, we 
propose, that mimicry of viral cell recognition patterns could possibly also offer a considerable increase 
in hepatic cell selectivity and should therefore be investigated far more intensively.54  
 
 3.4 Liver sinusoidal endothelial cells  
Under healthy conditions, LSECs control the intrahepatic blood flow and act as sieve plates that enable 
the fluid exchange between sinusoidal capillaries and the metabolically active hepatocytes. However, as 
LSECs have been found to play a considerable role in stellate cell activation and increasing hepatic 
resistance during liver fibrosis as well, nanotherapeutic approaches to target LSECs would also be of 
great importance.92 Even though they possess the highest vascular permeability among all endothelial 
cell types due to their intracellular fenestrations, LSECs also have a significant endocytotic capacity, 
thereby contributing to hepatic waste clearance of liver residential Kupffer cells. One example of 
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substances, that are degraded by LSECs is the extracellular matrix component hyaluronic acid. In that 
context, the corresponding HA receptor was found a promising target for LSEC-selective 
nanomaterials.127,128 Kren et al. manufactured poly(ethylene imine)-DNA (PEI-DNA) nanoparticles of 
approximately 25 nm, that contained the transposon system Sleeping Beauty to treat hemophilia A, a 
bleeding disorder due to lack of Factor VIII. HA-modified NPs thereby efficiently accumulated in 
LSECs and showed a considerable therapeutic effect in vivo.129 Interestingly, the authors also used NPs 
that carried a natural ligand for the above mentioned ASGPR. These otherwise identical nanocarriers 
could be found in ASGPR-expressing hepatocytes, thereby proving, that the same nanomaterial can be 
directed to two different cell types in imminent proximity just by the usage of different targeting ligands. 
However, targeted receptors thereby need to be sufficiently characteristic for the respective cell type. In 
that context, Akhter et al. had originally equipped PEGylated liposomes with a peptide sequence that 
should facilitate hepatocyte-selective NP targeting via the above-mentioned LDL receptor. However, 
NPs were found both in LSECs and hepatocytes in vitro and almost entirely accumulated in LSECs  in 
vivo.130 Even though the experienced effect was used in a follow-up study to selectively deliver siRNA 
to LSECs in vivo131, the addressed LDL receptor might not be optimal for cell-selective drug delivery, 
as already mentioned above. Trying to maximize endothelial cell selectivity for sufficient gene delivery 
to LSECs, Abel et al. described an interesting approach of equipping lentiviral gene vectors of 80 - 100 
nm with a single-chain variable fragment against endothelial cell surface marker endoglin (CD105).132 
Targeted vectors thereby exhibited a remarkable in vivo LSEC transduction selectivity, which could also 
be used for drug delivery approaches. The authors explain the experienced selectivity with the 
significantly enhanced CD105 expression of LSECs compared to other endothelial cell types but also 
state, that factors like accessibility and blood circulation kinetics played a decisive role.  
 
3.5 Kupffer cells  
In contrast to circulating macrophages, stationary Kupffer cells (KCs) are permanently located in the 
liver sinusoid under healthy conditions, acting as sentinels for possible pathogens or other xenobiotics. 
As central part of the MPS, KCs have a remarkable phagocytic activity, thereby degrading cellular debris 
or possibly liver-damaging substances.133 Consequently, almost all nanotherapeutic approaches try to 
minimize MPS recognition and subsequent phagocytosis of administered NPs by equipping nanocarriers 
with described “stealth” elements or optimizing surface charge and size.93   
However, NP phagocytosis into KCs could also be harnessed for various therapeutic concepts since KCs 
play a crucial role in a multitude of liver pathologies. For instance, progredient liver fibrosis and 
cirrhosis are in part initiated by the activation of Kupffer cells and subsequent secretion of pro-
inflammatory cytokines, that in turn stimulate stellate cells to become pro-fibrotic myofibroblasts.90 As 
KCs possess the above described phagocytic activity for many nanoparticulate systems, several 
approaches successfully target KC passively without equipping NPs with additional active targeting 




PPARγ agonist rosiglitazone to treat obesity-induced macrophage inflammation.134 Systemic application 
of rosiglitazone NPs led to a significant decrease of inflammation levels and thereby showed fewer side 
effects compared to the free drug. In a very detailed study, Dolina et al. presented lipid NPs that 
contained siRNA silencing the expression of PD-L1 in Kupffer cells.135 Via activation of corresponding 
PD-1 protein, this ligand plays a critical role in suppression of immune responses by natural killer (NK) 
and CD8+ T cells during certain virus infections. Manufactured siRNA-carrying NPs were selectively 
endocytosed by KCs, leading to a significant PD-L1 silencing, which in turn, enhanced NK and CD8+ 
T cell activation in an adenovirus/cytomegalovirus in vivo model. Since KCs contribute to the 
phagocytosis of harmful microorganisms such as bacteria, they are equipped with various receptors to 
recognize specific lipopolysaccharides on the bacterial cell surface, among which the mannose receptor 
(MR) plays a central role. In that regard, equipping nanoparticulate structures with mannose sequences 
has been found to further enhance KC accumulation.136 He et al. analogically encapsulated anti-TNF-α 
siRNA into mannose-modified chitosan NPs to reduce liver inflammation and subsequent damage in an 
in vivo model of acute hepatic injury.137 Remarkably, NPs in this and a follow-up study were orally 
applied, showing sufficient stability and intestinal permeation.138 Jing et al. presented a dual liver 
targeting system, where solid lipid nanoparticles were modified with either KC-targeting mannose or 
HepG2 tumor targeting  transferrin.139 Containing GFP plasmid, mannose-modified NPs thereby showed 
a significantly enhanced KC transfection efficiency in vivo while transferrin-NPs mainly transfected 
HepG2 cells. 
Table 2 provides an overview of discussed liver cell-selective targeting approaches. Especially for 
hepatic stellate cells, many approaches have successfully manufactured nanomaterials, that were 
equipped with selective targeting elements and carried pharmacological substances, that could 
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Table 2. Targeting concepts for hepatic cells. 
Cell type NP type Size 
(nm) 
Ligands Targets  Drug delivery In 
vivo 
Ref. 
Stellate Cells HSA 30-40* M6P M6P receptor Doxorubcicin/pentoxifylline 
rho kinase/ALK5 (-) 
+ 97–100 
 HVJ-liposomes 200 “-“ “-“ - - 102 
 Liposomes 135 “-“ “-“ Rosiglitazone + 103 
 Liposomes 150 Vitamin A RBPR siRNA + 104 
 Diblock 
copolymer NPs 
35 “-“ “-“ S-nitrosoglutathione + 105 
 Liposomes 80 cSRNLIDC PDGFR IFN- γ + 108 
 Liposomes n.a. cRGD Col VI 
receptor 
Oxymatrine + 111 
 PEG-PCL 95 RGD “-“ “-“ + 112 
 Liposomes 90 cRGD “-“ Hepatocyte growth factor + 113 
 PLA 60 HA  HA rec.  Curcumin + 114 
 HA micelles 300 “-“ “-“ Losartan + 115 
Hepatocytes Liposomes n.a. Galactose ASGPR Quercetin + 118 
 Liposomes 140 “-“ “-“ siRNA + 119 
 PAMAM-
cyclodextrin 




50-100 NAcGal “-“ siRNA + 123 
 Lipid NPs 50-70 NAcGal “-“ siRNA + 124 
 PEI NPs 20 Asialoorosomucoid “-“ DNA + 129 
 LDL 25 LDL LDL rec. siRNA - 125 
 HBV L 
particles 
80 L protein HBV rec. - + 126 
LSECs Poly-
Lysin/PLA 
50 HA HA rec. - - 127 
 PEI 25 “-“ “-“ DNA + 129 
 Liposomes 100 Peptide sequence LDL rec. siRNA + 130,131 
 Lentivirus 80-100 Anti-CD105 CD105 - + 132 
Kupffer  Cells PLGA/PVA 200 - - Rosiglitazone + 134 
 Lipid NPs 70-80 - - siRNA + 135 
 HSA 30-40* Mannose Mannose rec. Dexamethasone + 136 
 Chitosan 150 “-“ “-“ siRNA + 137,138 
 Lipid NPs 200 “-“ “-“ - + 139 
 
*The authors did not present data on the size distribution of HSA-NPs. We therefore estimated the size according to the approximate 




4 Vascular targeting 
4.1 General aspects of the vasculature 
Even if nanomaterials are not administered intravenously, almost any application strategy eventually 
leads to a NP transfer to the bloodstream, followed by circulation through the vascular system. 
Consequently, exposure to the vasculature greatly influences eventual bioavailability and possible off-
target accumulation. Even though the phagocytic activity of vascular endothelial cells (VECs) is 
considerably lower than for the components of the MPS, the sheer scale of endothelial cell number and 
surface, that NPs are exposed to, can play a decisive role in NP targeting. Under a physiological aspect, 
the vasculature is – apart from the heart – the central key player to guarantee proper blood circulation. 
Consequently, damage or impaired function of the vascular system is regarded as the most critical 
pathology with ischemic heart disease and stroke as the two leading causes of death worldwide.6 These 
vascular complications are mostly caused by atherosclerosis (Figure 4), i.e. the progredient 
development of subendothelial plaques due to the accumulation of low-density lipoprotein (LDL) 
cholesterol followed by increasing levels of inflammation and possible rupture of the plaque.140 Yet, an 
impaired endothelial function also plays a significant role in a variety of other diseases such as 
pulmonary inflammation during chronic obstructive pulmonary disease (COPD) or asthma, two diseases 
that also affect millions of patients worldwide.141 As described for renal or hepatic diseases, cell-
selective therapy of the pathologically remodeled endothelium could therefore also dramatically 
improve current medical options.  




Figure 4. Vascular physiology. The vasculature is generally divided into the venous and arterial system, whereas 
oxygen- and nutrient- rich arterial blood is compartmentalized into the capillary system which subsequently 
merges into the venous pool, that is then transported back to the heart and the pulmonal system, where gas 
exchange takes place. Apart from direct uptake into endothelial cells or extravasation in above discussed hepatic 
or renal as well as splenic areas, circulating NPs cannot leave the vessel under physiological conditions, which is 
due to the continuous connection of endothelial cells by impermeable tight junctions. However, pathological 
changes such as atherosclerotic remodeling can increase the leakiness of the endothelium, thereby facilitating NP 
extravasation and accumulation in pathological sites of interest such as an atherosclerotic plaque. 
 
4.2 Vascular endothelial cells 
For a successful targeting of the vasculature, it is essential for NPs to initially bind to the cell surface of 
endothelial cells. Thereby, blood flow and resulting shear stress as well as red blood cells and other 
blood components have been shown to strongly influence and oftentimes decrease efficient NP 
margination from the vessel interior to the marginal endothelial cell layer.142–145 In order to increase 
endothelial binding of circulating NPs, most approaches therefore use various cell adhesion molecules 
(CAMs), that are usually involved in the attraction of blood components such as platelets, leukocytes or 
monocytes.146 In that context, Dziubla et al. successfully targeted platelet-endothelial cell adhesion 




enzyme catalase.147 NPs thereby showed significant endothelial binding in vitro, leading to an excellent 
protection against oxidative stress due to the effects of encapsulated catalase. In an in vivo 
biodistribution study, NP accumulation could mainly be found in the lungs, where a high proportion 
(~30%) of endothelial cell surface is present. In a highly insightful study, Han et al. refined this concept 
and assessed the impact of anti-PECAM-1 ligand density as well as the flow dynamics on the vascular 
targeting capacity of polystyrene NPs. The authors concluded that PECAM-1 mediated endocytosis is 
significantly enhanced, when NPs are functionalized with a greater number of antibodies (50 vs. 200), 
as these NPs could benefit from a multivalency effect. Additionally, they found, that in vitro exposure 
of endothelial cells to a constant flow significantly decreased NP uptake, which they explained with an 
observed actin reorganization and consequently, a reduced endocytic capacity. Interestingly, in vivo 
analysis of pulmonary NP biodistribution showed a corresponding trend with NPs predominantly 
accumulating in smaller capillaries, where blood flow is significantly lower compared to larger 
arterioles.148,149  
Intercellular adhesion molecule (ICAM) was found to be another highly promising target for efficient 
EC targeting. The glycoprotein is involved in intercellular contacts but also facilitates leukocyte 
attachment and transmigration, especially under pathological conditions such as inflammation or 
atherosclerosis. Muro et al. found, that anti-ICAM functionalized polymer NPs efficiently targeted ECs, 
both under static and flow conditions in vitro.150 Additionally, isolated rat mesenteric vessels were 
perfused with anti-ICAM NPs, which showed a significant endothelial deposition within 30 minutes of 
perfusion. Finally, in vivo biodistribution analysis showed maximum NP deposition in the lung, thereby 
further proving the concept of EC-directed targeting. While several studies successfully harnessed the 
concept of ICAM-mediated EC targeting151–153, VCAM-1 was additionally identified as a potent 
targeting sequence, as it is also involved in a variety of EC binding processes and drastically upregulated 
in various vascular pathologies such as atherosclerosis. Homem de Bittencourt et al. manufactured a 
VCAM-1 targeted, liposomal carrier system for an antiproliferative cyclopentenone (CP) prostaglandin, 
which significantly ameliorated disease parameters in LDL-receptor deficient and thus highly 
atherosclerotic mice.154 Calin et al. presented a comparable approach by equipping liposomes with a 
VCAM-1 targeting peptide sequence to treat activated endothelial cells with an encapsulated chemokine 
receptor antagonist, that should prevent excessive monocyte transmigration during atherosclerosis.155 In 
an in situ model of atherosclerosis-prone apolipoprotein E (ApoE) - deficient mice, targeted NPs showed 
an enhanced accumulation in mice aortas. Remarkably, NP-mediated delivery of  the encapsulated CC 
chemokine receptor (CCR) antagonist significantly decreased the adhesion of monocytes to the vessel 
wall. Papademetriou et al. combined the above described targeting of cellular adhesion molecules and 
functionalized polystyrene NPs with different combinations of antibodies against either ICAM, PECAM 
or VCAM.156 NP accumulation was assessed both in vitro and in an in vivo mouse model of 
lipopolysaccharide-induced vascular inflammation. Although results did not provide an ultimately 
optimal NP composition, combination of two or three CAM-targeting sequences showed beneficial 
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effects on the targeting capacity. In the context of mimicking physiological mechanisms of endothelial 
cell binding, Xu et al. presented another, highly interesting approach of PLGA NPs imitating the platelet 
adhesion process onto ECs.157 To facilitate initial particle binding, NPs were thereby functionalized with 
glycoprotein 1b (GP1b), which mediates adhesion to activated (inflamed/injured) endothelial cells via 
P-selectin and von Willebrand Factor (vWF). To enable a sufficient subsequent internalization, NPs 
were additionally functionalized with transactivating transcriptional activator (TAT), a widely used cell 
penetrating peptide (CPP), which led to a significant endothelial uptake of targeted NPs under flow 
conditions. Additionally, NPs carrying anti-inflammatory dexamethasone showed a considerable 
decrease of arterial stenosis in an in vivo injury model. Finally, several approaches identified excessive 
VEC-mediated angiogenesis, which is an important factor during atherosclerosis progression158, as a 
possible target to both image and treat pathologically remodeled endothelial sites. In that regard, Winter 
et al. provided a dual approach of magnetic resonance imaging (MRI) as well as treatment of aortic 
plaque angiogenesis in atherosclerotic rabbits.159,160 The authors manufactured paramagnetic 
perfluorocarbon NPs with an RGD functionality to target αvβ3 integrin, which is drastically upregulated 
under angiogenic conditions. Targeted NPs additionally carried anti-angiogenic drug fumagillin and 
showed a considerable accumulation in angiogenic areas in vivo. Interestingly, one week after treatment, 
areas with a previously high MRI signal showed a significant decrease, indicating the therapeutic effect 
of the encapsulated drug and a subsequent decrease of integrin expression. Vader et al. used a similar 
approach to silence vascular endothelial growth factor receptor 2 (VEGFR-2) expression of αvβ3 
integrin-positive endothelial cells in vitro, using cRGD-modified liposomal siRNA carriers.161 
 
4.3 Plaque-associated macrophages 
Apart from an activated endothelium, infiltrating monocytes play a central role in atherosclerotic plaque 
development. Once these progenitor cells are converted to macrophages, they endocytose excessive 
oxidized LDL (oxLDL) and eventually become so-called foam cells, that form the later plaque. 
Targeting these activated macrophages is therefore a viable option to both image atherosclerotic areas 
in the vessel wall and treat pathologically remodeled sites. NPs could thereby passively accumulate in 
the target site via extravasation from both the affected larger arteries such as the aorta and the vasa 
vasorum, i.e. smaller vessels, that supply the vasculature. The reason for this is, that the endothelial cells 
of these vascular components often show enhanced permeability during atherosclerosis and the 
associated angiogenesis as well as neovascularization.162,163As the described uptake of LDL is mainly 
mediated via different forms of scavenger receptor (SR or CD36), targeting of SRs is mostly used to 
facilitate macrophage-specific delivery of therapeutic or diagnostic materials. Nie et al. manufactured 
liposomal nanovesicles, that carried oxidized phosphatidylcholine (oxPC), which can also be found on 
the surface of oxidized LDL and is assumed to be a ligand for CD36. Targeted NPs thereby showed 




Apart from (oxidized) LDL, high-density lipoprotein (HDL) can also interact with the macrophage SR. 
However, HDL uptake into vascular macrophages does not lead to the describe atherosclerotic effects 
but facilitates cholesterol removal and hepatic excretion and is therefore regarded beneficial. In that 
context, Sanchez-Gaytan et al. presented hybrid NPs consisting of a PLGA core and a surrounding 
phospholipid corona with the physicochemical characteristics of HDL. Particles thereby significantly 
increased cholesterol efflux from targeted macrophages in vitro and showed considerable levels of 
accumulation in atherosclerotic vessels of ApoE knockout mice in vivo.165 Duivenvoorden et al. 
presented a similar concept to deliver anti-inflammatory simvastatin to atherosclerotic plaques using 
HDL-lipid NPs.166 Macrophage content as well as inflammation levels in an ApoE KO model could 
thereby be significantly reduced, both in a one-week high-dose and a three-month low dose i.v. 
treatment. Iverson et al. investigated an alternative approach of macrophage SR targeting by 
manufacturing amphiphilic polymer NPs with physicochemical characteristics, that facilitate efficient 
interaction with SR A-1.167 NPs additionally delivered an agonist for liver receptor X, which regulates 
the above described efflux of cholesterol from activated macrophages. Both drug-loaded NPs and NPs 
themselves thereby showed beneficial therapeutic effects in vivo, lowering levels of accumulated 
cholesterol and decreasing macrophage activity. Further approaches have harnessed described 
phagocytic activity of SRs for a macrophage- and plaque-selective targeting by manufacture of NPs 
carrying either described HDL functionalities or structural components with a comparably high SR 
affinity (Table 3).168–170 Again, it is especially the combination of described passive extravasation and 
active targeting that seems to play a key role for the described effects. 
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Table 3. Vascular targeting approaches. 
Cell type NP type Size 
(nm) 
Ligands Targets  Drug delivery In 
vivo 
Ref. 
VECs PEG-PLGA 170 Anti-PECAM-1 PECAM-1 Catalase + 147 
 Polystyrene 180-
200 
“-“ “-“ - + 148,149 
 Polystyrene/PLGA 200 Anti-ICAM ICAM - -  150 
 PLGA 220 “-“ “-“ - - 152 
 Polystyrene 180 “-“ “-“ - + 153 
 PLGA 175 Peptide sequence “-“ - + 151 
 Liposomes n.a. Anti-VCAM-1 VCAM-1 CP-prostaglandin + 154 









- + 156 




Dexamethasone + 157 
 Paramagnetic NPs 175-
220 
RGD Integrin αvβ3 Fumagillin + 159,160 
 Liposomes 200 cRGD “-“ siRNA - 161 
Macrophages Liposomes 100 oxPC Scavenger 
receptor 
- + 164 
 HDL-PLGA 40-80 HDL “-“ - + 165 
 HDL-lipid NPs 30 “-“ “-“ Simvastatin + 166 
 HDL polymer NPs 100-
200 
“-“ “-“ - + 169 
 Amphiphilic NPs 100 Polymer 
characteristics 





“-“ “-“ - - 170 
 “-“ 100-
400 











5 Implications for future nanotherapeutic approaches 
In this review, our goal was to give a comprehensive overview over existing nanotherapeutic strategies 
to target specific cell types located in organs or tissues with a usually inevitable NP deposition such as 
the kidney or liver. While the presented concepts thereby used various nanomaterials and incorporated 
a great number of different pharmaceutically active substances, one trend became obvious during our 
assessment: All NP concepts, that showed considerable targeting potential for the intended cell type, 
profited not only from a functionalization with suitable active recognition patterns but to a large extent 
also from harnessing their general passive accumulation at the respective sites. For instance, NP 
accumulation in glomerular mesangial cells was successful with various active targeting principles but 
was in all cases also largely based on the fact, that applied nanomaterials could profit from an 
extravasation into mesangial regions due to their size. Accordingly, NP targeting of vascular endothelial 
cells and the therapy of related pathologies could be significantly enhanced by actively exploiting 
surface structures such as CAMs. However, NP uptake would have been dramatically lower, if the 
vasculature was not also generally subject to a considerable particle exposition.  
In this context, tumor-targeted nanomaterials show a comparable phenomenon. While the EPR effect 
was seen as a groundbreaking option to dramatically enhance NP tumor accumulation and therapy, there 
is growing evidence, that not all malignant tissues share the same extent of morphological traits, that the 
effect is based on. Consequently, NP-mediated therapy of primary or metastatic tumors with actively 
targeting nanomaterials is also largely dependent on the magnitude of vascular accessibility, which 
differs not only between distinct tumor types, but to some extent even within one heterogeneous tumor 
itself.171 
Taking into consideration these observations, we argue that future NP developments need to change 
their focus in order to sustainably increase the clinical translation of nanomedical devices. In classic 
approaches, complex nanomaterials - oftentimes equipped with highly selective recognition sequences 
– are mostly designed with regard to their capacity to target one specific cell type within the body. While 
target uptake or selectivity is thereby initially tested in vitro, in vivo biodistribution and target 
accumulation are only tested in a second step, whereas off-target deposition is generally regarded as an 
unavoidable drawback of nanomaterials, that can be minimized at the most. 
In contrast, we believe that novel nanotherapeutic studies should initially put a much greater emphasis 
on general sites of in vivo NP accumulation and only then analyze, which cell types or pathologies within 
these deposition sites could be treated with nanomaterials (Figure 5). When it then comes to the final 
target cell-selective NP uptake, plentiful strategies already exist for the majority of cell types in organs 
or tissues such as the kidney, liver and vasculature (Tables 1-3). These technologies could then be used 
and modified in order to reach a sufficient targeting of respective tissues, however with a generally 
enhanced in vivo accumulation due to the previous assessment of general NP biodistribution. Apart from 
this change of procedure, a much greater focus should also be placed on the actual practicability of 
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developed nanomaterials, i.e. the required routes of administration and dosing intervals. In that regard, 
approaches such as a controlled release of NPs from biodegradable hydrogels or concepts for an oral 
administration of nanomaterials could be valuable options to further expand therapeutic NP options.172–
175 Lastly, we regard it as essential that the final nanotherapeutic devices are manufactured not only with 
a narrow focus on the chosen target cell or tissue, but still also take into account remaining off-target 
sites, that inevitably will always be subject to a significant dose of administered NPs. In those regions, 
both the utilized NP materials and the chosen pharmaceutical agent should therefore show minimal 
toxicity or adverse effects that could potentially decrease therapeutic success.  
    
Figure 5. Proposal for a novel nanoparticle design. New nanotherapeutic approaches should be designed with 
an initial focus on general sites of NP in vivo accumulation, that could then be harnessed to develop more promising 
cell-selective nanomaterials.   
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6 Conclusion and outlook 
There is hardly any other biomedical topic, that has seen such a dramatic shift from initial enthusiastic 
expectations to harsh criticism than the field of nanomedical devices. To our estimation, both extreme 
views do not reflect the realistic potential of NP-assisted therapy options. While numerous 
nanoparticular concepts have already reached clinical translation and marketability, it is also undoubted, 
that the experienced success rate has been disappointing so far. In our view, current nanomedicine 
research therefore needs to take a step backwards and rethink, why and most importantly in which cases 
the implementation of a NP system can make sense. In this case, the general criticism of a considerable 
off-target accumulation of most administered NPs has to be accepted and most importantly harnessed 
for potential therapies instead of developing more and more refined concepts, that show excellent in 
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The majority of existing pathologies can nowadays be detected more quickly and efficiently with the 
help of increasingly precise diagnostic tools as well as a constantly growing medical expertise. 
Additionally, development of highly potent pharmaceutical substances or also vaccines has reached a 
pace, that seemed unimaginable only a few years ago.1 Nevertheless, many therapeutic approaches with 
new drug candidates fail due to an old problem: insufficient distribution to the site of action within the 
organism. In this regard, drugs oftentimes provide an excellent target efficacy, but do not reach therapy-
relevant tissues in sufficient quantities after their application. Treatment with respective substances 
therefore requires the administration of higher doses, which often leads to side effects or even the 
discontinuation of therapy due to toxic events. For this handicap of modern drug therapy, already known 
to Paul Ehrlich, he had a "simple" solution: "...we must learn to aim, learn to aim chemically!".2 
For him, "chemical aiming" consisted of giving active substances a modified structure that does not 
impair their efficacy, but at the same time leads to a higher accumulation in the target tissue. In reality, 
unfortunately, such approaches often fail because it is not possible to optimize both described drug 
properties independently by merely changing the chemical structure of a molecule. Nanotherapy offers 
a key to solving this problem. It aims to exchange unfavorable physicochemical properties of a drug for 
more favorable characteristics of a transport vehicle. To this end, NPs with a typical size of 10 to 100 
nm are loaded with potent active ingredients. These drug ferries are designed to deliver the substance in 
a targeted manner to the intended site of action, which it otherwise cannot reach sufficiently under its 
own power. The transport thereby ideally leads to an increased concentration at the target tissue, 
combined with enhanced efficacy and fewer side effects, which is often referred to in the literature as 
the "targeting effect".3  
Despite the development of a wide range of such targeting concepts, it has become apparent that 
nanotherapeutics often show only insufficient final accumulation in the target cells and thus do not offer 
the hoped-for advantage over a conventional therapy with free drugs.4 For example, although 
nanoparticles can often accumulate passively in tissues such as tumors due to the EPR effect, they 
generally fail in a subsequent selective recognition of their target cells on site. Even the provision of 
special ligands to bind receptor proteins in the cell membrane often does little to improve the ability of 
nanotherapeutics to selectively recognize their target cells, as these receptors are usually found on a 
variety of other cell types as well.  
For viruses as natural NPs, on the other hand, cell identification and differentiation pose no problems. 
Viral particles depend on the selective infiltration of their respective target cells for successful 
reproduction and therefore, in the course of evolution, have developed a variety of highly efficient 
mechanisms for specific cell recognition and uptake. The basis of viral cell entry is thereby the ability 
to recognize several characteristic structures on the cell surface in a precisely "programmed" sequence 
and use them to overcome the cell membrane barrier.5  
Unlike human cells, viruses do not possess a metabolism and therefore depend on the infection of a host 
cell for replication. Viral particles consist of a short sequence of nucleic acids (DNA or RNA) that carry 
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the viral genetic information and, in most cases, are surrounded by an individually adapted protein 
envelope. The common goal of all viruses is the rapid replication of this genetic information and the 
formation of new virus particles. However, the host cell tools required for this are located inside the cell, 
so that viruses depend on the uptake into the cell for a successful reproduction. At the same time, many 
viruses are oftentimes specialized on individual cell types due to their transmission and reproduction 
pathway and therefore additionally rely on a prior recognition of the respective target cell. Numerous 
viruses therefore use membrane-bound receptor proteins both for cell identification and for 
internalization by endocytosis. In doing so, they usually harness already existing transport pathways and 
thus achieve a highly effective cell uptake without provoking possible host cell defense reactions.6 
For example, the uptake of cholesterol into the cell interior of hepatocytes occurs through attachment to 
low-density lipoprotein (LDL), which in turn binds to the LDL receptor and is transported into the cell 
by the latter. The hepatitis C virus uses this transport process, which is essential for the cell, to penetrate 
hepatocytes by also binding to the LDL receptor with the aid of its specially structured viral envelope. 
However, as almost all other cells also express this receptor, the virus would be unable to specifically 
recognize hepatocytes merely by the attachment to this surface structure. In order to still be selectively 
taken up by the target cell, hepatitis C, like many other viruses, uses the already described concept of 
"chemical aiming".7  
It does this by using additional, well-defined chemical structures to sequentially scan the cell surface for 
the presence of specific receptors or enzymes. In each case, binding to the next structure requires 
successful binding to a previous structure. The procedure is thereby similar to a cascade of "if-then" 
decisions used in programming algorithms. In total, the hepatitis C virus binds to at least 4 other 
membrane-bound receptors before internalization ultimately occurs. To make these sequential logical 
decisions, the virus "programs" its interface. Strictly defined chemical structures are used by the virus 
for each of its decisions as to whether the appropriate "chemical lock" for the respective "chemical key" 
is present on the cell membrane under investigation. Only in case of success, i.e. a logical "yes", the 
next key is shown.  
Viral targeting thus not only means the use of several specific molecular interactions for cell recognition, 
but at the same time the strict control of their sequence. It presupposes that the chemical makeup of the 
virus particle's surface enables it to interact with biological interfaces and change its surface structure in 
a success-dependent manner, thereby making multiple if-then decisions. 
Human adenoviruses have a particularly sophisticated form of this recognition and infection principle, 
which can cause, among other things, mild to moderate respiratory diseases. In a highly selective 
multistep process, adenoviruses bind various membrane receptors of the cell to be infected and even 
move along the cell surface together with the already bound receptors (Figure 1).8 
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Figure 1. Cell recognition and uptake of human adenovirus type 2 (AdV2). Initially, AdV2 attaches to the 
membrane-anchored coxsackie and adenovirus receptor (CAR) via button-like end linkers of fiber proteins that 
protrude from the virus capsule (capsid). The "docked" virus then moves laterally along the cell membrane together 
with the CAR (lateral drift), now presenting a previously shielded protein structure integrated into the viral 
envelope. Only if this recognition sequence can bind the αvβ3-integrin, receptor-mediated endocytosis occurs. As 
a consequence, the virus is taken up into the cell interior together with the bound receptors in a newly formed 
endosome. Further virus-induced reactions eventually lead to the rupture of the endosome and the entry of the viral 
capsid into the cytosol. Finally, the viral capsid opens and releases the previously protected viral genetic 
information in the form of a linear DNA strand. This DNA is finally introduced into the nucleus of the infected 
cell, where it is amplified by the cell's own enzymes, ultimately leading to the formation of new virus particles. 
 
Inspired by the highly complex infection strategy of AdV2, the goal of this work was trying to transfer 
described adenoviral traits to a NP system, which should also be able to identify target cells by means 
of a programmed sequence of different recognition steps.  
The physiological focus of research was thereby in the area of the kidney, where - in the context of a 
targeted treatment - drug-loaded NPs should reach renal mesangial cells. These play a crucial role in the 
filtration apparatus of the kidney by maintaining the structure of the vascular tangles (glomeruli) 
embedded in the mesangium, in which the continuous filtration of blood takes place.9,10 However, a 
plethora of diseases such as diabetes can cause severe pathological changes within the complex 
microarchitecture of these glomeruli, whereby mesangial cells act as a key player in facilitating a pro-
fibrotic turnover of various extracellular matrix components as well as interacting with glomerular 
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endothelial cells and podocytes.11 Caused by these pathological changes, the kidney progrediently loses 
its filtrating function, which in the worst case can lead to an irreversible renal failure.12  
Although a wide range of drugs exist, that would possess a high therapeutic potential in the context of 
described diseases, they oftentimes do not sufficiently reach mesangial cells due to disadvantageous 
physicochemical properties or an unfavorable distribution in the organism. Selective treatment of 
mesangial cells with targeted and drug-loaded nanoparticles could therefore offer a decisive advantage 
over currently available therapeutic options.13  
To make this possible, the surfaces of the designed NPs, i.e. the interfaces between the particles and 
their cellular environment, must be capable of selectively distinguishing mesangial cells from other cells 
in vivo. The nanotherapeutic approach of this work was thereby to create NPs that, like the above-
described viral models, scan the surface of potential target cells for relevant recognition structures in 
order to decide whether or not to induce endocytosis. Therefore, a ligand-mediated strategy of a 
sequential mesangial cell recognition was established. 
The concept is based on an initial binding to angiotensin II receptor type 1 (AT1r), a membrane-bound 
protein that is increasingly present on the cell membrane of mesangial cells in the course of described 
renal diseases.13,14 The NP-cell contact is thereby enabled by AT1r inhibitor EXP3174, which is 
covalently attached to the particle surface. This allows the particles to bind to the cell membrane via the 
receptor, however without an immediate uptake due to the antagonistic features of the ligand. 
For a subsequent mesangial identity verification including final cell endocytosis, the integrin receptor 
αvβ3 already described above for AdV2 infection was selected, as it is also present on the surface of 
mesangial cells. For integrin recognition, the nanoparticles were therefore equipped with a cyclic amino 
acid sequence (cRGDfK), whose binding to the αvβ3 receptor initiates particle uptake. However, to 
enable the mandatorily stepwise recognition process, cRGDfK was attached in closer proximity to the 
particle core, thus spatially shielded and initially not visible for the receptor (steric shielding effect). 
The first focus of the project lay in the manufacturing process of a NP species that was equipped with 
above-described ligands and could actually present them in a sterically controlled manner (Chapter 3). 
In this regard, all necessary polymeric components were initially synthesized to form hetero-multivalent 
block co-polymer nanoparticles functionalized with EXP3174 as well as cRGDfK. In a next step, the 
impact of both ligands to bind the AT1r and subsequently induce integrin-mediated endocytosis was 
assessed. Here, a central aspect lay in the confirmation of a sequential ligand presentation via the 
described steric shielding concept. After testing the mesangial cell specificity of resulting NPs in an in 
vitro co-culture assay with two off-target cell types, the robustness of the NP system to reach mesangial 
sites was finally assessed in a more realistic in vivo setting.  
In this regard, it became obvious that the intravascular transport of NPs after a systemic administration 
also plays a decisive role for the ligand-receptor interaction of NPs, the above-described shielding 
concept as well as an unfavorable off-target deposition in vascular endothelial cells. Therefore, an in 
vitro system of endothelial cell culture and subsequent NP incubation under more realistic dynamic flow 
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conditions was implemented to study the impact on the described virus-mimetic approach (Chapter 4). 
In this context, NPs with varying compositions of cRGDfK targeting and shielding elements were 
manufactured and analyzed regarding their interaction with endothelial cells under different flow 
conditions.  
Finally, the successfully tested adenovirus-mimetic NP system was loaded with cinaciguat (CCG), an 
activator of the soluble guanylate cyclase (sGC), which had previously shown great potential in the 
therapy of renal pathologies such as diabetic nephropathy (Chapter 5).15,16 Therefore the optimal 
parameters for an efficient and reproducible encapsulation process were initially determined. It was then 
tested whether resulting NPs still provided the necessary mesangial targeting features and drug-loaded 
NPs were subsequently analyzed for their capacity to potentiate the pharmacological effect of 
encapsulated CCG via a drug delivery effect. Finally, a TGF-β induced fibrosis model was implemented, 
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Viral infection patterns often rely on precisely coordinated sequences of distinct ligand-receptor 
interactions, leading in many cases to an outstanding target cell specificity. A successful mimicry of 
viral targeting strategies to create more site-specific nanoparticles (NPs) would therefore require 
particle-cell interactions to also be adequately controllable. In the present study, hetero-multivalent 
block-copolymer NPs present their attached ligands in a sterically controlled manner to create a 
sequential NP-cell interaction similar to the cell infiltration strategy of human adenovirus type 
2.Targeting renal mesangial cells, particles thereby initially bind angiotensin II receptor type 1 (AT1r) 
on the cell surface via a structurally flexible AT1r antagonist. After a mandatory spatial approach, 
particle-endocytosis is realized via binding of immobile αVβ3 integrins with a previously concealed 
secondary ligand, thereby creating a stepwise particle-cell interplay of primary NP attachment and 
subsequent uptake.Manufactured adenovirus mimetic NPs show great avidity for both target motifs in 
vitro, leading to a substantial binding as well as subsequent cell uptake into target mesangial cells. 
Additionally, steric shielding of secondary ligand visibility leads to a highly controllable, sequential 
ligand-receptor interaction, whereby hetero-functional NPs activate mesangial cell surface integrins 
only after a successful prior binding to the AT1r. This stepwise cell identification significantly enhances 
mesangial cell specificity in co-culture assays with different off-target cells. Additionally, described 
NPs display excellent in vivo robustness by efficiently accumulating in the mesangium upon injection, 









































Nanomaterials for biomedical applications suffer in many cases from poor availability at the intended 
site of action.1–3 A paradigm shift in material design can help to overcome poor target cell specificity, 
which has been identified as one of the main impediments for successful targeting.4,5 In this context, 
viruses can serve as a valuable template since they are endowed with the paramount ability to distinguish 
between off-target and target cells.6–8 For a successful transfer of this target specificity to novel 
nanoparticulate approaches, it is crucial to investigate the underlying structural characteristics of viruses 
and integrate them into the process of nanoparticle (NP) development. As most viral particles comprise 
of a multitude of targeting elements, equipping NPs with more than one targeting ligand as well could 
thereby be a viable option. However, most viral cell recognition strategies show a considerable level of 
complexity with a highly orchestrated sequence of consecutive binding events to a multitude of cell 
surface structures.9–12 Taking this into consideration, virus-mimetic nanomaterials should ideally also 
comprise targeting elements, whose course of interaction with their target structures is adequately 
controllable.13,14 While many approaches using multi-ligand NP systems already exist15–17, our focus lay 
not only on the manufacture of NPs with two different ligands, but the precise steerability of ligand-
receptor interactions, which, in our view, is crucial for the described viral target specificity. 
In that context, we recently presented influenza A mimetic NPs, that were enzymatically activated by a 
target cell ectoenzyme, thereby unveiling an additional ligand that triggered particle endocytosis via 
contact with its cell membrane receptor. This conditional and sequential target-cell recognition process 
led to a highly specific cell uptake in vitro, even in the presence of a 10-fold surplus of off-target cells.18 
In a follow-up study, we refined these enzymatically activated NPs to reach mesangial cells in vivo.19 
The mesangium was selected as target with respect to its prominent role within the glomerulus as well 
as in the development of diabetic nephropathy and other related kidney diseases.20–23  In this context, 
NPs accumulating in mesangial cells could possibly offer a starting point for a more rational therapy 
compared to the currently predominant gold standard, which is mainly based on control of blood 
pressure and glucose levels.24 Even though the influenza A mimetic concept resulted in an excellent NP 
accumulation in the mesangium, its underlying principle mandatorily requires the presence of an 
ectoenzyme on the cell of interest and thus, is not broadly applicable to cells and tissues lacking 
respective enzymes. 
Trying to overcome this major constraint, we were looking for a more versatile mechanism of endowing 
hetero-multivalent NPs with the ability to sequentially bind a multitude of distinct cell surface structures. 
In that context, we decided to mimic human adenovirus type 2 (AdV2) as a biological model. In order 
to infiltrate possible target cells, AdV2 initially binds to the coxsackievirus and adenovirus receptor 
(CAR) via its terminal fiber knobs.25–27 The laterally flexible virus-receptor complex then performs 
drifting motions alongside the cell membrane until it binds immobile integrins via its penton base RGD 
motif that finally triggers clathrin-mediated endocytosis.28 We were particularly interested in the  
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adenoviral infiltration strategy, as the initial virus-cell interactions do not involve any processing or 
enzymatic conversion of the virus, as it would be the case for above described influenza viruses or also 
SARS-CoV-2.29 Additionally, the primary CAR binding does not initiate any endocytotic mechanisms, 
but merely facilitates attachment to the cellular surface. To our estimation, this sequential process of 
primary attachment and subsequent uptake is highly promising to further increase target specificity of 
nanomaterials. Trying to integrate this stepwise process into a robust NP system, the  starting point of 
our considerations was, that the visibility of ligands tethered to a NP surface can be readily controlled 
by altering the ligand density, the linker length as well as the physical composition of the NP surface.19,30 
We therefore hypothesized, that the intended stepwise particle-cell interaction could be achieved by 
sterically controlling the ligand-receptor binding events. To facilitate initial attachment to the cellular 
surface, we decided to use EXP3174, a losartan metabolite and potent blocker of the angiotensin II 
receptor type 1 (AT1r), which is known to be significantly upregulated in mesangial cells during various 
kidney pathologies such as diabetic nephropathy.22,31 Due to its antagonistic features, EXP3174 should 
merely facilitate initial NP binding to AT1r, yet without immediate induction of uptake.32 Based on the 
above described adenoviral cell infiltration, cRGDfK (cyclo Arg-Gly-Asp-D-Phe-Lys), a well-
established αVβ3 integrin agonist, was chosen to initiate integrin-mediated particle uptake of previously 
bound NPs.33–35 
To enable primary AT1r binding, EXP3174 was tethered to longer block-copolymer chains, leading to 
the desired flexibility and consequently high availability of the AT1r antagonist. cRGDfK, in contrast, 
was bound to shorter block-copolymer strands and therefore only able to reach αVβ3 integrins after a 
mandatory first AT1r binding and subsequent spatial approach of the NP to the cell membrane (Figure 
1). This shielding of the second ligand should not only lead to described sequential particle-cell 
interaction, but also prevent premature exposition to integrin-positive off-target sites such as angiogenic 
endothelial cells or macrophages.36  
To investigate the feasibility of this recognition strategy, we used the same poly(ethylene glycol)-
poly(lactic acid) (PEG-PLA) block-copolymer NP design and same target tissue as for our influenza A 
mimetic concept. By doing so, we excluded any impact of unspecific factors such as differences in 
geometry or surface composition on the results.37–39  
In the present study, we first evaluated the validity of our targeting strategy in vitro, using mesangial 
cell mono-cultures, as well as co-cultures that additionally comprised a major fraction of off-target cells. 
In a follow-up in vivo experiment, adenovirus mimetic NPs were then tested for efficient accumulation 
in mesangial areas within the glomerulus (Figure S1), which should act not only as an adequate 
benchmark to compare our previous and new targeting concept but also as a prerequisite for a future 
NP-based treatment of mesangial cells.  
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Figure 1. Adenovirus mimetic NPs enter glomerular mesangial cells via a sterically controlled and thus sequential 
particle-cell interaction. NPs thereby initially bind the AT1r via EXP3174. After a subsequent spatial approach of 
the NP, αVβ3 integrin-mediated endocytosis is finally triggered via previously concealed cRGDfK. 
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2 Materials and Methods 
2.1 Materials 
Heterobifunctional hydroxyl poly(ethylene glycol)carboxylic acid with a molecular mass of 2000 and 
5000 g mol-1 (COOH-PEG2k/5k-OH) and hydroxyl poly(ethylene glycol)Boc-amine with a molecular 
mass of 2000 g mol-1 (Boc-NH-PEG2k-OH) were purchased from Jenkem Technology USA Inc. (Allen, 
TX, USA) while methoxy poly(ethylene glycol)with a molecular mass of 5000 g mol-1 (MeO-PEG5k-
OH) and Resomer RG 502 (PLGA, lactide:glycolide 50:50; molecular mass 13,400 g mol-1) were 
obtained from Sigma-Aldrich (Taufkirchen, Germany). EXP3174 (also known as losartan carboxylic 
acid) was purchased from Santa Cruz (Heidelberg, Germany), while cyclic RGDfK (cRGDfK) was 
obtained from Synpeptide Co. Ltd. (Shanghai, China). AlexaFluorTM 568 Hydrazide (Alexa568), 
CellTrackerTM Green Dye (CTG) and CellTrackerTM Deep Red Dye (CTDR) were purchased from 
Fisher Scientific GmbH (Schwerte, Germany).  
Amine-functionalized spherical gold NPs with an average diameter of 2.2 nm (Au2.2-NH2) were obtained 
from Nanopartz Inc. (Loveland, CO, USA). GoldEnhanceTM EM Plus kit was purchased from 
Nanoprobes (Yaphank, NY, USA). Goat-derived Integrin α-8 antibody was obtained from R&D 
Systems (Minneapolis, MN, USA). All other chemicals were purchased from Sigma-Aldrich in 
analytical grade if not stated differently. Ultrapure water was obtained from a Milli-Q water purification 
system (Millipore, Billerica, MA, USA). 
Rat-derived mesangial cells (rMCs) were a kind gift from Prof. Dr. Armin Kurtz (Institute of Physiology, 
University of Regensburg, Regensburg, Germany). NCI-H295R (CRL-2128) and HeLa (CCL-2) cells 
were purchased from ATCC (Manassas, VA, USA). All cell lines were cultured in RPMI 1640 medium 
containing 10 % fetal bovine serum, Insulin-Transferrin-Selenium (ITS) (1x) and 100 nM 
hydrocortisone. AT1r-YFP rMCs were generated by transfecting rMCs with a plasmid encoding the 
AT1r with a YFP-tag (CXN2-HA-AT1R-YFP), using Lipofectamine 2000 according to manufacturer´s 
instructions and as previously described.19 For culture of AT1r-YFP rMCs, RPMI1640 medium was 
additionally supplemented with geneticin (600 µg mL−1). 
 
2.2 Polymer synthesis 
COOH-PEG2k-PLA10k, Boc-NH-PEG5k-PLA10k and MeO-PEG5k-PLA10k block copolymers were 
synthesized via a ring-opening polymerization as previously described.37,40 In brief, heterobifunctional 
PEG polymers (1 equivalent = equiv) were mixed with 3,6-dimethyl-1,4-dioxane-2,5-dione (70 equiv) 
and 1,8-diazabicylo [5.4.0] undec-7-ene (3 equiv). The polymer mixture was stirred for 1 hour (h) at 
room temperature (RT) until polymerization was quenched with benzoic acid (14 equiv). Resulting 
block-copolymer was precipitated in diethyl ether, isolated via filtration and dried under  vacuum.
Molecular weight of synthesized polymers was determined in deuterated chloroform at 295 K using a 
Bruker Avance 300 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany). 
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For preparation of cRGDfK-PEG2k-PLA polymers, previously synthesized COOH-PEG2k-PLA10k was 
covalently coupled to the lysine residue of cRGDfK as shown before.30,41 In short, COOH-PEG2k-PLA10k 
(1 equiv) was activated using 3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine (EDC)/ N-
hydroxysuccinimide (NHS) (25 equiv) for 2 h at RT, followed by quenching with β-mercaptoethanol 
(BME) (30 equiv). Activated polymer was reacted with cRGDfK (3 equiv) and N,N-
diisopropylethylamine (DIPEA) (10 equiv) for 24 h at RT. After precipitation of resulting cRGDfK-
coupled polymer in diethyl ether/methanol (15:1 v/v), free cRGDfK and excess reactants were removed 
using dialysis against Millipore water (mpH2O).  
For EXP3174-PEG5k-PLA10k, the Boc-protecting group of Boc-NH-PEG5k-PLA10k was initially cleaved. 
In brief, Boc-protected polymer was dissolved in dichloromethane (DCM)/trifluoroacetic acid (TFA) 
(1:1 v/v). After stirring for 30 min (min), excess TFA was neutralized using a saturated sodium hydrogen 
carbonate solution. The organic phase was washed with mpH2O, followed by polymer isolation as 
described above. 
Resulting NH2-PEG5k-PLA10k was coupled to EXP3174 via the carboxylic acid residue of the imidazole 
component. EXP3174 (3.5 equiv) was activated with N,N'-dicyclohexylcarbodiimide (DCC)/NHS (3.3 
equiv) for 2 h at RT. After removal of resulting dicyclohexylurea via centrifugation, NH2-PEG5k-PLA10k 
(1 equiv) and DIPEA (17.5 equiv) were added and reacted for 24 h at RT. Resulting EXP3174-PEG5k-
PLA10k was precipitated in methanol/diethyl ether (1:5 v/v) and the product was dialyzed against 
ethanol/100mM borate buffer pH 8.5/water (1/1/8 v/v) for 24 h followed by mpH2O for 12 h to remove 
unreacted EXP3174 and excess reactants.  
 
2.3 PLGA labeling with fluorescent dyes 
For particle visualization, the core forming PLGA was covalently linked to fluorescent dyes prior to NP 
preparation. To that end, carboxylic acid-terminated PLGA was activated for 2 h using 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) as a catalytical agent. 
Activated PLGA was then reacted either with AlexaFluorTM568 Hydrazide or CFTM 647 amine for 24 h 
at RT. Labeled PLGA was dialyzed against mpH2O for 24 h to remove unreacted fluorescent dyes. 
 
2.4 PLGA labeling with nanogold 
For electron microscopy analysis, PLGA was conjugated to nanogold according to a method that was 
previously established by our group.42 PLGA was initially activated with EDC and NHS for 2 h in DCM. 
After DCM removal under reduced pressure, activated PLGA was dissolved in DMSO and mixed with 
DIPEA and lyophilized monoamino gold NPs with an average diameter of 2.2 nm (Au2.2-NH2). After 
stirring at RT for 24 h, gold-conjugated PLGA was precipitated in mpH2O, isolated via centrifugation 
at 2500g for 10 min and lyophilized. 
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2.5 NP preparation 
Block-copolymer NPs were manufactured using a common solvent evaporation technique. 
Corresponding amounts of PEG-PLA polymers and PLGA were mixed at a ratio of 70/30 (m/m) and 
diluted in acetonitrile (ACN) to a final concentration of 10 mg mL-1. To reach the desired ligand surface 
density for hetero-/homo-functional NP species, cRGDfK-PEG2k-PLA and/or EXP3174-PEG5k-PLA10k 
were mixed with COOH-PEG2k-PLA10k according to the calibration depicted in Figure S2 g/h. The 
organic phase was then added dropwise to vigorously stirring 10 % Dulbecco's Phosphate-Buffered 
Saline (DPBS) (v/v) (7.5 mM, pH 7.4) and stirred for 3 h at RT to remove the organic solvent.  
Resulting NP dispersions were concentrated via centrifugation at 1250g for 25 min using Pall Microsep 
filters (molecular weight cut-off 30 kDa; Pall Corporation, NY, USA).  To obtain the mass concentration 
of manufactured NPs, a method previously introduced by our working group was used.30 In brief, PEG 
content was assessed using a colorimetric iodine complexing assay.43 NPs were then lyophilized and 
gravimetrically analyzed to obtain the ratio of PEG content and NP weight. In the following 
experiments, this ratio was used to calculate mass concentration from the assessed PEG content for each 
NP species. The molar NP concentration was calculated as described before19, taking into account the 
NP mass concentration, an estimated NP density of 1.25 g cm-3 44 as well as the NP diameter assessed 
by dynamic light scattering measurements, assuming a spherical NP shape. 
 
2.6 NP characterization  
NP size and zeta potential was evaluated using a Malvern Zetasizer Nano ZS (Malvern, Herrenberg, 
Germany). Samples were measured with a 633 nm He-Ne laser at an angle of 173° (25 °C, RT) in 7.5 
mM DPBS, using either PMAA semimicro cuvettes (DLS; Brand, Wertheim, Germany) or folded 
capillary cells (zeta potential; Malvern, Herrenberg, Germany), respectively. For stability analysis, NPs 
were prepared as described above and incubated for 24 h at 37°C in DPBS as well as RPMI 1640 medium 
containing 10 % fetal bovine serum. At the displayed time points, a sample was taken, and the size was 
evaluated as described above. 
 
2.7 cRGDfK quantification 
The level of cRGDfK on the NP surface was assessed using a previously described method that is based 
on the measurement of arginine.35 In brief, 50 µL of NP samples (1 mg mL-1) were mixed with 175 µL 
of a working solution consisting of  9,10-phenanthrenequinone (150 µM in ethanol) and 2 N NaOH (6:1 
v/v). After 3 h of incubation at 60 °C, 1 equiv of sample was mixed with 1 equiv of 1 N HCl and 
incubated for another 1 h at RT. Finally, fluorescence was measured at a Synergy™ Neo2 Multi-Mode 
Microplate Reader (BioTek Instrument Inc., Winooski, VT, USA) with an excitation wavelength of 
312/7 nm and an emission wavelength of 395/7 nm. Dilutions of cRGDfK (0-40 µg mL-1) served as 
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calibration. cRGDfK molarity as well as the ratio of molar cRGDfK content and molar PEG content 
were determined and plotted against the theoretical value (Figure S2h).  
 
2.8 EXP3174 quantification 
To determine the surface level of EXP3174 on manufactured particles, 1 equiv of NP samples (1 mg 
mL-1) was mixed with 10 equiv of 0.2 M acetic acid. Dilutions of EXP3174 in 0.2 M acetic acid (0-30 
µM) served as calibration. Fluorescence of samples and standards was measured at a Synergy™ Neo2 
Multi-Mode Microplate Reader (see above) (excitation 250/ 10 nm, emission 370/5 nm). EXP3174 
molarity as well as the ratio of molar EXP3174 content and molar PEG content was determined and 
plotted against the theoretical value (Figure S2g). 
 
2.9 Calcium mobilization assay 
In order to investigate AT1r binding of NPs, intracellular calcium levels were measured using fura-2 as 
a Ca2+ chelator as previously described by our working group.45 In brief, rMCs were incubated with 5 
µM fura-2AM, 2.5 mM probenecid and 0.05 % Pluronics F-127 in Leibovitz´s L-15 medium for 1 h at 
RT. Cells were thereafter centrifuged (5 min, 200g, RT) and resuspended in Leibovitz´s medium. 45 µL 
of NPs or free EXP3174 at different concentrations were pipetted into 96-well plates (Greiner Bio One, 
Frickenhausen, Germany), followed by 45 µL of rMC suspension (2 x 106 cells mL-1). In the following, 
cells were incubated with samples for 45 min at RT. After incubation, 10 µL of 30 nM AT II was added 
to each well to activate uninhibited AT1r and consequently induce Ca2+ influx into the cell cytosol. 
Fluorescence signal during the first 30 seconds after injection was measured using a FluoStar Omega 
fluorescence microplate reader (BMG Labtech, Ortenberg, Germany) with excitation filters at 340/20 
nm and 380/20 nm and the emission filter at 510/20 nm, respectively. Maximal ratio of Ca2+ - bound to 
Ca2+ - unbound Fura-2 was evaluated by incubating loaded cells with 0.1 % Triton-X 100 and measuring 
fluorescence levels as described above. Analogously, minimal ratio was achieved by incubation with 
0.1 % Triton-X 100 combined with 45 mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA). Levels of intracellular calcium per sample was calculated using the equation 
of Grynkiewicz et al.46 Half maximal inhibitory concentrations (IC50) were calculated using GraphPad 
Prism (San Diego, CA, USA) and applying a sigmoidal dose-response equation (variable slope). 
 
2.10 CLSM analysis 
For a detailed analysis of NP-cell interaction, either rMCs or AT1r-YFP rMCs were seeded into 8-well 
slides (Ibidi, Gräfelfing, Germany) at a density of 15,000 cells well-1 and incubated for 24 h at 37 °C. In 
order to facilitate visualization of the cell cytosol, cells were stained with CTDR (25 µM, 45 min, 37 
°C) in serum-free RPMI 1640 medium prior to seeding. NPs were manufactured using AlexaFluorTM 
568-labeled PLGA and adjusted to 0.05 mg mL-1 in Leibovitz`s buffer supplemented with 0.1 % bovine 
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serum albumine (BSA). Mesangial cells were incubated with 250 µL of NPs for 15, 45 and 90 min at 
37 °C, washed with prewarmed DPBS and fixed with 4 % paraformaldehyde (PFA) in DPBS for 10 
min. AT1r-YFP rMCs were additionally stained for cell nuclei with a 1:200 dilution of 4′,6-Diamidine-
2′-phenylindole dihydrochloride (DAPI) in DPBS. After a final washing step, fixed samples were 
analyzed using a Zeiss LSM 710 (Carl Zeiss Microscopy GmbH, Jena, Germany). 
 
2.11 Flow cytometry 
To assess mesangial cell association of NP samples, rMCs were seeded into 24-well plates (Greiner Bio 
One, Frickenhausen, Germany) at a density of 40,000 cells well-1 and incubated for 48 h at 37 °C. NPs 
were manufactured using CFTM 647-labeled PLGA and adjusted to 0.05 mg NP mL-1 in Leibovitz´s 
buffer supplemented with 0.1 % BSA. To confirm αVβ3-dependence of NP cell entry, 300 µL of free 
cRGDfK (c = 500 µM) were added to the relevant cell samples for 15 min prior to NP incubation. Cells 
were washed with DPBS and 300 µL of prewarmed NP solutions were added for 45 min at 37 °C. For 
respective analysis of time-dependent uptake, cells were incubated over a time period of 120 min with 
NPs being removed after 0, 15, 30, 45, 60, 90 and 120 min. Cells were washed with DPBS, trypsinized 
and centrifuged for 5 min at 200g and 4 °C, followed by two further washing and centrifugation steps 
(DPBS, 200g, 5 min, 4 °C). Final samples were resuspended in DPBS and analyzed using a FACS 
Calibur cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). NP-associated fluorescence was 
excited at 633 nm and corresponding emission was recorded (661/16 bandpass filter). Flow cytometry 
data was analyzed using Flowing software 2.5.1 (Turku Centre for Biotechnology, Turku, Finland). 
Within the population of viable cells, geometric mean of cell-associated fluorescence was evaluated.  
 
2.12 Transmission electron microscopy 
To evaluate the cellular localization of NPs, rMCs were seeded into a 24-well plate at a density of 12,000 
cells well-1 and incubated for 72 h. NP formulations containing nanogold-conjugated PLGA were diluted 
in Leibovitz`s buffer containing 0.1 % BSA and added for 45 min at a concentration of 0.05 mg mL-1 
(V = 300 µL). After incubation, samples were washed with DPBS and prepared for electron microscopy 
analysis according to a pre-established protocol of our working group.42 In brief, cells were fixed with 
2.5 % PFA and 2.5 % glutaraldehyde in a 0.1 M sodium cacodylate solution (Caco buffer) for 60 min at 
RT, washed with Caco buffer and permeabilized with 0.1% Triton-X in DPBS for 10 min. After a 
washing step with mpH2O, samples were gold enhanced using a GoldEnhanceTM EM Plus kit 
(Nanoprobes Inc., Yaphank, NY, USA) according to the manufacturer´s specifications, followed by 
further washing and post-fixation in a 2.5 % sodium thiosulfate solution in mpH2O. Cells were stained 
with 0.5 % osmium tetroxide and dehydrated in rising concentrations of ethanol (50 – 99.5 %). For 
counterstaining, 2 % uranylacetate was applied for 5 min at 70 % ethanol concentration. After 
embedding in Epon, ultrathin sections of 150 nm were imaged using a 100 kV Zeiss Libra 120 electron 
microscope (Carl Zeiss NTS GmbH, Oberkochen, Germany) at a magnification of 6300x as well as 
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12,500x. For exact analysis of the NP size without gold-tag, EXPcRGD NPs were manufactured in 
mpH2O as described above and adjusted to 50 μg mL−1. Samples were thereafter pipetted onto carbon-
coated copper grids (300 mesh; Plano, Wetzlar, Germany) and incubated for 2 min. Excess NPs were 
removed with a filter paper, the grids were negatively stained with 1 % uranyl acetate solution and stored 
in a desiccator until TEM analysis.  
 
2.13 Co-culture experiments 
In order to assess cell specificity of manufactured NPs, we used a co-culture design that had been 
previously implemented by our group.18 For mono-culture NP uptake (Figure 6b), pre-seeded rMCs, 
NCI-H295-R or HeLa cells were incubated for 45 min with different CFTM 647-labeled NP types. Cell 
uptake was then assessed using flow cytometry as described above.  
For co-culture analysis, rMCs were seeded together with HeLa or NCI-H295R cells in 24-well plates at 
a density of 10,000 and 50,000/100,000 cells well-1 respectively and incubated for 48 h at 37 °C. To 
differentiate between cell types, rMCs were stained with CTG (15 µM, 45 min, 37 °C) in serum-free 
RPMI 1640 medium prior to seeding.  
Co-cultured cells were then incubated with CFTM647-labeled NPs at a concentration of 0.05 mg mL-1 
(V = 300 µL) for 45 min. Preparation of samples and flow cytometry analysis was performed as 
described above. Additionally, rMC-associated fluorescence was excited at 488 nm and recorded using 
a 530/30 bandpass filter. During data analysis, the population of viable cells was further gated for stained 
rMC cells and NP-associated fluorescence analyzed concerning cell specificity. 
For CLSM analysis, rMC cells were CTG-stained prior to seeding as described above. To visualize all 
cell types, HeLa or NCI-H295R cells were also stained using CTDR (25 µM, 45 min, 37 °C). After 
CellTrackerTM incubation, rMCs were seeded into 8-well Ibidi slides together with HeLa/NCI-H295R 
cells at a density of 2000 and 10,000/20,000 cells well-1. After 48 h of incubation at 37 °C, cell nuclei 
were stained with Hoechst 33258 (5 µg mL-1 in DPBS) for 20 min. Cells were washed twice with 
prewarmed DPBS and AlexaFluorTM568-labeled NPs were added at a concentration of 0.05 mg mL-1 (V 
= 250 µL) for 45 min at 37 °C. After NP incubation, samples were treated as described above and 
analyzed using a Zeiss LSM 710 microscope. 
 
2.14 In vivo cell targeting 
Animal experiments were performed according to the national and institutional guidelines and were 
approved by the local authority (Regierung von Unterfranken, reference number: 55.2-2532-2-329). 
Female, 10-week-old NMRI mice (Charles River, Sulzfeld, Germany) acted as model animals. After 
analgesia with buprenorphine (0.1 mg kg body weight-1 ), mice were anaesthetized with  isoflurane and 
100 µL of CFTM 647-labeled NPs (c = 120 nM) were injected via the vena jugularis (n = 6 for each NP 
species). Additionally, 100 µL of the free CFTM 647 dye were injected at a comparable concentration 
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(50 µM). Mice were kept in anesthesia and after 5 min, an initial blood sample was taken via i.v. 
puncture. After 60 min, mice were anaesthetized with ketamine/xylazine, a final blood sample was 
taken, and animals were killed via perfusion fixation. Both kidneys were removed and immediately 
transferred to a solution of 18 % sucrose and 1 % PFA in phosphate buffer (0.1 M pH 7.4). After 6 h, 
kidneys were washed with DPBS and cryoprotected at -80 °C until further processing. For cryosections, 
the organs were embedded in Tissue Tek® O.C.T.TM Compound (Sakura Finetek, Torrance, CA, USA), 
cut into 5 µm sections using a CryoStar NX70 cryotome (Thermo Fisher Scientific, Waltham, MA, 
USA) and fixed on SuperfrostTM plus glass slides (Thermo Fisher Scientific, Schwerte, Germany). 
For analysis of NP kidney deposition and glomerular fluorescence quantification, sections were rinsed 
in DPBS and blocked with 5 % BSA supplemented with 0.04 % Triton-X in DPBS for 10 min at RT. 
After further rinsing in DPBS, samples were stained for cell nuclei with a 1:400 dilution of DAPI in 0.5 
% BSA and 0.04 % Triton-X in DPBS. After a final washing step in DPBS and mpH2O respectively, 
cryosections were mounted with Mowiol mounting medium and analyzed at a Zeiss Axiovert 200M.  
For image analysis, Fiji software (Madison, WI, USA) was used. Glomerular fluorescence intensities 
were evaluated by measuring the integrated density of areas over a certain fluorescence threshold and 
division by the respective glomerular area.  
In order to assess the exact cellular location of NPs, kidney cryosections were prepared as described 
above. After washing and blocking of sections, samples were stained overnight at  4 °C with a goat-
derived integrin α-8 antibody (1:200 dilution in 0.5 % BSA/0.04 % Triton-X in DPBS). Samples were 
thereafter washed with DPBS and stained with a 1:400 dilution of Cy2® donkey anti-goat and DAPI in 
0.5 % BSA/0.04  % Triton-X in DPBS for 1h at RT. After a final washing step, samples were mounted 
and analyzed at a Zeiss LSM 710. 
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3 Results and Discussion 
3.1  Preparation of hetero-multivalent EXPcRGD NPs using a modular concept 
In order to create NPs with the desired adenovirus mimetic properties, we implemented a modular design 
that is based on the synergistic combination of different biocompatible polymer components into a 
hetero-multivalent particle species (Figure 2a). Thereby, biodegradable  poly(lactic-coglycolic acid) 
(PLGA) forms a hydrophobic NP core that not only guarantees enhanced structural integrity in aqueous 
media but also allows NP visualization via coupling of fluorescent dyes or nanogold.42,47 PEG-PLA 
block copolymers as second component offer the structural flexibility that is needed in order to 
implement our pursued virus-mimetic NP design.48 In a first step, PEG-PLA polymers with either longer 
(PEG5k-PLA10k) or shorter (PEG2k-PLA10k) PEG chains were synthesized via ring-opening 
polymerization of cyclic lactide (Figure S2a and Figures S3-S6).40   
Since EXP3174 was intended to initially bind the mesangial AT1r as a freely moving ligand, it was 
covalently coupled to the longer and thus more flexible PEG5k-PLA10k chains (Figure S2b). The second 
ligand (cRGDfK), in contrast, should not be able to interact with surface-bound integrins unless a first 
AT1r binding and subsequent spatial approach of the NP has taken place. To that regard, it was attached 
to shorter PEG2k-PLA10k (Figure S2c). NP surface density of both cRGDfK and EXP3174 could be 
tuned precisely by mixing distinct amounts of either ligand-functionalized or non-functionalized PEG-
PLA polymers with PLGA prior to NP manufacture via nanoprecipitation (Figure S2f-h).  
Hetero-functional EXPcRGD NPs as well as homo-functional (EXP NPs/cRGD NPs) and non-
functionalized, methoxy-terminated particles (Control NPs) were manufactured below a size threshold 
of 60 nm (Figure 2b). To our estimation, this size range was optimal for efficient extravasation from 
intraglomerular capillaries to reach mesangial areas, as endothelial fenestrations  have an average 
diameter of 60 - 100 nm.49,50 Stability analysis in DPBS and cell culture medium (Figure 2d/e) as well 
as transmission electron microscopy (TEM) (Figure S2i) showed uniformly shaped NPs with no 
considerable tendency towards aggregation. Addition of unfunctionalized COOH-PEG2k-PLA10k to the 
polymer mix resulted in negative zeta potential values (Figure 2c). These characteristics should help to 
further stabilize NPs and reduce unspecific binding to off-target cells. Also, extended serum protein 
adsorption and subsequent phagocytic clearance should be prevented.37,51 
 




Figure 2. Characterization of different NP species. (a) Particle design of hetero-functional EXPcRGD NPs as well 
as homo-functional (EXP NPs and cRGD NPs) or non-functionalized NP species (Control NPs). (b) Dynamic light 
scattering (DLS) analysis. All particle types were manufactured below a size threshold of 60 nm without 
considerable aggregation. (PDI: polydispersity index.) (c) Zeta potential measurements. (d)/(e) NP stability 
analyzed through DLS measurements. EXPcRGD NPs underwent no significant size variation or aggregation upon 
incubation for 24 h at 37 °C in either (d) DPBS or (e) cell culture medium supplemented with 10 % fetal bovine 
serum. Results represent mean ± SD (n = 3). 
 
 
3.2 Hetero-multivalent EXPcRGD NPs display excellent ligand affinity for target motifs 
While it has been previously demonstrated that homo-functional EXP3174- or cRGDfK-carrying NPs 
can be used to effectively target cell types expressing either AT1r or αVβ352,53, we intended to prove, that 
the merger of both ligands actually results in a hetero-multivalent nanomaterial that synergistically 
combines both ligands' features. We therefore initially evaluated the optimal surface density for each 
ligand to guarantee sufficient AT1r/integrin interaction. In a first step, we prepared homo-functional 
NPs with different ligand densities and performed DLS analysis to exclude any impact of the size-
differences on the later NP-cell interaction. As shown in Figure S7a/b, particle size and quality was 
thereby not significantly altered by the respective ligand density for both cRGD NPs and EXP NPs. We 
then assessed EXP3174-mediated NP binding to the AT1r expressed by rat mesangial cells (rMCs). As 
activation of Gq-coupled AT1r with its primary ligand angiotensin II (AT II) results in a calcium influx 
into the cell cytosol, intracellular Ca2+ levels after AT II stimulation can be used as a marker for AT1r 
activity after NP incubation. Thereby, low receptor activity indicates a high ratio of bound EXP3174, as 
the ligand itself acts as a potent antagonist.31  
Figure 3a shows intracellular Ca2+ levels of AT II-stimulated rMCs that had been pre-incubated with 
EXP3174-functionalized NPs or free EXP3174 for 45 min. Particles thereby carried 25 % of EXP3174 
on their surface, as this functionalization degree had been shown to sufficiently guarantee AT1r binding 
(Figure S7c). Both EXPcRGD NPs (IC50 = 276 ± 31 pM) and EXP NPs (IC50 = 552 ± 73 pM) showed 
excellent AT1r avidity, resulting in a highly effective inhibition of the receptor in the picomolar range 
Chapter 3: Adenovirus-Mimetic Nanoparticles 
85 
 
and consequent minimal intracytosolic Ca2+ levels. Furthermore, inhibition potency of EXP3174-
carrying NP types was even higher than for the free ligand (IC50 = 2.7 ± 0.9 nM). This strongly suggests, 
that EXP3174-functionalized particles were able to interact with the target receptor in a multivalent 
fashion, leading to an overall avidity gain, which was in line with our previous findings.45 As IC50 levels 
of both EXPcRGD and EXP NPs were found to be in the same range, we concluded that the combination 
of both EXP3174 and cRGDfK in one particle type did not significantly interfere with the binding 
capacity of EXP3174 itself. Interestingly, AT1r inhibition potency was thereby even slightly higher for 
EXPcRGD NPs than for homo-functional EXP NPs. To our estimation, this effect was caused by the 
complete and irreversible removal of AT1 receptors from the cell surface due to the cRGDfK-mediated 
endocytosis of AT1r-bound NPs (Figure 1). Consequently, endocytosed receptors could no longer be 
(re)activated, leading to a sharper decrease in Ca2+ influx upon AT II stimulation. Control NPs and cRGD 
NPs did not show any interaction with the AT1r, resulting in a maximal Ca2+ signal upon receptor 
stimulation and confirming the assay´s specificity for the AT1r (Figure S7d). Additionally, intracellular 
Ca2+ levels of AT1r-deficient HeLa cells were minimal upon EXPcRGD NP incubation and AT II 
stimulation, thereby further supporting the AT1r binding specificity of EXPcRGD NPs (Figure S7e).  
Having verified the AT1r binding capacity of adenovirus mimetic EXPcRGD NPs, our next goal was to 
investigate particle uptake into rMCs via cRGDfK-αVβ3 interaction. As for EXP3174, we therefore 
initially evaluated the optimal cRGDfK ligand density for sufficient integrin-mediated NP endocytosis. 
As depicted in Figure S7f, cRGDfK-mediated rMC uptake of cRGD NPs thereby gradually increased 
with higher ligand surface densities. In a next step, we introduced 25 % of longer COOH-PEG5k-PLA10k  
into these cRGDfK-functionalized NPs. This component should enable the above described concept of 
steric hindrance and result in a reduced visibility of the cRGDfK ligand (Figure S8), which was central 
for our approach of a sequential ligand-receptor interplay. As shown in Figure S7g, ligand-mediated 
endocytosis could thereby significantly be reduced for all cRGDfK densities, that we had tested before 
(Figure S7f). For the further course of our studies, we chose to prepare both cRGD NPs and EXPcRGD 
NPs with a cRGDfK density of merely 15 %, as this amount guaranteed a significantly enhanced ligand-
mediated rMC uptake, but could also be sufficiently regulated by addition of respective shielding 
elements. As shown in Figure 3b, we finally compared levels of rMC uptake for the established NP 
compositions. As discussed above, cell uptake of cRGDfK-functionalized NPs could thereby be 
significantly reduced by addition of described shielding elements. Interestingly, addition of an excess 
of free cRGDfK (c = 500 µM) prior to NP incubation led to a comparable decrease in cell uptake of 
unshielded cRGD NPs, thereby both proving αVβ3-dependency of NP uptake and supporting the 
hypothesis, that our shielding concept can equally inhibit ligand-integrin interaction. Remarkably, 
addition of EXP-PEG5k-PLA10k instead of unfunctionalized COOH-PEG5k-PLA10k (EXPcRGD NPs) 
reversed the shielding effect and significantly increased rMC uptake. We therefore concluded, that 
hetero-functional EXPcRGD NPs initially bound the AT1r and subsequently were able to spatially 
approach the cell surface, thereby reaching the endocytosis-mediating integrin. This assessment was 
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further supported by the observation, that addition of free EXP3174 (c = 1 mM) prior to NP incubation 
lead to a sharp decrease of EXPcRGD NP cell uptake, as NPs were no longer able to bind the AT1r and 
approach the rMC surface. To additionally confirm our concept of a sequential ligand-receptor interplay, 
we compared the decrease of AT1r activity of rMCs due to EXP3174-mediated NP binding with the 
cRGDfK-mediated cell uptake of hetero-functional EXPcRGD NPs. As shown in Figure 3c, AT1r 
activity thereby sharply decreased within the first 45 min and subsequently stayed on a minimal level. 
NP uptake, on the contrary, gradually increased with cell-associated fluorescence levels increasing even 
further after 45 min. This contrary time course further proved our assumption, that hetero-functional 
NPs initially bound the AT1r and only then initiated cell uptake via integrin activation. Interestingly, 
AT1r activity slightly increased again at 120 min, which we explained with a possible AT1r recycling 
after completed uptake with bound NPs.  
 
Figure 3. NP interaction with target motifs. (a) Intracellular calcium levels after AT1r stimulation of rMCs treated 
with free or particle-bound EXP3174. Both EXPcRGD NPs (IC50 = 276 ± 31 pM) and EXP NPs (IC50 = 552 ± 73 
pM) effectively bound and thereby inhibited the AT1r. This effect was even stronger than for free EXP3174 (IC50 
= 2.7 ± 0.9 nM. (M = molar concentration of either NPs or free EXP3174.) (b) Flow cytometry analysis of rMC 
uptake for cRGD-carrying NPs. (c) Sequential NP-cell interplay. EXPcRGD NPs initially bound to the AT1r, 
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leading to a drastic decline in AT1r activity via EXP3174 receptor blockade. In contrast, αVβ3-initiated NP uptake 
increased mainly after 45 min.  (d) CLSM analysis of CTDR-stained rMCs after incubation with EXPcRGD NPs. 
Over time, increasing levels of NP-associated fluorescence (purple) could be detected in vesicular structures within 
the rMC cytosol (grey). (Scale bar 20 µm.) (e) Flow cytometry analysis of NP uptake into rMCs over 120 min. 
Hetero-multivalent EXPcRGD NPs showed a substantially increased cell-uptake compared to Control NPs as well 
as homo-functional NPs. Results represent mean ± SD (n = 3).* P < 0.05, *** P < 0.001, **** P < 0.0001. (AFU, 
arbitrary fluorescence units.) 
 
For a better visualization of the time-dependent NP uptake, mesangial cells were incubated with 
fluorescently labeled NPs and the cellular distribution was analyzed via confocal laser scanning 
microscopy (CLSM). To exactly assess the dimensions of the cell body, rMCs were pre-treated with 
CellTrackerTM Deep Red (CTDR). Figure 3d shows strong intracellular accumulation of 
AlexaFluorTM568-labeled EXPcRGD NPs in spherical structures, that represent endocytotic vesicles.54 
Over time, both the number and intensity of visible accumulations increased. Especially between 45 and 
90 min of incubation, vesicles appeared to considerably gain size. These findings demonstrate, that after 
successful AT1r binding, EXPcRGD NPs could efficiently bind to the integrin receptor, triggering 
internalization through integrin-mediated endocytosis and accumulation in intracellular vesicles. It is 
well described in literature, that these endocytic vesicles can fuse to larger endosomes and therefore 
gain size as well as intensity over time.55,56 Finally, we performed flow cytometry analysis of NP-treated 
rMCs and determined the cell-associated fluorescence over an incubation period of 120 min. As shown 
in Figure 3e, levels of NP-derived fluorescence were highest for EXPcRGD NPs compared to all other 
NP species over the entire incubation period. While EXP NPs as well as Control NPs merely showed 
moderate fluorescence signals, substantial levels of cell-association could be detected for cRGD NPs. 
However, respective fluorescence levels reached a plateau after approximately 60 min, while EXPcRGD 
NPs´ cell-association further increased. This strongly supports our hypothesis of a sequential interaction 
between EXPcRGD NPs and their target cell which results in a prolonged increase in fluorescence levels 
compared to homo-functional cRGD NPs.  
 
3.3 Ultrastructural analysis indicates sequential ligand-receptor interplay 
To further verify the concept of sequential AT1r binding and integrin-mediated NP endocytosis, we 
performed time-dependent CLSM analysis of NP interaction with rMCs expressing the AT1r tagged 
with yellow fluorescence protein (AT1r-YFP rMCs). Figure 4a thereby shows a significant 
accumulation of EXPcRGD NPs in intracellular vesicles over time, which was similar to the results 
depicted in Figure 3d. Additionally, AT1r-derived fluorescence considerably increased and intensified 
in also mainly spherical structures. While cRGD NPs showed a comparable intracellular accumulation 
with increasing incubation times (Figure 4b), no considerably enhanced AT1r signal could be detected. 
For a better visualization of observed differences, we assessed the exact localization of both NP-
associated and AT1r fluorescence after 45 min of incubation. As depicted in Figure 4c, signals for 
EXPcRGD NPs and the AT1r were thereby exactly colocalized, indicating, that these hetero-functional 
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NPs had initially bound the AT1r and only then initiated integrin-mediated endocytosis, leading to an 
uptake of both EXPcRGD NPs and bound AT1r into spherical endocytotic vesicles (Figure 1). Homo-
functional cRGD NPs, on the contrary, merely bound the integrin and thereby initiated cell uptake, 
however without any interaction with the AT1r, whose fluorescence signal accordingly was not 
colocalized to a significant extent (Figure 4d). As a control, we additionally analyzed NP-cell 
interaction for cRGDfK-lacking EXP NPs and Control NPs (Figure S9). 
While Control NPs did not show any significant rMC uptake or changes in AT1r signal over time (Figure 
S9b), considerable EXP NP-derived fluorescence was visible, however mainly located on the cell 
surface. This NP-associated fluorescence was colocalized with AT1r clusters, that had formed as a 




Figure 4. CLSM analysis of NP uptake (red) in rMCs (grey) transfected with YFP-tagged AT1r (green). (a) Time-
dependent uptake of EXPcRGD NPs. Signals for both EXPcRGD NPs and AT1r-YFP significantly increased with 
longer incubation times. Fluorescence thereby intensified in mainly spherical structures, indicating AT1r clustering 
and subsequent NP/AT1r endocytosis. (b) Time-dependent uptake of cRGD NPs. While cRGD NP-associated 
fluorescence increased similarly to (a), no considerable change in AT1r-YFP signal could be detected. (c) 
EXPcRGD NP /AT1r localization after 45 min. Fluorescence signals for EXPcRGD NPs and the AT1r were 
exactly colocalized (yellow merged regions), proving NP-AT1r binding and subsequent endocytosis. (d) cRGD 
NP/AT1r localization after 45 min. cRGD NP-associated fluorescence showed no considerable colocalization with 
the AT1r signal, indicating an AT1r-independent uptake of NPs. (Scale bar 20 µm. Smaller images show zoomed-
in view of the white boxes above.) 
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Finally, TEM analysis was performed to assess NP-cell interactions at an ultrastructural level.57–59 
Thereby, we used a NP labeling concept that we had recently established. In order to increase electron 
density and consequential TEM visibility of applied NPs, ultrasmall gold NPs with an average diameter 
of 2.2 nm were covalently coupled to PLGA which was then used for further NP manufacture (Figure 
S10a). Mesangial cells, that were incubated with these gold-tagged NPs, could then be gold-enhanced 
in order to intensify and thus visualize the particles´ gold core and assess their exact location. This 
retrospective gold-enhancement offers the substantial advantage that physicochemical characteristics of 
nanogold-labeled NPs do not significantly differ from unlabeled NPs (Figure S10b), which would not 
be the case for commonly used larger gold NPs. 
Figure 5a shows the cell body of two mesangial cells incubated with gold-tagged EXPcRGD NPs. 
Within the cell cytosol, numerous circular vesicles, filled with gold-enhanced NPs, could be detected. 
The distribution pattern showed remarkable similarity to the previously described CLSM results 
(Figures 3c/4), thereby strongly supporting our hypothesis of ligand-mediated NP endocytosis. 
Additionally, a major fraction of particles was present at the cell border, indicating that these NPs were 
still bound to membrane-located surface structures that most likely represent AT1r clusters. These 
findings further indicate that EXPcRGD NPs interacted with the target cell in a stepwise process of prior 
binding to the AT1r and subsequent integrin-mediated endocytosis.  
In accordance with this assessment, EXP NPs lacking the cRGDfK ligand could only be detected at the 
rMC membrane while no significant particle accumulations in endocytotic vesicles were found (Figure 
5b). Additionally, cell-particle association for Control NPs was only marginal (Figure 5c), which was 
also in line with our previous findings. cRGD NPs, in contrast, did accumulate in the rMC cytosol similar 
to EXPcRGD NPs, but showed only marginal binding to the cell surface, as these particles lacked AT1r 
ligand EXP3174 (Figure S11a). Particle-free cells were treated and prepared equally, to demonstrate 





















Figure 5. TEM analysis of NP interaction with mesangial cells. (a) EXPcRGD NPs accumulated in numerous 
vesicular structures (black arrows) within rMCs. Vesicles of differing sizes were present both in outer and inner 
parts of the cell cytosol, indicating intracellular processing and fusing into larger endosomes. Moreover, a 
substantial number of NPs was still located at the cell membrane, suggesting that particle underwent a stepwise 
process of initial cell binding and subsequent endocytosis. (Images on the right show zoomed-in view of black 
boxes on the left.) (b) EXP NPs, in contrast, merely accumulated at the cell border where they bound to distinct 
surface structures of rMCs, indicating a possible interaction with membrane-bound AT1r. (Image in top left corner 
shows zoomed-in view of black box.) (c) Control NPs showed only negligible interaction with rMCs with hardly 
any gold-enhanced NPs visible.  
 
3.4 Virus mimetic targeting concept facilitates enhanced mesangial cell specificity in vitro 
Having demonstrated, that hetero-multivalent EXPcRGD NPs synergistically combine both key features 
of their surface ligands and present them in a sterically controlled manner, we intended to demonstrate, 
that this design can actually be applied to increase mesangial cell specificity. We therefore implemented 
an in vitro based assay, in which target rMCs were co-cultured with a superior number (5-10-fold) of 
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off-target cells carrying merely one of the two target receptors. While HeLa cells express no AT1r and 
only low levels of αVβ3-integrin, NCI-H295R cells were chosen as they show high AT1r but no αVβ3 
expression 18,52 (Figures 6a/S12). To test the impact of different receptor expression levels on NP 
uptake, all cell lines were initially cultivated in mono-culture and incubated with the different NP 
formulations (Figure 6b). Particle uptake in rMCs was in accordance with previous results, showing the 
highest levels of cellular internalization for EXPcRGD NPs. On the contrary, HeLa cells were only able 
to take up cRGD NPs efficiently. EXPcRGD NP uptake was thereby drastically reduced, which can be 
explained by a combined effect of the cRGDfK shielding and a missing AT1r expression. NCI-H295R 
cells, on the contrary, showed high levels of cell-associated fluorescence for EXP NPs and EXPcRGD 
NPs, as these particle species could bind the abundantly present AT1r on the cell surface. In a next step, 
target rMCs were co-cultured with a superior number of either HeLa or NCI-H295R cells to test the 
NP´s rMC specificity. To differentiate between co-cultured cells in CLSM analysis, CellTrackerTM 
Green (CTG) was used to stain rMCs while off-target cells were marked with CTDR. After incubation 
with fluorescently labeled EXPcRGD NPs, cellular distribution of NPs was assessed. In the rMC/HeLa 
co-culture model, EXPcRGD NP-derived fluorescence could almost exclusively be detected within the 
areas of mesangial cells. HeLa cells, in contrast, showed merely weak interaction with NPs, resulting in 
marginal fluorescence levels (Figure 6c, top row). We accordingly concluded, that EXPcRGD NPs 
could specifically locate mesangial cells among HeLa cells due to the differences in AT1r expression 
on the cell surface. These findings were supported by flow cytometry analysis showing, that cell-
associated fluorescence of EXPcRGD NPs was significantly higher in rMCs than in off-target HeLa 
cells, while accumulation of cRGD NPs was considerable both in HeLa cells and rMCs (Figure 6d). 
In contrast, rMC/NCI-H295R co-culture provided a divergent particle distribution. NP-associated 
fluorescence could not only be found in rMCs, but also in areas covered by NCI-H295R cells. However, 
distribution patterns differed significantly. While fluorescence among rMCs was found in circular, 
vesicle-like structures as seen before, NCI-H295R-associated fluorescence was more diffuse and 
intensified mainly at the cell membrane (Figure 6c, bottom row). We therefore concluded, that while 
accumulating in endocytotic vesicles of rMCs as seen before, EXPcRGD NPs were merely able to bind 
AT1r present in the cell membrane of NCI-H295R cells but could not be taken up into the cytosol due 
to an absence of αVβ3 integrin. Additionally, flow cytometry analysis showed, that even though 
EXPcRGD NP-associated fluorescence for NCI-H295R cells was higher compared to HeLa cells, 
EXPcRGD NPs still showed a significantly enhanced signal in mesangial cells (Figure 6e). EXP NPs, 
in contrast, bound to both rMCs and NCI-H295R cells with no significant cell specificity. Interestingly, 
addition of an excess of free EXP3174 (c = 1 mM) prior to EXPcRGD NP incubation led to a sharp 
decrease of fluorescence levels for NCI-H295R cells, while cell-associated fluorescence for rMCs was 
still significantly higher. 
In summary, the co-culture model demonstrated, that hetero-multivalent EXPcRGD NPs have the 
capability to effectively identify receptor-positive mesangial cells in the presence of off-target cells, that 
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are not only prevailing in number but even express one of the two target receptors. The sequential ligand-
receptor interplay is thereby a decisive tool to minimize off-target accumulation, as NPs are only taken 
up into cells, that express the necessary surface characteristics. If one receptor is missing, NP uptake is 
drastically reduced, thereby maximizing  cell specificity for receptor-positive target cells.    
Figure 6. In vitro NP cell specificity in a mono- and co-culture assay. (a) Receptor expression of off-target HeLa 
and NCI-H295R cells in contrast to receptor double-positive rMCs. (b) Flow-cytometry analysis of NP uptake in 
mono-culture. EXPcRGD NPs showed maximum uptake into target rMCs (c) CLSM analysis of CTG-stained 
rMCs (green), co-cultured with CTDR-labeled HeLa or NCI-H295R cells (grey). Cell nuclei were stained with 
Hoechst 33258 (blue). For the rMC/HeLa co-culture (top row), NP-derived fluorescence (purple) could merely be 
detected within areas of rMCs. Co-culture of rMCs with AT1r-expressing NCI-H295R cells led to a diverging NP 
distribution (bottom row) with EXPcRGD NPs also binding to the surface of NCI-H295R cells, yet without any 
visible cell uptake (Scale bars 20 µm.) Flow cytometry analysis of rMCs co-cultured with either (d) HeLa or (e) 
NCI-H295R cells supported CLSM results as EXPcRGD NPs showed a significantly higher cell-association with 
rMCs in both cases. Results represent mean ± SD (n=3). ** P < 0.01, **** P < 0.0001. (n.s.: not significant. AFU, 
arbitrary fluorescence units.) 
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3.5 Accumulation of adenovirus mimetic EXPcRGD NPs in renal mesangial cells in vivo 
Both rMC binding and uptake studies successfully showed that the virus-mimetic concept of sequential 
ligand-receptor interaction enables hetero-multivalent EXPcRGD NPs to specifically target mesangial 
cells in vitro. However, transferring in vitro results into a robust system with sufficient in vivo efficiency 
has been shown to be the major obstacle in NP design as many strategies fail to deliver desired target-
specificity.60 While many targeting studies oftentimes focus on the time-dependent biodistribution of 
targeted NPs upon administration, we were mainly interested in the question, whether our adenovirus 
mimetic NP species is able to specifically accumulate in mesangial cells in vivo or not. To our estimation, 
reaching mesangial areas within the glomerulus requires not only adequate passive accumulation in the 
target region but also described active cell uptake and is therefore an ideal benchmark to enable the 
comparison between our novel adenovirus NPs and the previously tested influenza A mimetic design. 
To that regard, NPs were initially tested for potential cytotoxicity to guarantee pharmaceutical safety of 
the NP system. Both non-functionalized Control NPs and EXPcRGD NPs thereby showed no significant 
reduction of cell viability (Figure S13). In a next step, fluorescently labeled NPs were injected into 10-
week-old female NMRI mice. After 1 h of NP circulation, mice were sacrificed, and kidneys were 
extracted. Fluorescence analysis of prepared cryosections revealed, that EXPcRGD NPs effectively 
accumulated in glomerular areas while fluorescence in tubular parts of the kidney was neglectable 
(Figure 7). On the contrary, Control NPs as well as homo-functional EXP or cRGD NPs showed a 
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Figure 7. EXPcRGD NPs show strong intraglomerular accumulation in vivo. Transversal kidney cryosections 
were imaged using fluorescence microscopy. To facilitate histological evaluation, cell nuclei were stained with 
DAPI (blue) and tissue autofluorescence was recorded (green). EXPcRGD NPs (red) accumulated almost 
exclusively in glomerular areas of the cortex (white circles), while fluorescence in tubular areas was negligible. 
(From top-left to bottom-right, images show zoomed-in views of white boxes.)  
 
To quantify observed differences, we determined glomerulus-associated fluorescence levels by 
assessing the glomerular fluorescence intensity per area for all NP types (Figure 8a/b). EXPcRGD NPs 
thereby showed a more than 10-fold increase in fluorescence intensity compared to Control NPs. 
Moreover, glomerular accumulation of hetero-multivalent NPs was significantly greater than for both 
homo-functional NP types. Remarkably, cRGD NP fluorescence was even lower than for non-
functionalized Control NPs. We therefore hypothesized that cRGD NPs were not able to reach 
glomerular areas as a predominant number of particles bound αVβ3-expressing cells such as angiogenic 
endothelial cells shortly after injection and consequently left the bloodstream before reaching deeper 
areas of the kidney.61 This hypothesis was further supported by the finding, that relative blood plasma 
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levels of cRGD NPs after 1 h of incubation were lowest among all particle types (Figure S15). In 
EXPcRGD NPs, on the contrary, shorter cRGDfK-functionalized PEG-PLA chains were shielded from 
premature exposition to αVβ3 integrins by addition of longer, EXP3174-functionalized PEG-PLA chains. 
Consequently, hetero-multivalent particles avoided off-target deposition and therefore successfully 
reached glomerular areas within the kidney. Antibody staining for mesangial cell marker integrin-α8 
further revealed, that EXPcRGD NP-associated fluorescence in the glomerulus could almost entirely be 
found within mesangial cells (Figure 8c), proving our hypothesis of extravasation into the mesangial 
interstitium and subsequent endocytosis (Figure S1). In order to verify, that detected fluorescence in 
mesangial areas was derived from structurally intact NPs, we additionally injected a comparable dose 
of free fluorescent dye into mice and analyzed fluorescence deposition. While intraglomerular signal for 
these samples was negligible, tubular cells exhibited very strong fluorescence levels (Figure S16). This 
indicated that, in contrast to injected NP species, the low-molecular dye was filtrated into the tubular 
system. We therefore concluded that intraglomerular fluorescence for all NP types derived from intact 
particles as a degradation would have led to an increase in the tubular signal, otherwise.  
 
Figure 8. EXPcRGD NPs show a significantly enhanced accumulation in mesangial cells. (a) Fluorescence 
microscopy analysis revealed, that high fluorescence levels within glomeruli (white circles) could mainly be 
detected for EXPcRGD NPs. While EXP NPs showed a moderate accumulation in glomeruli, Control NPs and 
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cRGD NPs did not produce signals to any considerable extent. (Scale bar 20 µm. Calibration bar: 0 – 65535 Gray 
Value.) (b) Precise quantification of intraglomerular fluorescence intensity was achieved by assessing the 
integrated density per area of glomerulus for 60 glomeruli per sample. Thereby, EXPcRGD NPs showed far higher 
fluorescence intensities per glomerulus compared to all other particle types. Results represent mean ± SD (n = 60). 
****P < 0.0001. (AFU, arbitrary fluorescence units.) (c) Antibody staining for mesangial surface marker integrin 
α-8 showed that EXPcRGD NP-associated fluorescence (red) was found within areas covered by mesangial cells 
(green), indicating that EXPcRGD NPs were able to specifically infiltrate mesangial cells via endocytosis. Scale 
bar 20 µm. 
 
To our estimation, discussed in vivo studies successfully demonstrated the potential of our new, 
adenovirus mimetic NP design. Hetero-multivalent EXPcRGD NPs effectively accumulated in 
mesangial areas of the glomerulus, while homo-functional or unfunctionalized NP species failed to do 
so. This strongly suggests, that in order to reach sufficient levels of bioavailability, NPs do not only 
have to carry appropriate surface ligands but must also present them in an orchestrated fashion, that is 
suitable for the respective targeting strategy. Moreover, NP accumulation in the mesangium also proved 
that our adenovirus mimetic system of sterically controlled particle-cell interaction represents a viable 







In this study, we manufactured adenovirus-mimetic block-copolymer NPs capable of effectively 
targeting glomerular mesangial cells due to a sterically controlled, sequential ligand-receptor interaction, 
that is independent of previous enzymatic ligand activation. Hetero-multivalent NPs thereby not only 
showed precisely tunable physicochemical characteristics, but also displayed excellent avidity for both 
target motifs, leading to a substantial AT1r binding in the picomolar range and a significantly increased 
mesangial cell uptake compared to unfunctionalized NPs. Profiting from these features, virus-mimetic 
NPs could specifically target mesangial cells in vitro, even in a surrounding environment of off-target 
cells. Additionally, hetero-multivalent NPs displayed the necessary in vivo robustness, leading to an 
efficient accumulation in mesangial areas in vivo with only marginal off-target deposition within the 
kidney. Remarkably, hetero-multivalent EXPcRGD NPs thereby showed far better mesangial targeting 
compared to homo-functional cRGD or EXP NPs, although these previously had been found to also 
display substantial activity for receptor-positive cell lines in vitro.30,45 These findings strongly support 
our conviction, that in order to exhaustively profit from their ligand features in vivo, nanomaterials have 
to utilize them in an appropriate biomimetic manner. Our new concept of sterically controlled particle-
cell interaction thereby proved to be a viable alternative to our previous design of enzymatic ligand 
activation as it also led to a significant NP accumulation in the mesangium. As we were able to target 
the same distinct cell type in vivo with two divergent virus-inspired concepts, we conclude, that mimicry 
of viral infection patterns can offer promising starting points for further targeting concepts and should 
therefore be more thoroughly investigated. Moreover, our successful mesangial cell targeting moves a 
more refined therapy of mesangium-related kidney pathologies within reach, as it could dramatically 
increase drug delivery compared to all other currently available approaches. In that regard, we could 
already show, that the anti-fibrotic and therefore highly promising drug candidate pirfenidone (PFD) 
can efficiently be encapsulated in presented block co-polymer NPs using both the above described 
nanoprecipitation and a novel microfluidic technique.62  Especially when it comes to highly active 
substances such as PFD, drug delivery approaches using described virus-mimetic NPs could 
significantly decrease unfavorable off-target accumulation, thereby drastically improving currently 
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1 Mesangial passive targeting
 
Figure S1. Mesangial accumulation of adenovirus-mimetic NPs. (a) Upon i.v. administration, NPs rapidly enter 
glomerular areas of the kidney via the afferent arteriole that then diverges into the glomerular capillary system.1 
(b) Within the capillaries, particles larger than approximately 10 nm cannot pass the renal filter due to its multilayer 
structure.2–4 Interstitial mesangial cells, on the contrary, are easily accessible via extravasation through the 
fenestrated endothelium.5,6 Having accumulated in mesangial areas, NPs can then finalize cell uptake by 
mimicking previously described adenoviral cell infiltration (Figure 1). (AA: afferent arteriole; EA: efferent 
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2  Polymer synthesis and nanoparticle composition 
 
Figure S2. Synthesis concept for ligand-functionalized PEG-PLA block co-polymers. (a) Hetero-bifunctional 
PEG polymers (①) of varying chain length (2 kDa/5 kDa) were mixed with 3,6-dimethyl-1,4-dioxane-2,5-
dione (②) to synthesize NH2-PEG5k-PLA10k as well as COOH-PEG2k-PLA10k (③) via ring-opening 
polymerization using 1,8-diazabicyclo [5.4.0]undec-7-ene as a catalyst (please refer to the experimental section 
for a detailed description of the synthesis procedure). (b) Subsequently, NH2-PEG5k-PLA10k was covalently 
coupled to the carboxyl group of EXP3174 (④) via DCC/NHS chemistry, resulting in EXP3174-PEG5k-PLA10k 
(⑤). (c) Additionally, COOH-PEG2k-PLA10k was attached to the lysine residue of cRGDfK (⑥) via EDC/NHS 
chemistry, leading to shorter cRGDfK-PEG2k-PLA10k (⑦). (d) Coupling efficiency for synthesized EXP3174-
PEG5k-PLA10k and (e) cRGDfK-PEG2k-PLA10k was determined by independently measuring the concentration of 
both PEG and EXP3174. Molar concentration thereby did not significantly vary, indicating successful polymer 
functionalization. (f) EXP3174- and cRGDfK-functionalized PEG-PLA polymers were subsequently mixed with 
unfunctionalized COOH-PEG2k-PLA10k as well as PLGA (⑧) to manufacture hetero-multivalent EXPcRGD NPs. 
Quantification of EXP3174 (g) and (h) cRGDfK ligand surface density, respectively, after NP manufacture. 
Final surface content was directly proportional to the priorly added amount of ligand-functionalized polymer for 
both EXP3174 (R2 = 0.9871) and cRGDfK (R2 = 0.9957), thereby proving sufficient stability of ligand coupling 
to the respective polymers. (i) TEM imaging of EXPcRGD NPs (63,000x magnification). Results represent mean 
± SD (n = 3). 
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3-6 1H-NMR spectra of synthesized polymers 
Figure S3. 1H-NMR (CDCl3, 400 MHz) spectra of MeO-PEG5k-PLA10k. δ (ppm):  
1.56 ppm (-C(CH3)H-), 3.37 ppm (H3COCH2CH2-), 3.63 ppm (-OCH2CH2-), 4.16 (-OCH2CH2-O(CO)-), 5.15 ppm 
(-C(CH3)H-), 7.26 (solvent peak). 
Figure S4. 1H-NMR (CDCl3, 400 MHz) spectra of COOH-PEG2k-PLA10k. δ (ppm):  
1.56 ppm (-C(CH3)H-), 3.40 ppm (H3COCH2CH2-), 3.63 ppm (-OCH2CH2-), 4.13 (-OCH2CH2-O(CO)-), 5.17 ppm 
(-C(CH3)H-), 7.26 (solvent peak). 
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Figure S5. 1H-NMR (CDCl3, 400 MHz) spectra of COOH-PEG5k-PLA10k. δ (ppm): 1.56 ppm (-C(CH3)H-), 3.43 
ppm (H3COCH2CH2-), 3.63 ppm (-OCH2CH2-), 4.15 (-OCH2CH2-O(CO)-), 5.16 ppm (-C(CH3)H-), 7.26 (solvent 
peak). 
 
Figure S6. 1H-NMR (CDCl3, 400 MHz) spectra of NH2-PEG5k-PLA10k. δ (ppm):  
1.57 ppm (-C(CH3)H-), 3.39 ppm (H3COCH2CH2-), 3.61 ppm (-OCH2CH2-), 4.19 (-OCH2CH2-O(CO)-), 5.18 ppm 
(-C(CH3)H-), 7.25 ppm (solvent peak). 




7 Additional data on ligand properties 
 
 
Figure S7. DLS analysis of (a) EXP3174-functionalized and (b) cRGDfK-functionalized showed no significant 
impact of the ligand density on the NPs´ hydrodynamic diameter or a possible tendency for aggregation. (PDI: 
polydispersity index.)  (c) AT1r activity for rMCs treated with EXP NPs with varying EXP3174 surface densities. 
EXP NPs with 25 % and 35 % EXP3174 density showed a comparable AT1r blocking (IC50 (25%) = 552 ± 73 
pM; IC50 (35%) = 321 ± 81 pM), while a surface density of 15 % lead to a drastically reduced AT1r binding (IC50 
(15%) = 11 ± 1 nM). (M = molar NP concentration.) (d) AT1r activity for EXP3174-free NPs. Neither 
unfunctionalized Control NPs nor cRGD NPs could significantly bind the AT1r, resulting in maximum calcium 
levels upon ATII stimulation and confirming the specificity of the assay. (e) Intracellular Ca2+ levels for either 
rMCs (high AT1r expression) or HeLa cells (low AT1r expression)7 upon incubation with EXPcRGD NPs and 
stimulation with AT II. Measured intracellular Ca2+ levels in HeLa cells were far lower compared to rMCs due to 
the differences in AT1r expression. (M = molar NP concentration.) (f)/(g) Flow cytometry analysis of rMC uptake 
for cRGDfK-carrying NPs. (f) Cell uptake gradually increased with higher surface densities of cRGDfK, as 
described before.8 While cRGD NPs with a ligand density of 15% still showed sufficiently enhanced levels of 
endocytosis, 5% cRGD NPs provided  merely low internalization levels, comparable to unfunctionalized Control 
NPs. (g) By introduction of longer shielding elements (see Figure S8), respective rMC uptake could be 
significantly reduced for all cRGDfK ligand densities. * P < 0.05, ** P < 0.01, **** P < 0.0001. (AFU, arbitrary 
fluorescence units.) Results represent mean ± SD (n = 3). 
 
 




8 Shielding concept 
 
 
Figure S8. Shielding concept for cRGDfK. While ligand visibility of unshielded cRGD NPs was maximum, 
introduction of longer COOH-PEG5k-PLA10k chains significantly reduced the accessibility of the ligand due to a 
steric hindrance effect, leading to a decreased integrin binding and subsequent rMC uptake of shielded cRGD NPs. 
For EXPcRGD NPs, coupling of EXP3174 to longer PEG5k-PLA10k chains provided the necessary initial binding 
to the rMC surface. Resulting spatial approach of the NP then lead to a sufficient integrin binding via previously 


















9 CLSM images of NP-AT1r interaction 
Figure S9. Time-dependent CLSM analysis of NP interaction with AT1r-YFP rMCs (grey). (a) For EXP NPs, 
AT1r signal (green) could mainly be found on the cellular surface, where large receptor clusters became visible 
and were colocalized with NP-associated fluorescence (red). This indicates EXP NP binding to the AT1r, however 
without any significant endocytosis. (b) Control NPs showed merely negligible levels of rMC uptake. Fluorescence 
levels for the AT1r were also drastically reduced, as the receptors did not merge to larger formations and remained 
widely spread across the entire cell surface. (Scale bar 20 µm.) 
 
 





10 Gold-tagged NPs 
 
Figure S10. Gold-tagged NPs for facilitated TEM visualization. (a) NPs were gold-labeled by covalently 
attaching ultra-small gold NPs (diameter: 2.2 nm) to the carboxyl group of PLGA, prior to NP manufacturing. 
After incubation of rMCs with labeled NPs, the particle core was gold-enhanced by depositing further gold 
particles on the NP core, thereby increasing electron density of the sample and enabling visualization in TEM 
microscopy, where NPs appeared as dark black spots. (b) DLS analysis of NPs. Due to the encapsulation of gold 
NPs, Au-labeled EXPcRGD NPs showed a slightly increased hydrodynamic diameter with a PDI in a still 
acceptable range. Results represent mean ± SD (n = 3).  
 
 
11  Additional TEM images 
 
Figure S11. (a) TEM image of rMCs incubated with cRGD NPs. Comparable to EXPcRGD NPs, cRGD NPs 
showed significant accumulation in endocytotic vesicles within the rMC cytosol. However, NP density on the 
cellular surface appeared to be lower, indicating that NPs were already taken up to a large degree via integrin-
mediated endocytosis. (b) TEM image of untreated rMCs after gold-enhancement. Control cells were treated with 
the same TEM preparation protocol, however without NP incubation. Consequently, no gold deposition was 








12 αVβ3 expression  
 
 
Figure S12. αVβ3 expression by different cell types investigated by (a) flow cytometry and (b) CLSM. For 
cytometry analysis, unspecific binding sites were blocked with 2% BSA in DPBS and 105 cells were incubated for 
1 h with a 1:20 dilution of AlexaFluor® anti - CD51/61 antibody in 0.1% BSA in DPBS (AlexaFluor® Mouse 
IgG1, κ Isotype Ctrl (FC) served as unspecific control). Thereafter, cells underwent several steps of DPBS washing 
and centrifugation. Finally, samples were resuspended in DPBS and analyzed using flow cytometry as previously 
described (FACS Calibur, excitation: 633 nm, emission: 661/16 nm bandpass filter). αVβ3-derived fluorescence 
levels were thereby highest for rMCs. While NCI-H295R cells showed no significant integrin expression,  HeLa 
cells were found to have a rather low integrin density, which, however, was still significantly greater than for the 
isotype control. Results represent mean ± SD (n=3).****P < 0.0001, **P < 0.01, *P < 0.05. (AFU, arbitrary 
fluorescence units.) For visualization and confirmation of flow cytometry results, rMCs were seeded into 8-well 
Ibidi slides (15.000 cells well-1) and stained for αVβ3 integrin as described above. Cells were then washed with 
DPBS, fixed with 4% PFA in DPBS and analyzed at a Zeiss LSM 710. CLSM images revealed a strong integrin 
signal that was co-localized with rMC cell body, indicating a substantial αVβ3 receptor density on the surface of 















13 MTT assay 
 
Figure S13. L-929 cell viability after 24 h of incubation with Control and EXPcRGD NPs. (a) Cytotoxicity of 
unfunctionalized and ligand-carrying NPs was tested as described before9, using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction assay according to ISO 10993 – 5:2009 (Biological 
evaluation of medical devices, part 5: Tests for in vitro cytotoxicity). In brief, mouse fibroblast L-929 cells were 
seeded at a density of 10,000 cells per well and incubated for 24 h (37 °C / 5 % CO2). NPs were manufactured in 
mpH2O under aseptic conditions. To further decrease microbial contamination, NPs were exposed to UV-light 
for 3 h. Samples were thereafter adjusted to concentrations from 30 to 1000 µg mL-1 in EMEM medium 
containing 10 % FCS and incubated with cells for 24 h. (Positive control: 0.1 % SDS; negative control: pure 
medium.) Thereafter, samples were removed and 50 μL EMEM medium containing 1.0 mg mL-1 MTT were 
added. After 2 h of incubation, the MTT solution was aspirated and 100 μL isopropanol was added to each well. 
After 30 min of incubation under gentle shaking and light exclusion, absorbance at 570 and 690 nm was 
measured using a FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg, Germany). 
Viability was assessed using the difference in absorbance at 570 and 690 nm and  normalized to the negative 
control. Results represent mean ± SD (n = 6). (b) Brightfield images of L-929 cells incubated with either no NPs 














14 Fluorescence analysis of kidney NP accumulation 
 
Figure S14. Fluorescence analysis of kidney cryosections. Cell nuclei were stained with DAPI (blue). 
Additionally, kidney autofluorescence (green) was recorded to facilitate histological evaluation of samples. NP-
derived fluorescence is shown in red. (a) Unfunctionalized Control NPs showed only weak fluorescence levels in 
renal glomeruli, while EXP NPs (b) accumulated in a considerable amount in glomerular areas (white circles; 
arrows indicate fluorescence-positive glomeruli.). However, fluorescence intensity was significantly lower than 
for EXPcRGD NPs (Figure 7). (c) For cRGD NPs, fluorescence signal was minimal with no visible particle 
accumulation in any glomerulus. For all depicted NP species, tubular fluorescence was negligible, indicating that 
no renal filtration had taken place. (Images on the right show magnified sections of white boxes indicated in the 
respective left images.) 
 




15 Blood plasma fluorescence  
 
Figure S15. Relative blood plasma fluorescence after NP injection. Control NPs exhibited the highest blood 
circulation values with almost 50% residual blood plasma fluorescence after 60 min of injection compared to the 
value after 5 min. In contrast to EXP NPs as well as EXPcRGD NPs, that both showed tolerable residual 
concentrations, cRGD NPs were rapidly cleared from the blood. Results represent mean ± SD (n=3). ****P < 
0.0001, ***P < 0.001, **P < 0.01. (n.s.: not significant.) 
 
16 Kidney fluorescence distribution of free CFTM647 dye 
 
Figure S16. Fluorescence imaging of kidney cryosections after injection of free CFTM 647 fluorescent dye. To 
visualize cell nuclei, sections were DAPI-stained (blue). After injection of a comparable molarity of free dye, 
strong fluorescence signals (red to white) could be detected in tubular areas of the kidney, indicating free renal 
filtration of the low-molecular dye. As expected, no intraglomerular accumulation could be detected (white 
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One of the central impediments for the clinical translation of targeted nanomaterials is their extensive 
off-target deposition, which can be mainly attributed to addressed cellular surface structures being 
ubiquitously present in various other regions, such as the vascular system. This is especially important 
for the integrin receptor family, which is frequently addressed with ligands such as cRGD (cyclic Arg-
Gly-Asp-D-Phe-Lys). Aside from upregulation during tumor progression, integrins also play a 
prominent physiological role in endothelial cells, to whom particles are exposed immediately after 
injection. However, there is a lack of understanding of how to modulate the usually undesirable 
interaction of nanoparticles (NPs) with these cells, especially under physiological conditions, that 
include the imminent impact of blood flow dynamics on NP behavior. Therefore, in this study, we 
introduced a steric shielding concept that is based on the addition of longer PEG chains into the NP 
corona, thereby individually camouflaging the ligand activity of cRGD-functionalized polymer NPs. 
More so, we implemented a method of endothelial cell culture and particle incubation under a constant 
flow, mimicking physiological conditions (shear stress = 2-14 dyn cm-2). By controlling surface density 
(25-75 %) and length (3.5 kDa vs 5 kDa) of respective shielding elements, in vitro NP uptake into model 
endothelial cells could be precisely steered. Additionally, NP-cell interplay showed significant 
differences when examined under dynamic conditions, confirming the need for such investigations to 




































Approaches for cell-specific drug delivery using nanoparticles (NPs) have become more and more 
sophisticated in recent years1–4, yet the overall applicability of nanomaterials still remains at a 
comparably low level.5 In an attempt to overcome this predicament, many concepts try to enhance site-
selective targeting by equipping NPs with additional surface functionalities, thereby creating 
increasingly complex structures with oftentimes highly orchestrated cell recognition patterns.6–9 
However, the vast majority of NP targeting concepts still provides unsatisfactory bioavailability at the 
actual site of interest.10,11 In many cases, NPs thereby initially show excellent levels of cell-selective in 
vitro targeting, due to the described characteristic surface structures, but fail to sufficiently transfer these 
features into a robust in vivo system. The underlying difficulty is thereby oftentimes not the actual target 
cell recognition, but an excessive particle clearance or off-target deposition beforehand.12 In our view, 
the focus of NP targeting concepts should therefore not only lie on the final NP-target cell interaction, 
but the plentiful obstacles, that administered NPs have to pass before they reach their actual site of 
interest.13,14  
One key impediment is thereby a possible clearance of particles via immunological barriers such as the 
mononuclear phagocyte system (MPS).15 Yet, a frequently underestimated proportion of intravenously 
administered NPs fails to reach the target site not necessarily due to such active clearance patterns but 
rather because of a general accumulation in off-target regions that are passed through during blood 
circulation of NPs.16,17 In that regard, the vasculature itself generally accounts for a considerable amount 
of NP deposition, mostly because of the sheer scale of vascular endothelial cells, that injected NPs are 
exposed to. This factor becomes even more critical, if NPs are additionally equipped with cell 
recognition sequences for structures that can also be expressed by endothelial cells. 
Integrins, for instance, have frequently been used as a recognition motif for efficient tumor NP targeting 
due to their prominent role in cancer progression.18–22 However, expression of these transmembrane 
receptors is not limited to malignant cells, but can also be found for the majority of cell types by 
facilitating a multitude of essential intra- and intercellular processes.23–25 When it comes to vascular 
endothelial cells, αvβ3 integrin in particular has been found to be a key player during angiogenesis.26,27 
NPs, which carry αvβ3 integrin-targeting structures such as RGD (Arg-Gly-Asp)28, are therefore most 
likely also subject to unintended off-target binding to integrin-positive endothelial cells after injection, 
thereby considerably reducing the prospects of satisfactory accumulation at the actual target site. 
In that regard, we recently evaluated the in vivo accumulation of NPs functionalized with cRGD (cyclic 
Arg-Gly-Asp-D-Phe-Lys) in αvβ3 integrin-positive mesangial cells within renal glomeruli.29 The 
targeting concept was thereby based on an initial extravasation of administered NPs through endothelial 
fenestrations into interstitial mesangial areas. Here, NPs would then initiate a ligand-mediated, active 
mesangial cell uptake which would be facilitated by a considerably decreased blood flow in respective 
areas.  
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cRGD NPs thereby showed a substantial integrin-mediated mesangial cell uptake in vitro, which was 
directly proportional to the cRGD surface density on the NP. However, despite this substantial target 
efficacy, the final mesangial in vivo accumulation of cRGD NPs was only marginal. In contrast, a hetero-
functional NP species, that presented the cRGD ligand only after a spatial approach to the cell surface, 
mediated via an additional ligand, showed excellent levels of mesangial in vivo deposition. To our 
estimation, these sequentially binding NPs were protected from premature binding to integrin-positive 
endothelial cells by initially hiding the respective cRGD ligand. Following up on this observation, we 
were interested, whether these results could be used to create a novel flexible shielding concept for 
ligand-functionalized NPs.  
In this context, most previous approaches aimed to manufacture so-called “stealth” particles covered by 
additional protective layers of either PEGylated polymers or other surface components30,31, that should 
enable a generally low visibility for undesirable clearance routes such as the above mentioned MPS. In 
contrast, our concept was mainly focused on a more precise control of the actual ligand-receptor 
interaction (Figure 1a). By implementing additional shielding elements with a distinct length and 
surface density, excessive interaction of the cRGD ligand with off-target cell integrins should thereby 
be sterically hindered during initial NP circulation, while still allowing sufficient ligand-mediated NP 
uptake at the actual target region due to the decreased blood flow rate after extravasation. In this respect, 
a multitude of studies stress, that NP-cell interaction can be greatly influenced by parameters such as 
fluid dynamics, particle margination as well as physical forces within the vessel.32–35 These effects are 
sometimes overlooked and could potentially lead to false conclusions regarding cell-particle interplay36. 
As the endothelium is directly exposed to the circulating blood37, we considered it essential to evaluate 
the NP-cell interaction not only under the commonly applied static conditions, but also to assess the 
impact of fluid dynamics on the NP flow within the vessel and resulting cell uptake. In that regard, 
several studies have previously shown, that both the interaction between ligands and receptors and the 
spatial organization of macromolecular polymer chains can significantly be altered under flow 
conditions.38,39  
For a more accurate assessment of the described shielding approach, we implemented an in vitro concept 
of both endothelial cell culture and NP incubation mimicking physiological flow conditions (Figure 
1b). In that context, human umbilical vein endothelial cells (HUVECs) were initially cultured either 
under static conditions or under a constant shear stress to trigger flow-specific changes in cell 
morphology, that could potentially have an impact on cell-particle interactions.35 Subsequently, cRGD-
functionalized NPs containing different combinations of  shielding elements were tested for endothelial 
cell uptake both under respective static and flow conditions.  
The above mentioned shielding concept itself is based on a steric hindrance effect that has been 
described by a multitude of previous studies.40,41 It relies on the scalable introduction of longer, 
carboxylic acid terminated poly(ethylene glycol) (PEG) chains into the surface of ligand-carrying 
polymeric NPs. To that end, integrin-targeting cRGD tethered to a shorter 2 kDa (2k) PEG chain was 
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shielded with different amounts (25-75 %) of either 3.5 k or 5 k PEG chains. As described above, these 
PEG shielding elements should hinder the cRGD ligand from prematurely interacting with integrins 
expressed by off-target endothelial cells during the initial phase of blood circulation (Figure 1c).  
As a complete suppression of ligand activity would be counterproductive for the later intended NP 
uptake into the actual target cell, our goal was to realize a precise steerability of integrin-mediated NP 
uptake by adjusting both the density and length of respective shielding chains (Figure 2a). We 
hypothesized, that a partial shielding of cRGD visibility could potentially reduce excessive endothelial 
NP uptake while still guaranteeing sufficient target cell uptake due to the above described, more 
favorable physiological conditions as well as an overexpression of integrins at the target site.42  
In the present study, we initially evaluated the effect of above-mentioned shielding parameters on 
endothelial NP uptake under static conditions. In a next step, these results were tested on their 
transferability to a more realistic set-up mimicking physiological flow conditions. Finally, the impact of 
different flow parameters on NP uptake was analyzed.  
 
Figure 1. Experimental set-up and shielding concept. (a) Shielded cRGD NPs are designed to combine beneficial 
properties of both untargeted “stealth” and targeted cRGD NPs. (b) Static vs. dynamic cell culture and NP uptake. 
HUVECs were cultured for 3 days either under static conditions or under a constant shear stress of 10 dyn cm-2 to 
realistically mimic in vivo fluid dynamics. Subsequently, cells were incubated with different NP species, also either 
under static or under flow conditions (2/10/15 mL min-1), and final NP uptake was assessed. (c) Concept of steric 
ligand shielding from premature exposition to off-target endothelial cells. In contrast to unshielded, cRGD-
carrying NPs (top row), shielded cRGD NPs (bottom row) show a considerably reduced binding and uptake into 
αvβ3 integrin-positive endothelial cells. 
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2 Materials and Methods 
2.1 Materials 
Hydroxyl poly(ethylene glycol)carboxylic acid (Molecular weight: 2000, 3500 and 5000 g mol-1 ; 
COOH-PEG2k/3.5k/5k-OH) was purchased from JenKem Technology USA Inc. (Allen, TX, USA). 
Resomer RG 502 (PLGA; lactide:glycolide, 50:50; molecular mass, 13,400 g mol−1) was obtained from 
Sigma-Aldrich (Taufkirchen, Germany). Cyclic RGDfK (cRGDfK) was purchased from Synpeptide Co. 
Ltd. (Shanghai, China). AlexaFluorTM 568 Hydrazide (Alexa568), Anti-Human CD144 AlexaFluorTM 
488 (Anti VE-Cadherin) and CellMask™ Deep Red Plasma Membrane Stain (CellMask DeepRed) were 
obtained from Fisher Scientific GmbH (Schwerte, Germany). AlexaFluorTM 568 Phalloidin (Phalloidin) 
was purchased from Life Technologies GmbH (Darmstadt, Germany). The pump system, fluidic unit, 
perfusion sets, µ-slides I Luer 0.4 mm and µ-slides 8 Well were purchased from Ibidi GmbH (Planegg, 
Germany). All other substances were obtained from Sigma-Aldrich in analytical grade unless stated 
differently. Human Umbilical Vein Endothelial Cells (HUVECs) were obtained from PromoCell GmbH 
(Heidelberg, Germany). HUVECs were cultured in Endothelial Cell Growth Medium MV + 
Supplements (PromoCell GmbH) containing 10 % fetal bovine serum.  
 
2.2 Polymer synthesis, cRGDfK coupling and PLGA fluorescent labeling 
COOH-PEG2k/3.5k/5k-PLA10k block polymers were synthesized via a previously established ring-opening 
polymerization of heterobifunctional PEG polymers and 3,6-dimethyl-1,4-dioxane-2,5-dione.29,43–45 To 
receive ligand-functionalized polymers, synthesized COOH- PEG2k/3.5k/5k-PLA10k was then linked to the 
lysin residue of cRGDfK as described before.29,45,46 Resulting cRGDfK coupling efficiency as well as 
the later ligand surface density on prepared NPs were assessed with a pre-existing method using 9,10-
phenanthrenequinone.22,29 For a later NP visualization in CLSM and flow cytometry, NP core 
component PLGA was additionally coupled to either Alexa568 or CFTM 647 amine as previously 
stated.29,47 
 
2.3 NP preparation and characterization 
For NP manufacture, we used a previously described solvent evaporation technique, whereby the 
organic phase consisted of a mix of all polymeric components (PEG-PLA/PLGA : 70/30) at a certain 
ratio, depending on the intended final surface amount of respective PEG chains (Figures S1 and S4). 
The exact preparation procedure can be found in our previous publications.29,45,48
 




2.4 NP characteristics 
The hydrodynamic diameter and zeta potential levels of each NP batch were measured in 10 % (v/v) 
DPBS with a Malvern Zetasizer Nano ZS (Malvern, Herrenberg, Germany), using a 633 nm He-Ne laser 
(173° angle, 25 °C, RT). 
 
2.5 HUVEC culture under static and flow conditions 
To assess the impact of a constant media flow, HUVECs (passages 3-5) were seeded at a density of 
250,000 cells slide-1 in a µ-slide I Luer with a channel height of 0.4 mm. After 2 h of cell attachment, 
the slide was connected to a red perfusion set filled with HUVEC growth medium containing 10 % fetal 
bovine serum. The perfusion system was connected to an Ibidi fluidic unit and the applied media flow 
was gradually increased for 2 h to a final shear stress of 10 dyn cm-2. Cells were cultured under constant 
flow for 72 h at 37 °C and 5 % CO2. For the static experiments, HUVECs were seeded in a Ibidi 8 well 
µ-slide at a density of 4000 cells well-1 and cultured without any applied flow for 72 h at 37 °C and 5 % 
CO2, with media being exchanged every 24 h. Morphology changes during incubation were analyzed 
using a Leica DMIRB Inverted Microscope (Leica Microsystems, Wetzlar, Germany).  
 
2.6 Immunostaining of changes in cell morphology  
To compare cell morphology of HUVECs cultured under static and flow conditions, cells were cultured 
for 72 h as described above. Cells were thereafter washed with DPBS and fixed with 4 % 
paraformaldehyde (PFA) in DPBS for 10 min at RT. Samples were washed with DPBS, permeabilized 
with 0.1 % Triton-X 100 in DPBS for 10 min at RT, washed again and blocked for unspecific binding 
sites with a 1 % solution of bovine serum albumin (BSA) in DPBS for 30 min at RT. After an additional 
washing step with DPBS, a dilution of Phalloidin (1:200), 4′,6-Diamidine-2′-phenylindole 
dihydrochloride (DAPI, 1:200) and Anti VE-Cadherin (1:25) in DPBS was added for 1 h at RT. Samples 
were thereafter washed and analyzed at a Zeiss LSM 710 (Carl Zeiss Microscopy GmbH, Jena, 
Germany). For analysis of cell shape and orientation, Fiji software (Madison, WI, USA) was used. In 
brief, the signal for Anti VE-Cadherin staining was used to determine the shape of each cell, as VE-
Cadherin acts as a junction protein located at the cell border. For each cell, the divergence angle of the 
central axis from a horizontal line (from -90 ° to +90 °), the ratio of major to minor axis as well as a 
circularity value (0-1; 1 indicates a perfect circle) were assessed.  
 
2.7 Flow cytometry analysis of NP uptake under static conditions 
To test the effect of shielding components on NP uptake into endothelial cells, HUVECs were seeded 
into a 24-well plate (20,000 cells well-1) and incubated for 72 h at 37 °C and 5 % CO2. NPs containing 
CF647-functionalized PLGA were prepared as described above and diluted to 0.1 mg NP mL-1 in 
Leibovitz´s buffer supplemented with 0.1 % BSA (LB + BSA). Cells were washed and NPs (300 µL) 




were added for 45 min at 37 °C. After incubation, cells were washed, trypsinized and centrifuged for 5 
min at 200 g and 4 °C. This procedure was repeated twice and final samples were resuspended and 
analyzed using a BD FACSCantoTM II (BD, Heidelberg, Germany). NP-derived fluorescence was 
excited at 633 nm and emission was recorded using a 660/20 nm bandpass filter. Resulting cytometry 
data of the gated population of viable cells was analyzed with Flowing software 2.5.1 (Turku Centre for 
Biotechnology, Turku, Finland).  
 
2.8 CLSM analysis of NP uptake under static conditions  
For visualization of NP uptake, HUVECs were seeded into Ibidi 8 well µ-slides at a density of 4000 
cells well-1 and cultured for 72 h at 37 °C and 5 % CO2. NPs were manufactured as described above, 
however, in this case with Alexa568-modified PLGA. NP solutions were diluted to 0.1 mg NP mL-1 in  
prewarmed LB + BSA and 200 µL well-1 were added to the cells. After 45 min of incubation, NPs were 
removed, cells were washed with DPBS and cells were stained with CellMask Deep Red (1:1000 in LB) 
for 5 min at 37 °C. Cells were thereafter washed and fixed in 4 % PFA in DPBS for 10 min at RT. After 
a washing step, a 1:200 dilution of DAPI in DPBS was added for 10 min at RT. Finally, cells were 
washed with DPBS and analyzed at the CLSM as described above. 
 
2.9 Flow cytometry analysis of NP uptake under flow conditions 
For analysis of NP deposition under constant flow, HUVECs were initially cultured in µ-slides for 72 h 
under a constant shear stress (10 dyn cm-2) as described above. CF467-labeled NPs were adjusted to a 
final concentration of 0.1 mg mL-1 in LB + BSA. The µ-slide was disconnected from the perfusion set 
and washed with LB. The perfusion set was thereafter emptied, washed with LB, and filled with the NP 
solution. The µ-slide was connected to the perfusion set again and the NP solution was pumped through 
the system for 45 min at a flow rate of either 2 mL min-1, 10 ml min-1 or 15 mL min-1 (shear stress = 
1.8/9.2/13.8 dyn cm-2). After incubation, the µ-slide was disconnected, cells were washed with DPBS, 
prepared for flow cytometry, and analyzed as described above.  
 
2.10 CLSM analysis of NP uptake under flow conditions 
To visualize NP deposition under flow conditions, HUVECs were cultured under a constant shear stress 
for 72 h as described above. Alexa568-labeled NPs were manufactured, and cells were incubated with 
NPs at a flow rate of 2 mL min-1 (shear stress = 1.8 dyn cm-2) as described in the section above. Cells 








3 Results and Discussion 
3.1 Steric shielding can precisely regulate cRGD-mediated NP uptake under static conditions  
For the intended shielding concept, we could build on an already established modular NP system, that 
is based on the combination of poly(lactic-co-glycolic acid) (PLGA) with PEG−poly(lactic acid) (PEG-
PLA) block-copolymers of varying PEG chain lengths (Figure S1).29 While core forming PLGA is 
added for enhanced NP integrity as well as for fluorescence visualization29,47, carboxylic acid terminated 
PEG-PLA (COOH-PEG-PLA) polymers form a brush-like corona with protruding PEG chains due to 
their higher hydrophilicity. The targeting ligand cRGD was thereby covalently coupled to “short” 
PEG2k-PLA10k (cRGD-PEG2k-PLA10k), as previously described.29,45 For the manufacturing of all NP 
types except Control NPs (100 % COOH-PEG2k-PLA10k), 25 % of cRGD-PEG2k-PLA10k were added, 
thereby obtaining a corresponding cRGD surface density of 25 % (Figure 2d). This level of ligand-
functionalization was chosen as it had previously been shown to facilitate sufficient integrin-mediated 
NP uptake on the one hand and allow a precise control over shielding on the other hand.29 While 
unshielded cRGD NPs additionally contained likewise “short” COOH-PEG2k-PLA10k, shielded NP 
species were manufactured with rising amounts of either COOH-PEG3.5k-PLA10k (3.5k shielding) or 
COOH-PEG5k-PLA10k (5k shielding) (Figure S1).  Our assumption thereby was, that these longer PEG 
chains would gradually decrease the interaction between cRGD and the targeted αvβ3 integrin due to a 
steric hindrance effect. Despite the considerable changes in surface composition, all NP types could be 
manufactured in a narrow size range of 55 ± 10 nm (Figure 2b), thereby minimizing possible effects of 
size differences on the NP uptake.49  Due to the carboxylic residues of applied COOH-PEG-PLA, NPs 
had a negative zeta potential of -10 ± 5 mV (Figure 2c), which has been shown to reduce unspecific 
binding to off-target cells as well as minimize plasma protein binding and possible phagocytosis.44,50 
Since the above described shielding components should primarily decrease NP interaction with integrin-
positive endothelial cells, we decided to use HUVECs as a model cell type. These cells showed 
significant αvβ3 integrin expression as evaluated via immunocytochemistry using CLSM and flow 
cytometry (Figure S2).  





Figure 2. (a) Specification of tested NP species. (b) DLS analysis. (c) Zeta potential measurements. 
Due to the addition of negatively charged COOH-PEG-PLA, zeta potential values were all in a negative 
range of -7.5 to -12.5 mV. (d) cRGD quantification. cRGD surface density was evaluated by measuring 
the molar cRGD content per NP batch and normalizing it to the respective PEG content. Except for 
cRGD-free Control NPs, cRGD content was in a range of 25 ± 1.5% for all NP types. Results represent 
mean ± SD (n = 3). 
 
To initially test the practicability of our shielding concept, HUVECs were cultured for 72 h under static 
conditions and subsequently incubated for 45 min with the above described, fluorescently labeled NP-
formulations. Additionally, unshielded cRGD NPs with divergent ligand densities (5/15/35/50 %) were 
tested to assess whether the chosen cRGD amount of 25 % led to a satisfactory target efficacy compared 
to unfunctionalized NPs. Flow cytometry analysis of NP-cell interplay (Figure 3) revealed three major 
outcomes: First, NP uptake into endothelial cells gradually increased with a higher cRGD surface 
density, thereby proving the previously experienced endocytosis-mediating potential of the ligand 
(Figure 3a).29 Second, as postulated above, NPs with a cRGD surface density of 25 %  (“Unshielded 
cRGD NPs”) proved to possess a satisfactory on-target efficacy, showing a 4-5-fold higher NP uptake 
compared to Control NPs without the respective ligand (Figures 3a/b). This indicates the significant 
impact of a sufficient cRGD functionalization on integrin-mediated NP endocytosis and was further 
confirmed by the observation, that addition of an excess of free cRGD (c = 500 µM) led to a drastically 
declined cell-associated fluorescence. Lastly, the introduction of above-described shielding components 
significantly reduced integrin-mediated NP uptake even though these shielded NPs carried the same 
cRGD surface density of 25 % (Figure 3c). Cell-associated fluorescence thereby gradually decreased 
both with higher surface densities (25-75 %) and greater length (3.5k-5k) of the shielding elements. By 




adding 75 % of COOH-PEG5k-PLA10k (75 % 5k shielding), NP uptake could even be reduced to a level 
that was no longer significantly different from the result for Control NPs.  
 
 
Figure 3. NP uptake under static conditions. (a) HUVEC uptake for unshielded, cRGD-functionalized 
NPs significantly increased with a greater cRGD density on the NP surface. (b) NP uptake for particles 
with a cRGD density of 25 % (“Unshielded cRGD NPs”) was significantly higher than for 
unfunctionalized Control NPs. Addition of an excess of free ligand reversed this effect, thereby proving 
αvβ3-dependency of NP uptake. (c) While cell-associated fluorescence was highest for cRGD NPs 
without any additional shielding, the NP uptake gradually declined with higher surface density and 
length of the shielding elements. Results represent mean ± SD (n = 3). *P < 0.05. **P < 0.01. ***P 
<0.001 ****P < 0.0001. (n.s. not significant; AFU, arbitrary fluorescence units.) 
 
To confirm flow cytometry results, the NP-associated fluorescence was further analyzed using confocal 
laser scanning microscopy (CLSM) (Figure 4 and Figure S3). For a better cell identification, HUVECs 
were additionally stained with CellMaskTM Deep Red (CellMask). Figure 4 displays the results for 
unshielded cRGD NPs (25 % cRGD) as well as NPs carrying 25-75 % of 3.5k shielding elements. While 
non-shielded cRGD NPs showed the highest extent of accumulation in endocytotic vesicles, cell-
associated fluorescence was gradually declining for a higher surface density of 3.5k shielding elements. 




Analysis of NPs carrying 5k shielding components showed even lower fluorescence levels (Figure S3) 
with NP accumulation being only marginal for 50-75 % of 5k shielding. 
Both flow cytometry and CLSM analysis confirmed the practicability of our steric concept to shield 
cRGD from interaction with the targeted integrin by addition of longer PEG elements. While cRGD 
functionalization of NPs initially led to a sharp increase in HUVEC uptake compared to Control NPs, 
this effect could substantially be decreased by the addition of described shielding elements. However, 
as described shielded NP species carried a generally higher amount of PEG on their surface compared 
to unshielded cRGD NPs, we finally investigated, whether the experienced shielding was due to the 
postulated steric hindrance effect or merely because of a general increase in PEG surface amount, which 
could potentially also have an impact on the cRGD-integrin interaction or facilitate an extended NP 
circulation by lowering the tendency towards migration to the channel wall. To that end, unshielded 
cRGD NPs were manufactured not only with PEG chains of 2 kDa, but also with longer COOH-/cRGD-
PEG-PLA (3.5k/5k). Flow cytometry analysis of endothelial NP uptake under static conditions thereby 
revealed only minor differences between all three unshielded cRGD NP species (Figure S4). 
Additionally, unshielded NP species (2k/3.5k/5k) showed a significantly greater cell endocytosis 
compared to NP types carrying shorter cRGD-PEG2k-PLA10k and 75 % of either 3.5k or 5k shielding 
elements.  
Because of this observation, we concluded that NP uptake was mainly lowered due to the described 
steric hindrance effect on the cRGD-integrin interaction and could therefore be regulated by control of 
the surface density and length of the implemented shielding components.  
 





Figure 4. CLSM analysis of NP uptake under static conditions. Unshielded cRGD NPs (top row) 
showed a substantial accumulation in endocytotic vesicles (purple) within the HUVEC cytosol (grey). 
Addition of rising amounts of 3.5k shielding elements lead to a gradual decrease in cell-associated 
fluorescence, thereby proving flow cytometry results. (Scale bar 20 µm.) 
 
3.2 Implementation of a physiological flow during cell culture to mimic in vivo conditions 
As we were able to introduce a steric shielding strategy for satisfactory control of integrin-mediated NP 
uptake under static conditions, we were interested, whether this concept could be transferred to a set-up, 
that mimics actual in vivo conditions in a more realistic way.  
Since endothelial cells are constantly subject to a significant blood flow and resulting shear stress in the 
vessel, we chose to initially culture HUVECs under respective flow conditions for 72 h to create a more 
accurate cell environment for later NP uptake studies. Endothelial cells were therefore exposed to a 
constant shear stress of 10 dyn cm-2, which is in the range of physiological values and allows sufficient 
cell growth without excessive cell detachment or apoptosis.51,52 




While endothelial cells showed a random orientation right after seeding, morphology drastically 
changed within 3 days of culture under flow conditions (Figure 5a). HUVECs thereby showed a gradual 
elongation as well as orientation along the applied flow, indicating the morphological reaction to the 
constant shear stress. To better visualize changes in cell morphology, immunocytochemistry of 
HUVECs cultured both under flow and static conditions was performed (Figure 5b). Antibody staining 
of intercellular junction protein vascular endothelial cadherin (VE-cadherin) indicated that HUVECs 
not only oriented along the applied flow, but also intensified cell-cell contacts to create a more stable 
cell layer and prevent detachment. F-actin staining also showed, that cytoskeletal filaments became more 
aligned, flow-oriented and enhanced. A subsequent image analysis of performed VE-cadherin staining 
of cultured endothelial cells confirmed this assessment by revealing considerable changes in cell 
morphology that HUVECs underwent, while being exposed to a constant shear stress for an extended 
period of time (Figure S5). 
 
 
Figure 5. Changes in cell morphology due to the applied shear stress. (a) Brightfield images of 
HUVECS cultured under a constant shear stress (10 dyn cm-2) revealed considerable elongation and 
orientation of cell bodies. (Scale bar 100 µm.) (b) CLSM analysis of HUVECs cultured under static (top 
row) and flow conditions (bottom row). Immunostaining for VE-cadherin (red) and F-actin (green) 
revealed substantial changes in cell morphology due to application of flow during cell culture. In all 
images for dynamic conditions, flow was applied from left to right. (Scale bar 20 µm.)  
 




These results were in line with previous studies35,53,54 and show the importance of adequate culturing 
conditions to create a realistic cell environment for further studies.55 For all following NP uptake 
experiments, we decided to pre-culture HUVECs under the same flow conditions (10 dyn cm-2; 72 h). 
This should on the one hand guarantee a realistic cell environment for the uptake studies, but on the 
other hand exclude any additional impact of different culturing parameters and resulting changes in cell 
phenotype on the actual NP endocytosis. 
 
3.3 Steric shielding concept is transferable to more realistic flow conditions 
Having implemented a cell culture model under constant physiological shear stress, we next intended to 
test the steric shielding concept on its transferability to flow conditions. In that context, numerous studies 
have previously shown, that NP-cell interaction can be significantly altered, if particles are subject to a 
constant flow during incubation.35 Similar to the circulation in a blood vessel, NPs thereby not only have 
to migrate from the vessel or channel interior towards the wall (margination)56, but also bind to the cell 
surface swiftly enough to prevent immediate detachment due to the applied flow.57–59 Concerning our 
above-described shielding concept, it was particularly important to assess the impact of flow conditions 
not only on the actual ligand-receptor interplay, but also on the spatial organization of the polymeric 
shielding elements and their capacity to sufficiently camouflage the ligand activity. Therefore, we 
considered it essential to assess whether the discussed shielding of cRGD-integrin interaction is also 
maintainable once the particles are passing the endothelial cells at a certain flow rate.  
To that end, HUVECs were initially cultured under flow conditions, triggering the above-described 
morphological changes (Figure 5). To realistically mimic NP circulation in the blood vessel, 
fluorescently labeled NPs were not pipetted on the culture slides but filled into the perfusion sets. This 
enabled the incubation of endothelial cells with NPs under various flow rates.  
Figure 6 shows flow cytometry results of HUVECs after incubation with differently shielded NP species 
at a flow rate of 2 mL min-1 (equaling a shear stress of 1.8 dyn cm-2) . In accordance with the results 
under static conditions (Figure 3), cRGD-mediated NP uptake was the highest for unshielded NPs and 
gradually decreased with a higher surface density and greater length of shielding elements. We therefore 
concluded that integrin-mediated particle uptake was similarly controllable as under static conditions.  





Figure 6. Flow cytometry analysis of NP uptake into HUVECs under flow conditions (flow rate = 2 mL 
min-1; shear stress = 1.8 dyn cm-2). Comparable to static conditions, cell-associated fluorescence for 
unshielded cRGD NPs was highest and gradually decreased with higher surface densities and chain 
lengths of respective shielding chains. NPs carrying 75 % of 5k shielding elements thereby showed no 
significant difference in cell uptake compared to ligand-free control NPs, indicating complete inhibition 
of ligand-receptor interplay. Results represent mean ± SD (n = 3). ****P < 0.0001. (n.s. not significant; 
AFU, arbitrary fluorescence units.) 
 
CLSM analysis (Figure 7) further confirmed this observation with unshielded cRGD NPs showing the 
highest intracellular accumulation, while increasing amounts of 3.5k shielding elements lead to a 
substantial decline in fluorescence levels. This trend was even greater for longer 5k shielding elements, 
where only marginal fluorescence could be detected for higher amounts of 5k shielding (Figure S6).  
CellMask staining of HUVECs additionally showed the substantial elongation and alignment of cultured 
cells as a response to the previously applied shear stress. As the described concept of steric ligand 
shielding was also transferable to more realistic flow conditions, we were finally interested in the 
immediate impact of the applied flow rate on NP deposition. As the initially tested flow rate of 2 mL 
min-1 (shear stress = 1.8 dyn cm-2) can be assigned to smaller vessels in the circulatory system with 
lower blood supply, we decided to additionally test higher flow rates of 10 and 15 mL min-1 (shear stress 
= 9.2/13.8 dyn cm-2), which can be found in medium and larger arteries.60 





Figure 7. CLSM analysis of NP uptake under flow conditions. NP accumulation in endocytotic vesicles 
(purple) of the HUVEC cell cytosol (grey) was gradually decreasing with rising amounts of 3.5k 
shielding elements on the NP surface (top row to bottom row). CellMask staining also showed 
characteristic shear stress induced elongation of cultured cells as described above. (Scale bar 20 µm).  
 
Our hypothesis thereby was, that the shielded NPs would show only neglectable endothelial deposition 
at these higher flow rates, which should correspond to the initial phase of NP circulation in larger blood 
vessels. At lower flow rates, on the contrary, NP uptake should increase in comparison, thereby 
facilitating particle accumulation at the actual target sites, where in most cases the corresponding blood 








Figure 8. Flow cytometry analysis of NP uptake dependent on the applied flow rate. Cell-associated 
fluorescence for all flow rates gradually decreased with higher amounts and length of shielding 
elements. While cell uptake under a flow rate of 10 mL min-1 was significantly lower compared to a 
flow rate of 2 mL min-1 for almost all particle types, fluorescence levels for a high flow rate of 15 mL 
min-1 were considerably reduced with only marginal differences between the NP species. Results 
represent mean ± SD (n = 3). *P  < 0.05. ****P < 0.0001. (n.s. not significant; AFU, arbitrary 
fluorescence units.) 
 
Figure 8 shows the flow cytometry results of cells incubated with NPs under the above discussed flow 
rates. While the already described indirect proportionality of NP uptake and ligand shielding could also 
be found at flow rates of 10 and 15 mL min-1, the absolute values of cell-associated fluorescence 
substantially decreased compared to the results at 2 mL min-1. Interestingly, NP uptake into HUVECs 
was lower at higher flow rates even though the frequency and therefore the total amount of NPs passing 
by the cells was 5- and 7,5-fold higher. We therefore estimated, that due to the increased flow rate, 
cRGD-integrin interplay was additionally hindered, and NP were detached from the cell surface before 
they could initiate integrin-mediated endocytosis. This hypothesis was additionally supported by the 
observation, that levels of cell-associated fluorescence were minimal for the highest flow rate of 15 ml 
min-1. Here, differences between the administered NP species were only marginal. However, this 
generally reduced cell uptake of all NP types at very high flow rates would be highly beneficial, 
considering that these conditions are merely present in very large vessels such as the aorta, where NP 




In summary, the introduced concept of steric ligand shielding was satisfactorily transferable to more 
realistic flow conditions and could also be maintained under application of higher shear forces, thereby 
proving its robustness regarding a possible in vivo application. The observed differences in cell uptake 
dependent on the applied flow rate are equally promising as they could be used to implement the above 
discussed targeting strategy for areas of lower blood flow, such as the initially mentioned mesangium. 
In this context, it would be valuable to also test the experienced effects for NPs with a varying diameter 
as a multitude of studies stress, that these characteristics can greatly influence particle migration towards 
the vessel wall or unspecific cell binding of NPs in general.49,62  
Additionally, several further aspects would have to be assessed when it comes to the transferability of 
these results to an in vivo setting: First, in contrast to the applied continuous flow conditions, bigger 
arteries such as the aorta are subject to a pulsatile blood flow. However, it is important to mention, that 
cRGD-mediated NP deposition within these vessels would also be considerably hampered by to the 
substantial shear stress in these areas (Figure 8). Second, despite the above described low impact of the 
overall increased PEG surface amount on the actual cRGD-integrin interaction, NP in vivo circulation 
time would potentially be increased due to a general “stealth” effect, which even has been found for NP 
species with a very low PEG functionalization degree.63  In the present study, this effect most probably 
only played a minor role due to the merely short incubation time of 45 min. Lastly, further blood 
components such as red blood cells56,64, the constantly changing mixture of serum proteins as well as 
the MPS would certainly also have a significant impact on the transferability of this concept.  
 
4 Conclusion 
In this study, we were able to implement a steric shielding concept to efficiently control off-target 
accumulation of cRGD-functionalized NPs to integrin-positive endothelial cells in vitro. NP uptake 
could thereby be satisfactorily steered by addition of respective amounts of longer or shorter PEG-PLA 
components. Furthermore, the shielding concept was not only applicable under static conditions but 
could also be transferred to more realistic flow conditions. Interestingly, overall NP uptake was thereby 
decreasing with application of higher flow rates. Regarding possible in vivo applications, this fact could 
potentially be used to precisely target areas with lower blood supply like small arterioles or interstitial 
tissues such as the renal mesangium or the hepatic space of Disse. Thereby, partially shielded particles 
would initially be protected from off-target deposition in areas of high flow rates such as big arteries, 
which would increase the timespan for successful passive targeting strategies like extravasation through 
fenestrated endothelia in the kidney or liver.65,66 Once the NPs would reach the area of interest, ligand-
mediated endocytosis could be initiated due to the present lower flow rates and consequently greater 
timespan for the necessary cell-particle interaction. In that regard, we were already able to show, that 
partially shielded cRGD NPs still have a considerably enhanced mesangial target efficacy in contrast to 
ligand-free control NPs.29  




To our estimation, the present study demonstrates, that novel concepts of actively targeted NPs should 
not only try to maximize on-target efficacy of manufactured systems, but also focus on a satisfactory 
steerability of the implemented targeting functionalities. This aspect becomes even more critical, when 
the targeted cell recognition sequences cannot be exclusively attributed to one single cell type, which is 
the case for the majority of all active targeting approaches. The shielding concept itself is thereby not 
limited to the presented materials as the general principle of a sterically hindered ligand-receptor 
interaction could also be realized with different polymers or other targeting sequences, provided that the 
visibility of the NP-bound ligand is lowered via the addition of longer protruding surface components. 
In our view, the above discussed results not only demonstrate the potential of described steric shielding 
concept, but also show, that transferability of in vitro experiments largely depends on a realistic 
reconstruction of actual in vivo conditions. Future approaches for efficient drug delivery applications 
should therefore not only focus on the profuse refining of targeting strategies but also scrutinize 
prevalent experimental set-ups. In this regard, approaches to mimic the actual geometry of the 
circulatory architecture play a pivotal role in facilitating more efficient drug delivery concepts.34,67 
Nevertheless, most concepts eventually still need to be tested in an in vivo setting, as the complex 
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1 NP compositions 
 
 
Figure S1. PEG-PLA composition of different NP species. While all NP types were manufactured with a PEG-
PLA/PLGA ratio of 70/30, the composition of the respective PEG-PLA fraction was adjusted with regard to the 
intended particle features. Thereby, Control NPs contained 100 % of unfunctionalized COOH-PEG2k-PLA10k. To 
theoretically enable integrin-specific NP uptake, all other NP types were fabricated with an addition of 25 % 
cRGD-PEG2k-PLA10k. Besides, 25-75 % of either COOH-PEG3.5k-PLA10k or COOH-PEG5k-PLA10k were added to 
produce shielded NP species (3.5k/5k shielding).  
 
2 αvβ3 expression 
 
Figure S2. Quantification of αvβ3 expression by HUVECs. (a) Flow cytometry results. Antibody staining for αvβ3 
integrin showed a significantly stronger fluorescence signal compared to both the isotype and blank control, 
proving a substantial integrin expression by HUVECs. Results represent mean ± SD (n = 3). (b) CLSM analysis 
confirmed flow cytometry results and showed a considerable cell surface fluorescence of respective integrin 
antibody, compared to the isotype control. (Scale bar 20 µm.) 
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Figure S3. CLSM analysis of NP uptake under static conditions for 5k shielding and Control NPs. Addition of 
rising amounts of 5k shielding elements (row 1-3) lead to a gradual decrease in NP-associated fluorescence 
(purple) within the HUVEC cytosol (grey). NPs with 75 % 5k shielding showed only very weak NP uptake, which 
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4 Steric shielding effect 
 
Figure S4. Confirmation of a steric shielding effect. (a) To assess a possible impact of the general composition of  
the NP PEG corona on the cRGD-integrin interaction and the resulting NP uptake, unshielded cRGD NPs (25 % 
cRGD) were manufactured not only with a PEG chain length of 2 kDa, but also with longer COOH-/cRGD-
PEG3.5k/5k-PLA10k. (b) DLS analysis thereby revealed no considerable changes in NP diameter or size distribution. 
(c) Flow cytometry analysis of NP uptake under static conditions. While unshielded cRGD NPs (2k) showed a 
maximum endothelial cell uptake, fluorescence levels for unshielded cRGD NPs with longer PEG chain lengths 
(3.5k/5k) were comparably high, indicating that higher amounts of PEG on the NP surface had only a minor effect 
on the interaction between cRGD and integrin αvβ3. In contrast, sterically shielded NPs, that were manufactured 
with shorter cRGD-PEG2k-PLA10k but also carried 75 % of longer shielding chains (3.5k/5k), showed a 
significantly reduced endothelial cell uptake compared to all unshielded cRGD NP species (2k/3.5k/5k). Results 
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5 Morphological changes under flow incubation 
 
 
Figure S5. In order to quantify observed morphological changes between static and flow conditions, individual 
cell dimensions were assessed by image analysis of previously described VE-cadherin staining (Figure 5b). (a) 
Cells cultured under flow conditions showed only minimal divergence from the horizontal flow direction while 
cells cultured under static conditions were randomly spread without any apparent alignment. (b) Distribution of 
axis ratios for HUVECs cultured under flow showed a considerable right-shift compared to the static control, 
indicating substantial cell alignment. (Axis ratio = major axis/minor axis.) (c) Cell circularity under flow 
conditions was considerably decreased compared to static conditions. (Circularity value of 1.0 indicates a perfect 
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6 CLSM uptake under flow conditions 
 
 
Figure S6. CLSM analysis of NP uptake under flow conditions (flow rate: 2 mL min-1) for 5k shielding and Control 
NPs. NP-associated fluorescence (purple) within the HUVEC cell body (grey) gradually decreased for higher 
levels of shielding elements. NPs containing 50-75 % of 5k shielding did not show a considerably higher cell-
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Diabetic nephropathy (DN) ranks among the most detrimental long-term effects of diabetes, affecting 
more than 30% of all patients. Within the diseased kidney, intraglomerular mesangial cells play a key 
role in facilitating the pro-fibrotic turnover of extracellular matrix components and a progredient 
glomerular hyperproliferation. These pathological effects are in part caused by an impaired functionality 
of soluble guanylate cyclase (sGC) and a consequentially reduced synthesis of anti-fibrotic messenger 
3´,5´-cyclic guanosine monophosphate (cGMP). Bay 58-2667 (cinaciguat) is able to re-activate 
defective sGC, however the drug suffers from poor bioavailability and its systemic administration is 
linked to adverse events such as severe hypotension, which can hamper the therapeutic effect. In this 
study, cinaciguat was therefore efficiently encapsulated into virus-mimetic nanoparticles (NPs) which 
are able to specifically target renal mesangial cells and therefore increase the intracellular drug 
accumulation. NP-assisted drug delivery thereby substantially increased in vitro potency of cinaciguat-
induced sGC stabilization and activation as well as the related downstream signaling four- to five-fold. 
Also, administration of drug-loaded NPs provided a considerable suppression of the non-canonical 
transforming growth factor β (TGF-β) signaling pathway and the resulting pro-fibrotic remodeling by 














































With an estimated number of almost 500 million cases worldwide and an ever-growing prevalence 
throughout all age groups, diabetes ranks among the top global causes of death.1 While the imminent 
consequences of a poor blood sugar homeostasis are minor, long-term diabetic complications severely 
limit the life expectancy of patients. Among these, chronic kidney disease (CKD) and eventual end-
stage renal disease (ESRD), i.e. the ultimate loss of kidney function, are regarded to be most critical.2–4 
Within the plentiful concomitants of CKD, diabetic nephropathy (DN) plays a central role, affecting 
more than 30% of diabetes patients.5,6 When it comes to DN, a plethora of pathological renal processes 
are initiated by a prolonged state of hyperglycemia and eventually culminate in a progredient decline in 
glomerular filtration capacity.7 Among these processes, increasing podocyte damage, basement 
membrane thickening as well as an increased glomerular hypertrophy and fibrosis have been found to 
play a substantial role.8,9 In that context, the glomerular mesangium acts as a key player by facilitating 
a fundamentally altered production of extracellular matrix components as well as a broad range of 
paracrine interactions with glomerular endothelial cells and podocytes.10–12 Within the highly complex 
network of molecular mechanisms, that are responsible for this pathological remodeling, progredient 
activation of transforming growth factor β (TGF-β) signal cascades has been shown to be a central 
element, especially regarding an increased ECM remodeling and glomerular hyperproliferation.13–15 
However, there is also unanimous evidence, that apart from other pathological triggers such as elevated 
oxidative stress or an enhanced activity of the renin angiotensin aldosterone system (RAAS), a 
dysfunctionality of nitric oxide (NO) and its downstream cascade plays a pivotal role.16–18 Under 
physiological conditions, NO can bind the intracellularly located soluble form of the guanylate cyclase 
(sGC), that then transforms guanosine triphosphate (GTP) to 3´,5´-cyclic guanosine monophosphate 
(cGMP), a central messenger for the downregulation of excessive glomerular fibrosis and 
hyperproliferation.19–21 Under hyperglycemic conditions, however, NO production is impaired due to a 
progrediently dysfunctional endothelium.22 Also, the above mentioned, hyperglycemia-induced 
oxidative stress can lead to an oxidation or even loss of the sGC heme prosthetic group (Fe3+-/Apo-
sGC), making the enzyme unresponsive to any NO activation.23,24 Initially, pharmacological research 
concerning the NO-cGMP cascade – particularly in the field of cardiovascular disease - was mainly 
focused on an increase of nitric oxide levels via NO-donating substances or an inhibition of cGMP-
degrading phosphodiesterases.25 However, the impact of these approaches as well as sGC stimulators 
such as riociguat relies on a sufficient residual activity of sGC and is therefore severely limited, if an 
sGC heme oxidation or loss has already taken place. In contrast, sGC activators such as Bay 58-2667 
(cinaciguat; CCG) are able to specifically bind and thus re-activate defective Fe3+-/Apo-sGC 
independently of the presence of NO. This characteristic provides the fundamental advantage, that a 
therapeutic effect is also achievable in a more advanced stage of disease. Initial research on CCG was 
mainly focused on its therapeutic effects regarding the cardiovascular system26, however there is also 
promising evidence concerning a beneficial role in above discussed renal fibrosis and 
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hyperproliferation27–29, whereby a CCG-mediated sGC activation has been shown to reduce TGF-β 
expression as well as non-canonical TGF-β signaling via extracellular-regulated protein kinase 1/2 
(ERK 1/2).30,31 While these results were highly encouraging, CCG can however also potentially cause 
unfavorable adverse events such as a strong hypotension due to its imminent effect on the vasculature 
after a systemic administration.32 The application of the free drug is additionally complicated by its 
profound lipophilicity which could possibly hamper the therapeutic success due to a reduced solubility 
or a generally disadvantageous biodistribution.33 To our estimation, CCG would therefore substantially 
profit from a drug delivery system, that is able to considerably increase the drug accumulation in target 
regions such as the above discussed mesangium while minimizing interactions with off-target sites like 
the vasculature.   
When it comes to targeted drug delivery, nanoparticular approaches provide the considerable benefit, 
that they enable the differentiation of targeted tissues from un-favorable off-target sites via 
functionalization with cell-selective recognition sequences for target cell surface structures.34,35 
Implementation of this principle already led to a great number of nanoparticular devices with a 
substantial specificity for target cells within various tissues such as the colon, liver or also the kidney.36–
38 In that regard, we recently presented an actively targeted nanoparticle (NP) species, that enabled a 
highly specific mesangial in vivo targeting within the kidney.39 The NP system is based on a virus-
mimetic presentation of two ligands that selectively recognize mesangial surface components and enable 
a reliable discrimination of mesangial sites and possible off-targets. Inspired by its biological model, 
human adenovirus type 240, the NP thereby interacts with the cell surface in a sequential manner of initial 
binding to the angiotensin II receptor type 1 (AT1r) via an AT1r blocker (EXP3174), followed by a 
presentation of previously shielded cyclic amino acid sequence (cRGD), that activates mesangial surface 
integrin αvβ3 and eventually triggers cell endocytosis (Figure 1a).41  
As this NP system provided excellent mesangial in vivo specificity, we hypothesized, that virus-mimetic 
NPs loaded with CCG (Figure 1b) could substantially increase drug delivery into intracellular 
compartments of target mesangial cells. After a subsequent processing and endolysosomal degradation 
of the NP system, the active substance would be released and then bind and thus stimulate cytosolic 
sGC, both in its oxidized and heme-free form, which would eventually lead to a significant rise in cGMP-
mediated signaling (Figure 1a).    
In this study, we therefore initially loaded our NP system with CCG and assessed, whether a 
therapeutically relevant amount of drug could be encapsulated while still preserving the described active 
mesangial NP targeting functionalities. In order to subsequently test the pharmacological impact of the 
NP-mediated drug delivery, we compared the effect of both free and NP-encapsulated CGG on its target 
as well as various further downstream elements of the sGC-cGMP cascade such as the cGMP-dependent 
activation of protein kinase 1 α (PKG1-α). Finally, we determined the anti-fibrotic potential of the 
system in a TGF-β induced in vitro fibrosis model (Figure 1a).  
 




Figure 1. Therapeutic concept. a) NP-assisted CCG delivery to intracellular Apo-/Fe3+-sGC of target mesangial 
cells. After a sequential and thereby highly cell-selective mesangial NP uptake, CCG is released into the cytosol 
due to endolysosomal degradation of the NP. Here, CCG binds and thus activates both oxidized and heme-free 
sGC, leading to an increased production of cGMP and a PKG1-α mediated inhibition of TGF-β induced 
pathological remodeling. b) Manufacturing principle for CCG-loaded virus-mimetic NPs.   
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2 Materials and Methods 
2.1 Materials 
BAY 58-2667 (Cinaciguat hydrochloride) was purchased from Axon Medchem BV (Groningen, 
Netherlands). For NP preparation, heterobifunctional poly(ethylene glycol) components were obtained 
from Jenkem Technology USA Inc. (Allen, TX, USA), while methoxy poly(ethylene glycol) and 
Resomer RG 502 (PLGA) were purchased from Sigma-Aldrich (Taufkirchen, Germany). EXP3174 
(losartan carboxylic acid) was obtained from Santa Cruz (Heidelberg, Germany) and cyclic RGDfK 
(cRGD) was purchased from Synpeptide Co. Ltd. (Shanghai, China). AlexaFluor 568 Hydrazide 
(Alexa568) and CellTracker Deep Red Dye (CTDR) were purchased from Fisher Scientific GmbH 
(Schwerte, Germany). For Lowry protein determination and later western blot analysis, DC protein assay 
and Clarity™ Western ECL Blotting substrate were obtained from Bio-Rad Laboratories GmbH 
(Munich, Germany). Immobilon® PVDF membranes were purchased from Millipore GmbH 
(Schwalbach, Germany). For western blot analysis, the following primary antibodies and dilutions were 
used: sGC β1 (ER19), rabbit, 1:500 (Sigma-Aldrich); phospho-VASP (Ser239), rabbit, 1:1000;  VASP 
(9A2), rabbit, 1:1000; phospho-p44/42 MAPK (p-ERK1/2), rabbit, 1:1000; p44/42 MAPK (ERK1/2), 
rabbit, 1:1000; GAPDH, rabbit, 1:1000 (all from Cell Signaling Technology, Cambridge, UK); PKG1-
α, rabbit, 1:500 (own production 42); Col1α1, rabbit, 1:500; α-SMA, mouse, 1:500 (Abcam, Cambridge, 
UK); vinculin, mouse, 1:500 (R&D Systems, Wiesbaden-Nordenstadt, Germany). Secondary 
antibodies: mouse-IgG horse radish peroxidase-conjugated, 1:10000 (Sigma-Aldrich); rabbit-IgG horse 
radish peroxidase-conjugated, 1:25,000 (Dianova GmbH, Hamburg, Germany). Transforming growth 
factor-β1 human (TGF-β) as well as all other utilized chemicals were purchased from Sigma-Aldrich in 
analytical grade if not stated differently. Immortalized, rat-derived mesangial cells (rMCs) were a kind 
gift from Prof. Dr. Armin Kurtz (Institute of Physiology, University of Regensburg, Regensburg, 
Germany). rMCs were isolated and cultured in RPMI 1640 medium containing 10% fetal bovine serum, 
insulin-transferrin-selenium (ITS) (1×), and 100 nM hydrocortisone as previously described.43,44  
2.2 Synthesis and functionalization of NP polymer components 
COOH-/NH2-PEG2k/5k-PLA10k block copolymers were synthesized and functionalized with EXP3174/ 
cRGDfK as previously published by our working group39,41,45–47, yielding longer EXP3174-PEG5k-
PLA10k and shorter cRGD-PEG2k-PLA10k. When needed, core component PLGA was additionally 
coupled to Alexa568 as described before to enable fluorescence imaging of NPs.39 
2.3 NP manufacture and CCG encapsulation 
Using above mentioned unfunctionalized/ligand-carrying block copolymers and core-forming PLGA, 
EXPcRGD NPs as well as ligand-free control NPs were manufactured via a well-established 
nanoprecipitation method39,46,47. In brief, all polymeric components were mixed in acetonitrile 
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(ACN), whereby different ratios of PEG-PLA/PLGA (70/30; 60/40; 50/50) were prepared to test the 
ideal composition for CCG encapsulation. For ligand-carrying EXPcRGD NPs, the PEG-PLA 
proportion thereby consisted of 25% EXP3174-PEG5k-PLA10k, 15% cRGD-PEG2k-PLA10k and 60% 
COOH-PEG2k-PLA10k (ligand-free NPs: 100% COOH-PEG2k-PLA10k), which had previously been 
found to be ideal for the desired stepwise targeting concept.39 The polymer mix was finally added 
dropwise to vigorously stirring millipore water (mpH2O), yielding above-described NP species.  
For drug encapsulation, a stock solution of 2 mg mL-1 CCG in a mixture of ACN/dimethyl sulfoxide 
(DMSO) (21/1; V/V) was prepared and rising volumes of the CCG solution were added to the polymer 
mix prior to nanoprecipitation. The NP solution was stirred for 3 h at room temperature (RT) to remove 
all organic solvents and subsequently purified from non-encapsulated CCG via centrifugation using Pall 
Microsep filters (molecular weight cut-off, 30 kDa; Pall Corporation, NY, USA). The NPs were thereby 
centrifuged three times (1250g; 10 min) and washed with mpH2O after every centrifugation step.  
2.4 NP characterization 
Manufactured NPs were analyzed regarding their hydrodynamic diameter with a Malvern Zetasizer 
Nano ZS (Malvern, Herrenberg, Germany). For a more thorough discussion of these aspects and the 
surface density of EXP3174 and cRGDfK on the NP surface, please refer to our previous 
publications.39,41 
2.5 HPLC analysis of drug encapsulation 
For a detailed analysis of CCG encapsulation, HPLC analysis was performed using a PLRP-S column 
(Agilent Technologies Inc., Santa Clara, CA, USA) at 40 °C. The mobile phase consisted of a 10 mM  
sodium phosphate buffered solution (pH 7.4; A) and ACN (B) (gradient: 0 min 95% A / 5% B; 9 min 
65% A / 35% B; 25 min 20% A / 80% B; 45 min 20% A / 80% B; 50 min 95% A / 5% B), eluted at 1.0 
mL min-1.48 CCG was detected at a wavelength of 230 nm (retention time = 12 min). For calibration, 
CCG dilutions of 0.0125 - 0.8 mg mL-1 in DMSO were prepared, injected in the HPLC system and the 
resulting peak area was analyzed (injection volume = 15 µL). To investigate drug encapsulation 
efficiency for the different NP types, freshly prepared particles were freeze-dried for 72 h, weighed, and 
subsequently dissolved in DMSO and injected into the HPLC system (injection volume = 15 µL), 
yielding a CCG peak at the same retention time (Figure 2a).  
2.6 Calculatory determination of encapsulation parameters 
For a detailed explanation of the calculation of the Flory-Huggins parameter, please refer to our previous 
publication.49,50 The encapsulation efficiency (EE) was calculated as depicted in equation 1 (E1), 
whereby me is the mass of encapsulated drug and ma is the mass of initially added CCG.  
 
   [%] =  "#"$  ×  100                                                                                                                         (E1) 
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For the lyophilized NP batches, we then assessed the amount of NPs (nNP) using E2, whereby mNP is the 
gravimetrically determined mass of the NP batch, ρ(NP) is the estimated density of the NPs (1.25 g cm-3) 
49, dh is the experimentally determined hydrodynamic diameter and NA is the Avogadro constant.45 
 




/  × 7'8                                                                                                                                   (E2) 
 
Next, the amount of CCG molecules per batch (nCCG) was calculated from the HPLC results and the 
number of CCG molecules per NP (Nexp) was determined with E3. 
 
9:;< =  >??@>)*                                                                                                                                              (E3) 
 
We then calculated the theoretical volume of the NP core (Vcore) for every NP sample as described 
before.49 Assuming a maximum packing efficiency of 90%51 as well as the molecular volume of CCG 
(VCCG = 0,725 nm3) 52, we then calculated the ideal number of CCG molecules per NP (Nideal) using E4.  
 
9AB:CD =  EFGH#E??@  ×  0,9                                                                                                                                 (E4) 
 
Finally, the CCG entrapment efficiency (EET) was determined using the experimentally determined Nexp 
and E5. 
 
 KL[%] =  
'#MN
'O4#$P
 ×  100                                                                                                                         (E5) 
2.7 CLSM analysis of NP uptake 
To confirm ligand-mediated NP uptake, target rMCs were initially stained with CTDR for 45 min (25 
µM in serum-free medium, 37 °C, 5% CO2), subsequently seeded into 8-well slides (Ibidi, Gräfelfing, 
Germany) at a density of 8000 cells well-1 and incubated for 48 h at 37 °C and 5% CO2. CCG-loaded 
EXPcRGD NPs as well as ligand-free particles were prepared as described above, however with Alexa 
568-labeled PLGA (40% PLGA; 10 µg CCG addition per batch).  Resulting NPs were adjusted to a 
concentration of 0.4 nM using Leibovitz´s buffer supplemented with 0.1% bovine serum albumine 
(BSA) and added to the cells for 90 min. After, cells were washed with Dulbecco´s phosphate buffered 
saline (DPBS) and fixed with 4% paraformaldehyde (PFA) in DPBS for 10 min. To enable visualization 
of the cell nuclei, cells were thereafter stained for 5 min with a 1:200 dilution of 4′,6-diamidine-2′-
phenylindole dihydrochloride (DAPI) in DPBS. Final samples were subsequently analyzed at a Zeiss 
LSM 710 (Carl Zeiss Microscopy GmbH, Jena, Germany).  
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2.8 Analysis of CCG effect on intracellular targets  
To study the effect of free and NP-encapsulated cinaciguat on mesangial intracellular targets, cells were 
seeded into 6-well plates (Corning Inc., Corning, NY, USA) at a density of 200,000 cells well-1 and 
grown for 48 h (37 °C, 5% CO2). Subsequently, cells were incubated for 1 – 24 h with either free CCG 
(c = 0.2/2 µM), CCG-loaded EXPcRGD NPs (c(NP) = 0.4 nM; c(CCG) = 0.2 µM) or CCG-free 
EXPcRGD NPs (c(NP) = 0.4 nM). All samples were thereby adjusted to the specified concentrations 
using serum-free RPMI 1640 medium. After incubation, samples were aspirated, and cells were 
processed as previously described. 53 In brief, cells were washed with DPBS and harvested by adding 
80 µL of lysis buffer (2% Lubrol, 20 mM  Tris, 150  mM NaCl; protease inhibitors:  0.5 µg mL-1 
leupeptin, 1 mM benzamidine, 0.3 mM phenylmethylsulfonyl fluoride) and using a cell scraper. Cells 
were thereafter homogenized and centrifuged for 15 min at 16,500 g and 4 °C to remove cell remnants. 
For the following determination of the protein concentration of cell lysates, a modified method of Lowry 
was used.54 Cell samples were thereafter denatured, separated using a 11.5% SDS-PAGE (30 µg protein 
lane-1) and western blotted using above-described primary antibodies against sGC, (P-)VASP, PKG1-α 
as well as GAPDH. Horse radish peroxidase coupled secondary antibodies were added and finally, 
activity was assessed after addition of Clarity™Western ECL Blotting substrate, using a 
chemiluminescence detector (ChemiDoc MP System; Bio-Rad Laboratories) and ImageLab software. 
Results for both sGC and PKG1-α were thereby normalized to the GAPDH content per sample. For 
VASP, the ratio of P-VASP and VASP was determined and normalized to the P-VASP/VASP ratio of 
untreated control cells.  
2.9 Analysis of anti-fibrotic CCG effects 
To determine the anti-fibrotic potential of CCG-loaded EXPcRGD NPs, we implemented a fibrosis 
model, whereby rMCs were initially seeded into 6-well plates as described above and serum-starved 
after 24 h in order to exclude any impact of serum-derived TGF-β.55 After another 24 h, free CCG, CCG-
carrying or CCG-free EXPcRGD NPs were added as described above. After incubation for 3 h, 10 ng 
mL-1 of TGF-β per well was added to induce pro-fibrotic changes. Also, for a second group, free 
CCG/NPs and TGF-β were added simultaneously. Cells were thereafter incubated for either 1 h (ERK1/2 
phosphorylation) or 72 h (α-SMA/Col1α1 content), depending on the intended read-out (see also Figure 
6a). After incubation, cells were harvested as described above, followed by SDS-PAGE and western 
blot analysis with the respective antibodies. Resulting band intensities of α-SMA/Col1α1 were finally 
normalized to the respective vinculin content, while for ERK1/2, the ratio of P-ERK1/2 and ERK1/2 
was determined and normalized to the P-ERK1/2/ERK1/2 ratio of untreated cells. 
2.10 Cell proliferation assay 
To assess the impact of discussed samples on a TGF-β induced mesangial hyperproliferation, a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay was performed. In brief, 
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rMCs were seeded into a 96 well plate (Corning Inc.) at a density of 3000 cells well-1 and incubated for 
48 h, whereby cells were serum-starved after 24 h. Cells were thereafter incubated for 72 h with samples 
and TGF-β in serum-free RPMI medium, as described in the previous section. After 72 h, samples were 
removed and 50 µL of RPMI medium containing 1 mg mL-1 MTT were added per well. After 3 h of 
incubation, the MTT solution was aspirated and 100 µL of isopropanol were added for 30 min under 
light exclusion and gentle shaking. Finally, absorbance at 570 and 690 nm was assessed at a FluoStar 
Omega fluorescence microplate reader (BMG Labtech, Ortenberg, Germany). For cell viability, the 
difference in absorbance at 570 and 690 nm was determined. Results were finally normalized to 
untreated control cells.  
2.11 CLSM analysis of α-SMA expression 
For visualization of changes in α-SMA deposition, rMCs were initially seeded into 8-well Ibidi slides 
as described above. After 24 h, cells were serum-starved, and after another 24 h, cells were incubated 
with either free CCG, CCG-loaded or CCG-free EXPcRGD NPs for 3 h, followed by a TGF-β 
stimulation for 72 h (c = 10 ng mL-1) in serum-free RPMI medium. Cells were thereafter washed, fixed 
with 4% PFA for 10 min at RT and permeabilized with 0.1% Triton-X in DPBS for 10 min at RT. After 
a washing step,  unspecific binding sites were blocked by addition of a 1% solution of BSA in DPBS 
for 30 min. Subsequently, cells were incubated overnight with a mix of AlexaFluor® 488-coupled 
antibody against α-SMA (Sigma-Aldrich) and DAPI (1:500 in 0.1% BSA in DPBS), followed by CLSM 
analysis.  
2.12 Statistical Analysis 
Results are expressed as mean ± standard deviation (SD), whereby n represents technical replicates. 
Statistical parameters were calculated using GraphPad Prism 6 software. One-way analysis of variance 
(ANOVA) as well as Tukey post-test were performed for calculation of statistical differences between 
analyzed groups. The resulting p-values are stated in each individual figure.  
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3 Results and Discussion 
3.1 Efficient and reproducible encapsulation of CCG into targeted NPs 
To enable a NP-mediated, targeted delivery of CCG to mesangial sites, we initially assessed whether a 
pharmacologically sufficient amount of drug can be encapsulated into our NP system. The NP itself 
thereby consists of shell-forming poly(ethylene glycol)−poly(lactic acid) (PEG-PLA) block-copolymers 
carrying the above described targeting functionalities as well as poly(lactic-co-glycolic acid) (PLGA), 
which both stabilizes the NP core and can be used to encapsulate suitable active agents such as CCG 
(Figure 1b). In this regard, we recently presented a study discussing the necessary physicochemical 
properties of encapsulated compounds in order to achieve a satisfactory NP loading.49 We therein found, 
that for a successful encapsulation, substances on the one hand need to possess a sufficient lipophilicity 
and on the other hand, the miscibility of encapsulated drug and core forming PLGA has to exceed a 
certain threshold in order to guarantee NP stability. With regard to these prerequisites, CCG was found 
to be a promising candidate for NP encapsulation, showing a substantial lipophilicity (logP ≈ 7) and a - 
calculatorily determined - high miscibility with PLGA. In that regard, the Flory-Huggins parameter for 
CCG and PLGA was found to be around 0.005, indicating that both components are excellently 
miscible.50  
Based on these initial considerations, we decided to test three different NP compositions with a varying 
proportion of core PLGA (30/40/50%) to find an ideal compromise between high drug loading, 
satisfactory encapsulation efficiency and small NP diameter. It was thereby particularly important, that 
resulting NPs would not exceed 90 – 100 nm to still guarantee a sufficient in vivo extravasation through 
the fenestrated glomerular endothelium into mesangial areas.56 For every NP composition, we then 
added rising levels of CCG to the polymer mix and - after nanoprecipitation and lyophilization of NPs 
- assessed the amount of encapsulated drug via high performance liquid chromatography (HPLC). Both 
free CCG and NP-derived CCG could thereby be reproducibly detected at a wavelength of 230 nm 
(Figure 2a and Figure S1).  
As Figure 2b indicates, larger amounts of initially added drug led to a progredient rise in finally 
encapsulated CCG (CCG loading) for all three NP compositions, whereby NP quality (size/dispersity) 
still remained satisfactory (Figure S2a-c). However, an addition of more than 10 µg CCG per 4 mg NP 
batch did not produce any further rise in CCG loading, but rather increased the tendency of NPs to form 
larger aggregates, indicating that the general NP loading capacity was exceeded (Figure S2d). For the 
following analysis, we therefore decided to add 10 µg  of drug during nanoprecipitation to both enable 
a maximum CCG loading and preserve the NPs´ stability.   
In a next step, we determined several physicochemical parameters to assess the optimal PLGA 
proportion per particle (for a more detailed description, please also refer to the Methods section, Figure 
S3a/b as well as49). While the NPs´ hydrodynamic diameter was found to be below 100 nm for all three 
NP types (Figure S2c), the encapsulation efficiency was significantly rising with a greater 
Chapter 5: Targeted Delivery of Cinaciguat 
168 
 
proportion of PLGA in the NP core (Figure 2c). This was expected due to the greater volume of the NP 
core as well as the excellent miscibility of CCG and PLGA. To enable a more realistic assessment of 
the actual amount of encapsulated drug per NP, we then calculated the number of CCG molecules per 
NP (Figure 2d), whereby a similar trend of rising levels of encapsulated substance could be found. 
Based on the hydrodynamic diameter of each NP type, we then calculated the respective NP core volume 
and determined the number of CCG molecules, that would ideally fit into one NP. Finally, this number 
was used to calculate the CCG entrapment efficiency, i.e. the ratio of the number of actually 
encapsulated and the ideally encapsulated CCG molecules. We thereby found a contrary trend for the 
tested NP compositions. Here, higher proportions of PLGA led to a generally decreasing entrapment 
efficiency, indicating that although NPs with a higher ratio of PLGA could generally encapsulate more 
drug, the actual rise in CCG molecule numbers was not as high as theoretically possible (Figure S3c). 
We therefore hypothesized, that the general composition of our NP system might not allow any higher 
CCG loading due to its substantial lipophilicity and a possible destabilizing effect of greater drug 
concentrations in the NP core. However, we estimated. that the successfully encapsulated amount of 
drug was already sufficient to enable a substantial pharmacological effect due to the considerable 
mesangial targeting capacity and the resulting drug delivery impact of the NP system.  
We finally chose to proceed with the NP species consisting of 40% PLGA and 60% PEG-PLA, as this 
NP type showed a satisfactory encapsulation efficiency (~ 46%) and CCG loading (~ 600 CCG 
molecules per NP) while still possessing an ideal diameter of around 80 nm.  
 
 
Figure 2. a) Representative HPLC chromatograms of free CCG as well as CCG-loaded or drug-free NPs. CCG 
could thereby be reproducibly detected at a retention time of 12 min (black arrow).  b) CCG loading per NP batch 
and the respective encapsulation efficiency (EE) for NPs carrying either 30, 40 or 50% PLGA as core component. 
EE was thereby highest for an addition of 10 µG CCG per 4 mg NP batch (red arrow). c) EE (10 µg CCG addition) 
gradually increased with larger amounts of PLGA addition. d) Calculated number of CCG molecules per NP type. 
(see also Figure 3a/b). Results represent mean ± SD (n = 3). *P<0.05 **P<0.01 ***P<0.001 ****P<0.0001.  
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As we were able to reproducibly encapsulate a considerable amount of CCG into our NP system, we 
next intended to assess, whether these CCG-loaded NPs could still harness their attached ligands to enter 
intracellular regions of target mesangial cells. As described above, NP cell entry is thereby based on an 
initial AT1r binding and a subsequent presentation of previously shielded cRGD functionalities, that 
enable an integrin-mediated endocytosis.39,41 We therefore used a rat-derived mesangial cell line (rMCs), 
that showed a substantial expression of both targets (AT1r/αvβ3 integrin), as our previous studies had 
already confirmed.39 
In a first step, rat mesangial cells (rMCs) were incubated for 90 min with CCG-loaded NPs (10 µg per 
NP batch). The particles either carried both active ligands (EXPcRGD NPs) or were ligand-free control 
NPs. To enable a better visualization of particle uptake, a fluorescent label was covalently coupled to 
the PLGA prior to particle preparation and cell cytosol was stained using CellTracker® Deep Red dye 
(CTDR). As depicted in Figure 3a, ligand-functionalized EXPcRGD NPs showed a substantial 
mesangial accumulation, which corresponded to our previous results. 39 In contrast, no visible cellular 
uptake could be detected for ligand-free control NPs, indicating that the mesangial cell uptake of 
EXPcRGD NPs was mediated via described ligand-receptor interactions. However, as the CCG target 
sGC is located intracellularly, we finally also assessed the exact location of visible NP accumulations 
to further confirm NP endocytosis and exclude a mere binding to the cell surface. We therefore 
performed z-stack analysis of rMCs after 90 min of EXPcRGD NP incubation and found, that NP-
associated fluorescence could almost entirely be found in sections representing intracellular segments 
of the cell body (Figure 3b). These observations were in line with our previous studies, that showed a 
maximum mesangial NP endocytosis after 90 – 120 min.39  
Taken together, these results confirmed our hypothesis, that the active agent CCG can be efficiently 
transported into intracellular regions of mesangial cells via encapsulation in adenovirus-mimetic 
EXPcRGD NPs. The encapsulation process was thereby satisfactory and reproducible and did not 
interfere with the NPs´ ability to initially bind the AT1r via EXP3174 and subsequently initiate αvβ3 
mediated cell endocytosis.  
 




Figure 3. a) CLSM analysis of CCG-loaded NP-cell interaction. In contrast to ligand-free control NPs, targeted 
EXPcRGD NPs (purple) reached a substantial uptake into endocytotic vesicles of mesangial cells (cell cytosol = 
grey; cell nuclei = blue). b) z-stack analysis further confirmed the intracellular localization of targeted NPs 
(EXPcRGD NPs) (z0 - z4 = bottom to top z-plane). Scale bar = 20 µM.  
 
3.2 Targeted CCG delivery potentiates sGC activation and stabilization 
Having confirmed, that actively targeted EXPcRGD NPs can be loaded with a pharmacologically 
relevant amount of CCG, our next goal was to investigate, whether a more efficient transport of the 
active agent into the mesangial cytosol could possibly increase the drug´s potency due to a drug delivery 
effect. This hypothesis was based on the general assumption, that the cellular uptake and cytosolic 
accumulation of free CCG might be limited, partly because of its substantial lipophilicity and the 
resulting poor solubility in aqueous systems and because of a merely passive diffusion into the target 
cell, which requires a constant concentration gradient. In contrast, CCG-loaded EXPcRGD NPs would 
be able to enter intracellular compartments more efficiently and release the active agent due to an 
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endolysosomal degradation of the NP structure.57,58 Also, the active targeting functionalities would 
enable a more selective in vivo transport of EXPcRGD NPs – and therefore also CCG – to mesangial 
sites within the kidney. This observation was already shown in our previous publication, where 
EXPcRGD NPs showed a considerably increased mesangial accumulation compared to ligand-free 
NPs.39  
To test the above-described drug delivery effect, we therefore decided to compare four major groups 
(Figure 4a): First, free CCG was administered at a concentration of 2 µM. This concentration was 
chosen, as in previous studies, it had been shown to exhibit a satisfactory and reproducible activation of 
the sGC cascade, which also led to an anti-fibrotic effect. 31 The second group consisted of CCG-loaded 
EXPcRGD NPs at a concentration of 0.4 nM, which on the one hand was comparable to our previous in 
vitro studies, whereby no cell-toxic effects had been observed39, and on the other hand contained CCG 
at approximately 10% of the free dose (0.2 µM vs. 2 µM). By administering merely a tenth of the free 
CCG dose, we wanted to test, whether the encapsulation in targeted NPs could increase the CCG potency 
as described above and eventually provide comparable effects with fewer drug needed. As a third group, 
we therefore also applied free CCG at a lower concentration of 0.2 µM, which was similar to the NP-
delivered amount of drug and should theoretically provide a merely limited effect compared to the free 
drug at 2 µM.31 Finally, CCG-free EXPcRGD NPs were administered in the same concentration as CCG-
loaded NPs to exclude any possible impact of the NP-cell or ligand-receptor binding on the CCG effect.  
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Figure 4. a) Experimental set-up. In contrast to free CCG (c = 2 µM), drug-loaded EXPcRGD NPs carried merely 
10% of the CCG dose to assess a possible drug delivery effect. b) Western blot analysis of sGC β1 content upon 
sample incubation over 24 h showed significantly increased sGC β1 levels both for free CCG (2 µM) and the NP-
encapsulated drug (0.2 µM), compared to a lower concentration of free CCG (0.2 µM) or drug-free NPs.  
Results represent mean ± SD (n = 3). ***P<0.001 ****P<0.0001. (n.s. not significant.) 
 
We initially incubated rMCs with each of the four groups for 1 to 24 h and subsequently analyzed the 
sGC β1 content. Although CCG mainly acts as an activator of oxidized/heme-free sGC, previous studies 
indicated, that due to a stabilizing effect, CCG-bound sGC can also be prevented from undergoing 
proteasomal degradation.59–61 In our case, a corresponding trend could be observed, as shown in Figure 
4b: Incubation with 2 µM of free CCG led to a substantial increase in sGC β1 content over 24 h. 
Interestingly, CCG-loaded EXPcRGD NPs provided a comparable effect, even though here, merely 10% 
of drug was administered in total. In contrast, free CCG at a similarly low concentration of 0.2 µM only 
showed a slight increase in sGC β1 levels, supporting our hypothesis, that the NP-mediated CCG 
delivery can potentiate the pharmacological potency of the active substance. In this context, a possible 
impact of ligand-receptor or NP-cell interactions was negligible, as incubation with CCG-free NPs did 
not lead to an increase in sGC β1 content, but rather showed a constant or slightly declining trend.  




Figure 5. a) Phosphorylation of PKG1-α substrate VASP-Ser239 significantly increased over 24 h, both for free 
CCG (2 µM) and CCG-loaded EXPcRGD NPs (0.2 µM), indicating a substantial activation of the kinase. b) WB 
analysis of total PKG1-α levels after 24 h incubation showed no considerable changes in protein content for any 
sample. Results represent mean ± SD (n = 3). *P<0.05 **P<0.01 ***P<0.001  ****P<0.0001. (n.s. not significant.) 
 
Since the main anti-fibrotic effect of sGC activators such as CCG is mediated via an eventual cGMP-
derived activation of PKG1-α, we consequently also analyzed the respective impact of administered 
CCG/NPs on this kinase. In order to determine changes in activity, we chose to monitor the level of 
PKG1-α mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at serine 239 (P-
VASP).62 As shown in Figure 5a, VASP phosphorylation thereby increased substantially over 24 h of 
incubation, both for free CCG (2 µM) and CCG-loaded NPs, which again carried merely 10% of the 
free CCG dose. Interestingly, this trend was initially higher for the free drug while at later time points, 
CCG-loaded NPs had a significantly increased effect on PKG1-α activity. To our estimation, this 
observation can be explained by the endolysosomal degradation, that CCG-carrying NPs initially had to 
undergo until CCG was released into the cytosol. Again, incubation with a lower concentration of free 
CCG (0.2 µM) did not produce any noteworthy changes in VASP phosphorylation, even though here, 
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the same amount of drug was applied as with the NP delivery system. Also, CCG-free NPs did not 
provide any changes in P-VASP/VASP ratio. To confirm, that the observed upregulation of VASP 
phosphorylation was mediated via an enhanced PKG1-α activity, we additionally analyzed the PKG1-α 
content (Figure 5b). Here, no significant differences between any examined group could be found, 
supporting the hypothesis of a cGMP-mediated activation of PKG1-α.  
The depicted results clearly confirmed our initial hypothesis, that CCG-loaded NPs can potentiate the 
agent´s pharmacological effect on sGC and its downstream cascade. The experienced sGC β1 
activation/stabilization as well as the increase in PKG1-α activity was thereby comparable to the effect 
of the free drug, even though EXPcRGD NPs carried merely 10% of the dose. Remarkably, the free 
administration of the same CCG amount as in the NP system (0.2 µM) provided a considerably reduced 
pharmacological effect. In our view, this observation indicated, that highly lipophilic drugs such as CCG 
can substantially profit from a more efficient delivery into intracellular regions of their target cells and 
thereby reach a comparable therapeutic effect in a significantly reduced concentration range.   
 
3.3 CCG-loaded NPs show a substantial anti-fibrotic effect via suppression of the non-
canonical TGF-β pathway 
As the NP-mediated CCG delivery led to a significantly potentiated activation of the sGC cascade, we 
lastly determined the anti-fibrotic potential of the system. In this context, previous studies had suggested, 
that CCG-mediated sGC activation can be harnessed to substantially alleviate glomerular pathologies 
caused by elevated levels of TGF-β associated fibrosis.30,31 We therefore implemented a TGF-β based 
in vitro fibrosis model and analyzed the therapeutic potential of free CCG (2 µM) as well as CCG-loaded 
EXPcRGD NPs (0.2 µM) (Figure 6a), as these two samples had provided a sufficient activation of the 
sGC-cGMP cascade as described above. Again, drug-free EXPcRGD NPs served as a control to exclude 
any possible impact of the ligand-receptor or NP-cell interaction. Prior to cell incubation with described 
samples, rMC were starved from fetal bovine serum (FBS) for 24 h, as a significant amount of TGF-β 
is also present in FBS and could therefore have an impact on the later observed results. 
Our first point of interest lay in ERK1/2, as previous studies had already indicated a substantial CCG-
mediated suppression of the non-canonical TGF-β signaling pathway.31 After 3 h of incubation with 
either free CCG (2 µM) or CCG-loaded EXPcRGD NPs (0.2 µM CCG), rMCs were therefore exposed 
to 10 ng mL-1 of TGF-β for 1 h and ERK1/2 phosphorylation was determined. Both for the free drug 
and CCG-loaded NPs, levels of P-ERK1/2 were thereby significantly reduced compared to a TGF-β 
control and CCG-free NPs. Similar to the experiments depicted in Figures 4 and 5, EXPcRGD NPs 
carried merely 10% of the drug dose, but provided a comparable result, thereby further supporting our 
initial hypothesis of a drug delivery effect. We additionally tested the impact of a pre-incubation on the 
inhibitory effect by adding CCG/NPs as well as TGF-β at the same time-point (Figure 6c). Here, 
reduction of ERK1/2 phosphorylation was significantly lower compared to the pre-incubation. This 
trend was most noticeable for CCG-loaded  EXPcRGD NPs, where only a minor inhibitory effect could 
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be detected. To our estimation, these results indicated that the CCG-mediated effect was only possible 
after a successful intracellular uptake and degradation of NPs, thereby proving our hypothesized route 
of CCG delivery.  
Figure 6. a) In order to assess the anti-fibrotic potential of CCG-loaded NPs, a TGF-β based fibrosis model was 
established, whereby fibrotic key elements were analyzed at different time points. b) Incubation of rMCs with free 
CCG (2 µM) or CCG-loaded EXPcRGD NPs (EC_CCG; 0.2 µM, 10% of the free drug dose) prior to TGF-β 
exposure significantly reduced ERK1/2 phosphorylation compared to CCG-free NP species (EC_0). c) In contrast 
to a pre-incubation (“pre”), co-addition (“co”) of CCG/NPs and TGF-β led to a considerably lower reduction in 
ERK1/2 phosphorylation, especially for CCG-loaded NPs. Results represent mean ± SD (n = 3). *P<0.05 
***P<0.001 ****P<0.0001. (n.s. not significant.) 
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As another key element of a TGF-β associated remodeling is a substantial hyperproliferation of tissues, 
we next investigated the effect of our NP system on a possible reduction of cell proliferation. We 
therefore incubated rMCs with CCG/NPs as well as TGF-β similar to the experiments above, and after 
72 h, performed an MTT proliferation assay. As depicted in Figure 7a, TGF-β induced 
hyperproliferation could thereby almost entirely be suppressed both with free CCG and EXPcRGD NPs, 
again carrying merely 10% of the free CCG dose. Drug-free NPs, in contrast, did not provide any 
significant anti-proliferative or cell-toxic effect. In this context, we also assessed a possible effect of the 
above-described serum starvation on the general cell viability of rMCs. As expected, deprivation of cells 
from FBS thereby led to a slight decrease in overall cell proliferation. However, no cell toxicity such as 
elevated levels of apoptosis could be observed, confirming the applicability of the model (Figure S4) 
in our set-up.     
In a final step, we determined the inhibitory potential of the system on the expression of α-SMA as well 
as Col1α1, two key elements of a TGF-β derived, myofibroblast-like differentiation of cells. Antibody 
staining and CLSM analysis of α-SMA content thereby revealed a trend, which was similar to the above-
described effects (Figure 7b): While stimulation of rMCs with TGF-β led to a considerable increase in 
α-SMA signal within the cell body of rMCs, pre-incubation with EXPcRGD NPs carrying CCG 
substantially suppressed this effect, especially compared to CCG-free NPs. These observations were 
further supported by western blot analysis of α-SMA content, where a similar anti-fibrotic effect was 
noticeable (Figure 7c). Accordingly, pre-incubation with CCG-loaded EXPcRGD NPs also 
significantly reduced expression of Col1α1 (Figure 7d). Again, the observed effect was comparable to 
the application of ten times as much free drug. 
Taken together, we suggest that the presented results confirmed our initial hypothesis of a potentiated 
CCG effect due to a NP-derived drug delivery. Compared to the administration of the free drug, CCG-
loaded NPs thereby showed a similar activation of the sGC pathway and suppression of the non-
canonical TGF-β pathway, even though they carried merely 10% of the dose. To our estimation, this 
effect was mainly based on the fact, that EXPcRGD NPs could transport their cargo more efficiently 
into cytosolic compartments of the target cell in contrast to the highly lipophilic free drug.




Figure 7. a) MTT cell proliferation assay revealed a significant reduction of TGF-β induced hyperproliferation by 
pre-incubation with CCG-loaded EXPcRGD NPs. b) CLSM analysis of α-SMA expression showed a considerable 
reduction of pro-fibrotic α-SMA (green) for free CCG as well as CCG-carrying NPs. Cell nuclei = blue. Scale bar 
= 20 µM. WB analysis of  c) α-SMA and d) Colα1 expression proved the observation of a considerable anti-
fibrotic potential of CCG-loaded EXPcRGD NPs. Results represent mean ± SD (n = 3). **P<0.01 ***P<0.001 










The above discussed results of this study revealed three major outcomes: First, a pharmacologically 
relevant dose of CCG could be reproducibly encapsulated into our virus-mimetic NP system while still 
guaranteeing a highly efficient mesangial NP uptake due to the previously presented targeting 
functionalities. Second, NP-assisted delivery of CCG into the mesangial cytosol substantially 
potentiated the sGC activating effect of the drug. In this regard, NP-mediated transport of 10% of the 
original free dose led to a comparable pharmacological effect concerning sGC stabilization and 
activation. Remarkably, the same concentration did not provide any noteworthy effect, when it was not 
delivered via the NP system, but merely administered in its free form. As above mentioned, this outcome 
was possibly based on a more efficient and prolonged transport of NP-encapsulated CCG into cytosolic 
regions of the target cells. Lastly, activation of the sGC-cGMP cascade via CCG-loaded NPs led to a 
considerable reduction of non-canonical TGF-β signaling, resulting in significantly decreased levels of 
pro-fibrotic markers and a substantially reduced hyperproliferation. Again, the described effects could 
be realized with merely 10% of the free CCG dose, indicating the great potential of the NP system in 
the therapy of renal fibrosis and further pathologies. It would therefore be of utmost interest to test the 
described system in an in vivo disease model. In that regard, future studies would also have to elucidate, 
whether glomerular damage can not only be prevented, but also be reversed by the administration of 
CCG-loaded NPs. As this effect has already been shown repeatedly for the free CCG drug or for sGC 
stimulators29–31, we suppose, a NP-mediated drug delivery could potentially even increase the observed 
therapeutic effect. In that regard, CCG transport via our virus-mimetic NP system would additionally 
provide the substantial advantage, that it can prevent an imminent interaction of CCG with the 
vasculature and thereby minimize possible adverse effects such as a drop in blood pressure. When it 
comes to diabetes and the related kidney pathologies, this new treatment option would be highly 
beneficial as it would not only be able to prevent further kidney damage like the currently predominant 
therapy options (control of blood sugar/pressure), but also have a substantial effect in the case of an 
already further progressed state of disease. In this regard, NP-assisted delivery of active substances such 
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1 HPLC chromatograms 
 
Figure S1. HPLC chromatograms. a) Representative HPLC chromatograms for the calibration of free 
Cinaciguat. b) HPLC calibration. Results represent mean ± SD (n = 3). c) Representative chromatograms for NP 
species carrying 30-50% PLGA and an initial CCG addition of 10 µg per 4 mg NP batch.  
 
2 DLS data 
 
Figure S2. a) DLS size distribution of NP species containing 30/40/50% PLGA (from left to right). b) Merged 
DLS graphs. c) Size and polydispersity index (PDI) data for different NP species. d) Representative DLS graph 
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of 40% PLGA NPs and an addition of 17.5 µg per 4 mg NP batch, showing a strong tendency for larger 
aggregates (see right peak).  
 
3 Physicochemical parameters 
 
Figure S3. a) Results for calculation of NP core volume for each sample. b) Results for calculation of CCG 
encapsulation as well as entrapment efficiency. c) CCG entrapment efficiency per NP type.                      
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4 Impact of serum starvation 
 
Figure S4. a) Brightfield images of rMCs cultured for 72 h during the cell proliferation assay either without (top) 
or with (bottom) addition of 10 % FBS. (Scale bar 100 µm). b) MTT assay results of rMC proliferation after 24 h 
and 72 h with and without addition of 10 % FBS. (Note: The results for samples “No serum 72 h” and “TGF-β 72 
h (no serum)” represent the blank-normalized samples “Blank cells” and “TGF-β” in Figure 7a of the main 











































































































































Although modern pharmaceutical research is able to identify promising drugs for a plethora of existing 
diseases at a growing pace, a great number of possible therapeutic candidates show limited efficiency 
due to an unfavorable biodistribution or severe side effects in off-target tissues after administration. 
While nanoparticular drug delivery approaches could potentially provide a solution for this predicament, 
criticism over the disappointing outcome of many NP-assisted therapy approaches has intensified in 
recent years.1 One key aspect is thereby the oftentimes low bioavailability, that (targeted) NP systems 
have shown despite the implementation of more and more complex materials.2,3 Apart from a general 
clearance via the MPS, the majority of currently existing nanoparticular concepts thereby also suffer 
from a  considerable off-target accumulation in the usual suspects, i.e. the liver, kidney, and the vascular 
system. It would therefore be a promising approach to harness this to some extent inevitable deposition 
and combine it with active targeting concepts to treat pathologically remodeled cell types within the 
respective tissues or organs (Chapter 1). NPs would thereby profit not only from their cell-selective 
recognition patterns, but also from a considerable passive targeting effect via the intravascular transport 
into respective regions. 
Filtrating the entire blood volume for approximately 300 times a day, the kidney is thereby one particular 
interesting region for NP-mediated drug delivery as a substantial portion of intravenously administered 
NPs will inevitably pass the organ. Within the kidneys´ glomeruli, mesangial cells act as key players in 
controlling the structural support of the actual filtration apparatus consisting of podocytes, a basement 
membrane end glomerular endothelial cells.4,5 However, various renal diseases such as diabetic 
nephropathy are accompanied by a progredient malfunction of described mesangial cells, leading to a 
pro-fibrotic turnover of extracellular matrix components and a pathological remodeling of the 
glomerular filtration barrier.6 In this regard, NP-assisted drug delivery into the mesangium could offer 
a highly beneficial alternative to currently existing therapeutic options, as particles are able to passively 
accumulate in mesangial regions via extravasation through the fenestrated glomerular endothelium.7 
In this work, mimicry of adenoviral host cell identification was used to substantially increase target cell 
specificity of NPs during their active recognition of mesangial surface structures (Chapter 2). Inspired 
by AdV2, NPs thereby initially bind mesangial AT1r to enable NP-cell attachment without immediate 
cell uptake. Only after a resulting spatial approach, NPs present a previously shielded second ligand, 
which triggers NP endocytosis via activation of mesangial surface integrin αvβ3 (Chapter 3). While 
functionalization of block-copolymer NPs with AT1r antagonist EXP3174 thereby led to an efficient 
binding of AT1r and thus the mesangial cell surface, attached integrin activator cRGDfK enabled a 
substantial receptor-mediated endocytosis of targeted NPs into the mesangial cytosol. Also, introduction 
of a steric shielding concept, that initially limited the visibility of the second ligand, led to an adenovirus-
mimetic and therefore sequential NP-cell interaction of initial AT1r binding and subsequent integrin-
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mediated NP uptake, thereby drastically increasing the NPs´ target cell specificity in an in vitro co-
culture assay with off-target cells. Hetero-multivalent EXPcRGD NPs eventually also 
showed a substantial in vivo accumulation within mesangial regions, proving the potential of a 
combination of passive and active targeting functionalities. 
When it comes to the design of actively targeted NP systems, the impact of the actual particle transport 
within the blood vessels is generally overlooked. However, ligand-receptor interactions can be greatly 
influenced by the imminent dynamic blood flow, that administered NPs are subject to.8–10 Also, off-
target deposition into vascular endothelial cells can severely limit targeting efficiency of NPs, as the 
addressed cell surface structures such as integrins are to some extent also expressed in the endothelium. 
In this regard, the concept of sterically shielding cRGD sequences from premature presentation to off-
targets such as vascular endothelial cells provided promising results as NP-cell interaction could be 
precisely regulated by the introduction of varying densities of longer protruding shielding elements 
(Chapter 4). The concept could thereby be maintained both under static and more realistic dynamic 
flow conditions. Also, cRGD-integrin interaction was minimal at higher flow rates and intensified at 
lower flow rates, where the timespan for NP-cell interaction and following ligand unveiling was 
increased. This observation could in part explain the successful in vivo targeting of mesangial regions 
with the adenovirus-mimetic NP system. Due to the shielding effect as well as the substantial blood flow 
in larger vessels, particles initially showed only marginal off-target deposition to vascular endothelial 
cells. Only after an extravasation into the mesangium, flow rate decreased, and NPs could interact with 
their target cells in the described sequential manner.  
As mentioned above, the mesangium plays a central role in the fibrotic remodeling of the renal filtration 
apparatus during pathologies such as diabetic nephropathy.11,12 Therefore, encapsulation of anti-fibrotic 
drug candidates into adenovirus-mimetic NPs could offer a substantial benefit for the therapy of 
respective renal diseases. In this regard, sGC activator cinaciguat is an ideal candidate for NP drug 
delivery, as it has previously shown a considerable therapeutic potential for pathologically affected 
mesangial cells but suffers from a poor biodistribution and unfavorable side effects after 
administration.13–16 Based on its substantial lipophilicity and a sufficient miscibility with the NP core 
component PLGA, CCG could be reproducibly encapsulated into the adenovirus-mimetic NP system, 
whereby resulting NPs could maintain their active mesangial targeting functionalities (Chapter 5). Due 
to an efficient transport into cytosolic regions of mesangial cells, resulting CCG-loaded NPs could 
significantly increase the pharmacological potency of the drug regarding sGC stabilization and 
activation of the sGC-cGMP cascade. Also, therapeutic NPs showed beneficial results regarding an anti-
fibrotic effect in a TGF-β model compared to the application of the free drug.  
Taken together, the depicted results show the considerable potential of the combination of passive 
targeting strategies into general sites of NP biodistribution with virus-inspired active cell recognition 




placed on relevant physiological parameters such as blood flow dynamics or the microarchitecture of 
the target tissue. 
 
2 Conclusion 
This work led to the manufacture of an adenovirus-mimetic NP system, that is able to successfully 
imitate the sequential target cell recognition process of its viral model AdV2. The functionalization of 
block-copolymer NPs with two different ligands and, most importantly, the step-wise presentation of 
these ligands led to a substantial mesangial specificity both in vitro and in vivo. In this regard, the 
concept of a steric shielding of the second, uptake-mediating ligand could also be maintained under 
more realistic conditions of a dynamic flow cell culture and NP incubation. More so, the encapsulation 
of sGC activator cinaciguat into the adenovirus-mimetic NPs led to a substantially increased 
pharmacological potency and a considerably enhanced anti-fibrotic effect compared to the 
administration of the free drug.  
Taken all together, the described findings demonstrate the immense potential of a NP-assisted therapy 
of kidney pathologies such as diabetic nephropathy. In this regard, future nanotherapeutic research will 
hopefully lead to a better treatability of these oftentimes detrimental long-term effects of diabetes, for 
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α-SMA    α-smooth muscle actin 
ACE    Angiotensin converting enzyme 
ACN    Acetonitrile 
AdV2    Human adenovirus type 2 
AFU    Arbitrary fluorescence unit 
Alexa568   AlexaFluor568 hydrazide 
ANOVA   Analysis of variance  
Phalloidin   AlexaFluor 568 Phalloidin 
ApoE    Apolipoprotein E 
ASGPR   Asialoglycoprotein receptor 
AT-I/-II   Angiotensin I/II 
AT1r    Angiotensin II receptor type 1 
ATTR    Amyloidogenic transthyretin 
BME    β-mercaptoethanol 
BSA    Bovine serum albumine 
CAM    Cell adhesion molecule 
CAR    Coxsackie and adenovirus receptor 
CCG    Cinaciguat 
CCR    CC chemokine receptor 
CellMask   CellMask deep red plasma membrane stain 
cGMP    3´,5´-cyclic guanosine monophosphate 
CKD    Chronic kidney disease 
CLSM    Confocal laser scanning microscopy 
Col1α1    Collagen 1α1 
COPD    Chronic obstructive pulmonary disease 
CP    Cyclopentenone 
CPP    Cell penetrating peptide 
cRGDfC   Cyclo(-Arg-Gly-Asp-D-Phe-Cys) 
cRGDfK   Cyclo(-Arg-Gly-Asp-D-Phe-Lys)  




CTDR    CellTracker Deep Red 
DAPI    4′,6-diamidine-2′-phenylindole dihydrochloride 
DCC    N,N′-dicyclohexylcarbodiimide 
DCM    Dichloromethane 
DFG    German research foundation 
DIPEA    N,N-diisopropylethylamine 
DLS    Dynamic light scattering 
DMSO    Dimethyl sulfoxide 
DMTMM   4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
DN    Diabetic nephropathy 
DPBS    Dulbecco´s phosphate-buffered saline 
EDC    3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine  
 
ECM    Extracellular matrix 
EE    Encapsulation efficiency 
EGTA    Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
ERK1/2   Extracellular-regulated kinase 1/2 
ESRD    End-stage renal disease 
FBS    Fetal bovine serum 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GBM    Glomerular basement membrane 
GFB    Glomerular filtration barrier 
GFP    Green fluorescent protein 
GFR     Glomerular filtration rate 
GTP    Guanosine triphosphate 
HA    Hyaluronic acid 
HBV    Hepatitis virus B 
HDL    High-density lipoprotein 
HPLC    High-performance liquid chromatography 
HSA    Human serum albumine 
HSC    Hepatic stellate cell 
HUVEC   Human umbilical vein endothelial cell 
HVJ    Hemagglutinating virus of Japan 




ICAM    Intercellular adhesion molecule 
IFN-γ    Interferon-γ 
ITS    Insulin-transferrin-selenium 
KC    Kupffer cell 
LB    Leibovitz´s buffer 
LDL    Low-density lipoprotein 
LSEC    Liver sinusoidal endothelial cell 
MC    Mesangial cell 
M6P    Mannose 6-phosphate 
mpH2O    Millipore water 
MPS    Mononuclear phagocyte system 
MR    Mannose receptor 
MRI    Magnet resonance imaging 
mTOR    Mechanistic target of rapamycin 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAcGal   N-acetyl-D-galactosamine 
NHS    N-hydroxysuccinimide 
 
NK    Natural killer cell 
NO    Nitric oxide 
NP    Nanoparticle 
NNM    Nanomedicine  
oxLDL    Oxidized low-density lipoprotein 
oxPC    Oxidized phosphatidylcholine 
PAMAM   Polyamidoamine 
PCL    Poly(caprolactone) 
PDGFR   Platelet-derived growth factor receptor 
PDI    Polydispersity index 
PECAM-1   Platelet-endothelial cell adhesion molecule-1 
PEG    Poly-(ethylene glycol)   
PEI    Poly(ethylene imine) 
PFA    Paraformaldehyde 
PFD    Pirfenidone 




PLGA    Poly(lactic-co-glycolic acid) 
PPARγ    Peroxisome proliferator-activated receptor γ 
PVA    Polyvinyl alcohol 
RAAS    Renin-angiotensin-aldosterone system 
RBPR    Retinol binding protein receptor 
rMC    Rat mesangial cell 
RT    Room temperature 
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sGC    Soluble guanylate cyclase 
SD    Standard deviation 
SR    Scavenger receptor 
TAT    Transactivating transcriptional activator 
TEM    Transmission electron microscopy 
TFA    Trifluoroacetic acid 
TGF-β    Transforming growth factor β 
TLR-4    Toll-like receptor 4 
VCAM-1   Vascular cell adhesion molecule 1 
VEC    Vascular endothelial cell 
VEGFR-2   Vascular endothelial growth factor receptor 2 
vWF    Von Willebrand Factor 
VE-cadherin   Vascular endothelial cadherin 
VASP    Vasodilator-stimulated phosphoprotein 
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